

Aspirin in the primary and secondary prevention of vascular disease: a meta-analysis of individual participant data from randomised controlled trials

Lancet, The

373, 1849-1860

DOI: 10.1016/s0140-6736(09)60503-1

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 297.	1.1	21
2	Chick-Embryo Deaths Traced to Tincture of Iodine. Journal of Infectious Diseases, 1973, 127, 581-581.	4.0	0
3	Human U1 small nuclear RNA pseudogenes do not map to the site of the U1 genes in 1p36 but are clustered in 1q12-q22.. Molecular and Cellular Biology, 1985, 5, 2172-2180.	2.3	42
5	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. Cellular and Molecular Life Sciences, 2005, 62, 599-605.	5.4	13
6	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 fBT /Overlock 10 T	2.2	2,331
7	Survey of Literature: Current Literature Review. Journal of Sexual Medicine, 2008, 5, 257-261.	0.6	2
8	Clinical Applications of Aspirin. , 0, , 223-365.		0
9	ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS. Rational Pharmacotherapy in Cardiology, 2009, 5, 55-58.	0.8	0
10	Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. Medical Journal of Australia, 2009, 191, 356-357.	1.7	1
11	Aspirin for primary prevention of cardiovascular disease?. Drug and Therapeutics Bulletin, 2009, 47, 122-125.	0.3	9
12	Does an Aspirin a Day Keep the Doctor Away?. Canadian Pharmacists Journal, 2009, 142, 200-200.	0.8	0
13	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis, 2009, 101, 333-339.	3.4	114
14	Management of Hypertension. InnovAiT, 2009, 2, 714-720.	0.0	0
15	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Circulation, 2009, 120, 1296-1336.	1.6	117
16	Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2009, 339, b4531-b4531.	2.3	333
17	Physicians' Attitudes Toward Post-MI Aspirin Prophylaxis: Findings from an Online Questionnaire in Europe and Latin America. Postgraduate Medicine, 2009, 121, 44-53.	2.0	10
19	Antiplatelet Treatment in Ischemic Stroke Treatment. Current Topics in Medicinal Chemistry, 2009, 9, 1298-1316.	2.1	3
20	Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVEâ€¢, European CRT survey, German preâ€¢SCD II registry, and MADITâ€¢CRT. European Journal of Heart Failure, 2009, 11, 1214-1219.	7.1	42

#	ARTICLE	IF	CITATIONS
21	WHO Should Consider the Benefits of Aspirin Prophylaxis in Middle Age?. American Journal of Hypertension, 2009, 22, 811-812.	2.0	0
22	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.5	1,236
24	Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clinical Research in Cardiology, 2009, 98, 691-699.	3.3	7
25	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy, 2009, 23, 489-499.	2.6	6
27	Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis. British Journal of Clinical Pharmacology, 2009, 68, 647-650.	2.4	1
28	Antithrombotic therapy for heart failure in sinus rhythm. Fundamental and Clinical Pharmacology, 2009, 23, 705-717.	1.9	8
29	Future directions in antiplatelet therapy: efficacy versus safety. Future Prescriber, 2009, 10, 20-23.	0.1	0
30	Aspirin for the primary prevention of vascular events?. Public Health, 2009, 123, 787-788.	2.9	20
32	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Journal of the American College of Cardiology, 2009, 54, 1364-1405.	2.8	80
33	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	1.5	351
34	Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate. Platelets, 2009, 20, 471-477.	2.3	10
35	The Pharmaceutical Medicine Year that Was. Pharmaceutical Medicine, 2009, 23, 259-261.	1.9	1
36	Aspirin for the Primary Prevention of Cardiovascular Events. Diabetes Care, 2009, 32, 2300-2306.	8.6	93
37	Aspirin in primary prevention: sex and baseline risk matter. Lancet, The, 2009, 373, 1821-1822.	13.7	20
38	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply. Lancet, The, 2009, 374, 26-27.	13.7	2
39	Aspirin in the primary prevention of vascular disease. Lancet, The, 2009, 374, 877.	13.7	0
40	Aspirin in the primary prevention of vascular disease. Lancet, The, 2009, 374, 877-878.	13.7	1
41	Aspirin in the primary prevention of vascular disease. Lancet, The, 2009, 374, 878.	13.7	2

#	ARTICLE	IF	CITATIONS
42	Aspirin in the primary prevention of vascular disease. Lancet, The, 2009, 374, 878-879.	13.7	1
43	Aspirin in the primary prevention of vascular disease – ATT secretariat's reply. Lancet, The, 2009, 374, 879.	13.7	0
44	Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings, 2009, 84, 741-757.	3.0	111
46	A matter of judgement: clinical guidelines and scientific reductionism. Current Opinion in Lipidology, 2009, 20, 446-447.	2.7	1
47	Polypill: the evidence and the promise. Current Opinion in Lipidology, 2009, 20, 453-459.	2.7	18
48	Does the Dose Do It?. Journal of Neurologic Physical Therapy, 2009, 33, 177-178.	1.4	4
49	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Yearbook of Vascular Surgery, 2010, 2010, 41-42.	0.0	0
50	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Yearbook of Cardiology, 2010, 2010, 289-291.	0.0	0
51	Aspirin for asymptomatic atherosclerosis?. Nature Reviews Cardiology, 2010, 7, 306-307.	13.7	3
52	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Yearbook of Medicine, 2010, 2010, 365-367.	0.1	0
53	The Use of Platelet Function Assays May Help to Determine Appropriate Antiplatelet Treatment Options in a Patient With Recurrent Stroke on Baby Aspirin. Stroke, 2010, 41, 2398-2399.	2.0	16
54	A practical approach to the metabolic syndrome: review of current concepts and management. Current Opinion in Cardiology, 2010, 25, 502-512.	1.8	30
55	Statin prescription in men and women at cardiovascular risk: to whom and when?. Current Opinion in Cardiology, 2010, 25, 484-489.	1.8	17
56	The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology, 2010, 25, 321-328.	1.8	14
57	Women and elderly: subgroups under-represented in clinical trials. Current Opinion in Cardiology, 2010, 25, 335-339.	1.8	11
58	Pharmacist Interventions: Improving Adherence to Evidence-Based Therapy. Canadian Pharmacists Journal, 2010, 143, 74-76.	0.8	1
59	99, 473-479.	0.0	0
61	Role of cholesterol crystals in myocardial infarction and stroke. Clinical Lipidology, 2010, 5, 57-69.	0.4	7

#	ARTICLE	IF	CITATIONS
62	Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal, 2010, 74, 597-607.	1.6	239
63	Drugs in type 2 diabetes: their properties and recommended use. The Prescriber, 2010, 21, 19-41.	0.3	1
64	How to Use an Article About Quality Improvement. JAMA - Journal of the American Medical Association, 2010, 304, 2279.	7.4	113
65	Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technology Assessment, 2010, 14, 1-206.	2.8	171
66	Aspirin use in elderly women receiving medication therapy management services. Advances in Therapy, 2010, 27, 613-622.	2.9	1
69	Treatment of Angina and Microvascular Coronary Dysfunction. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 355-364.	0.9	39
70	Aspirin for the Primary Prevention of Cardiovascular Disease in Women. Current Cardiovascular Risk Reports, 2010, 4, 209-215.	2.0	0
72	Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. International Journal of Hematology, 2010, 92, 296-301.	1.6	41
73	Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. Current Cardiology Reports, 2010, 12, 321-329.	2.9	10
74	Fractalkine as an Important Target of Aspirin in the Prevention of Atherogenesis. Cardiovascular Drugs and Therapy, 2010, 24, 1-3.	2.6	4
75	Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis, 2010, 30, 240-249.	2.1	1
76	Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics. Pharmaceutical Research, 2010, 27, 2365-2373.	3.5	17
78	Primary and secondary prevention. Medicine, 2010, 38, 409-413.	0.4	1
79	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2010, 38, 632-637.	0.4	0
80	Cost-Effective Prevention of Coronary Heart Disease. Journal for Nurse Practitioners, 2010, 6, 754-764.	0.8	2
81	An Aspirin a Day: Are We Barking Up the Wrong Willow Tree?. Pharmacotherapy, 2010, 30, 115-118.	2.6	8
82	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) Tj ETQq0 0 0 ngBT /Overlock 10 Tf	2.6	8
83	Aspirinâ€”A Drug Whose Time Has Gone?. American Journal of Cardiology, 2010, 105, 577-578.	1.6	1

#	ARTICLE	IF	CITATIONS
85	Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1040-1051.	1.3	26
86	Patients under anti-platelet therapy. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 41-50.	4.0	13
88	Current Literature Review. <i>Journal of Sexual Medicine</i> , 2010, 7, 2626-2632.	0.6	0
89	Antiplatelet therapy in secondary stroke prevention – state of the art. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2552-2560.	3.6	9
91	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 641-650.	3.8	15
92	High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 906-913.	3.8	32
93	The role of weight and enteric coating on aspirin response in cardiovascular patients. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2323-2325.	3.8	67
94	Application of cardioprotective medication. <i>International Journal of Clinical Practice</i> , 2010, 64, 529-532.	1.7	0
95	A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (â€polypillâ€™™) on cardiovascular risk factors. <i>International Journal of Clinical Practice</i> , 2010, 64, 1220-1227.	1.7	113
96	Antiplatelet drug interactions. <i>Journal of Internal Medicine</i> , 2010, 268, 516-529.	6.0	39
97	The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. <i>International Journal of Impotence Research</i> , 2010, 22, 77-90.	1.8	65
98	Therapeutic Hypothermia for Acute Ischemic Stroke: Ready to Start Large Randomized Trials?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1079-1093.	4.3	164
100	Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.1	3
102	Patient Self-Medication with ASA 81 mg. <i>Canadian Pharmacists Journal</i> , 2010, 143, 192-198.	0.8	3
103	Aspirin in Cardiovascular and Cerebrovascular Events: Does Market Failure Matter?. <i>American Journal of Economics and Business Administration</i> , 2010, 2, 120-128.	0.3	1
104	COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR). <i>Rational Pharmacotherapy in Cardiology</i> , 2010, 6, 796-802.	0.8	0
105	Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. <i>Pharmaceuticals</i> , 2010, 3, 2146-2162.	3.8	157
106	Differences in Efficacy and Safety of Pharmaceutical Treatments between Men and Women: An Umbrella Review. <i>PLoS ONE</i> , 2010, 5, e11895.	2.5	19

#	ARTICLE	IF	CITATIONS
107	Might salicylate exert benefits against childhood cancer?. Ecancermedicalsecience, 2010, 4, 156.	1.1	0
108	High-dose clopidogrel, prasugrel or ticagrelor: trying to unravel a skein into a ball. Drugs and Therapy Studies, 2010, 1, 13.	0.6	0
109	LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS?. Rational Pharmacotherapy in Cardiology, 2010, 6, 703-708.	0.8	1
110	Risk assessment and aspirin use in Asian and Western populations. Vascular Health and Risk Management, 2010, 6, 943.	2.3	21
111	Impact of race and gender on antithrombotic therapy. Thrombosis and Haemostasis, 2010, 104, 471-484.	3.4	68
112	Ischaemic stroke “prevention is better than cure. Journal of the Royal College of Physicians of Edinburgh, The, 2010, 40, 56-63.	0.6	19
113	Anti-platelet therapy: Is it all over in peripheral artery disease?. Thrombosis and Haemostasis, 2010, 103, 689-691.	3.4	2
114	Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin. Drug, Healthcare and Patient Safety, 2010, 2, 191.	2.5	2
115	Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Thrombosis and Haemostasis, 2010, 104, 1085-1088.	3.4	25
116	Combination Antithrombotic Therapies. Circulation, 2010, 121, 569-583.	1.6	112
117	A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 344-348.	2.0	31
118	Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index_{title>>A Randomized Controlled Trial}. JAMA - Journal of the American Medical Association, 2010, 303, 841.	7.4	548
119	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y ₁₂ receptor antagonists?. Heart, 2010, 96, 1693-1694.	2.9	41
120	Advancing Aspirin Utilization: A Review of Clinical and Systems-Based Interventions. American Journal of Medical Quality, 2010, 25, 351-358.	0.5	1
122	Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes. Circulation, 2010, 122, 2201-2211.	1.6	61
123	Primary and Secondary Prevention of Ischemic Stroke. European Neurology, 2010, 63, 267-278.	1.4	35
124	A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention. Journal of Medical Economics, 2010, 13, 418-427.	2.1	17
125	Coronary artery disease: medical therapy. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2010, 52, 305-306.	0.6	0

#	ARTICLE	IF	CITATIONS
127	The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine, 2010, 61, 49-61.	12.2	24
128	Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 679-684.	1.9	85
129	Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting. Diabetes Care, 2010, 33, 317-321.	8.6	35
130	Aspirin in Alzheimer's Disease. Stroke, 2010, 41, 2690-2692.	2.0	55
131	Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diabetes and Vascular Disease Research, 2010, 7, 274-288.	2.0	8
132	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Diabetes Care, 2010, 33, 1395-1402.	8.6	211
133	Diagnosis and treatment of renal artery stenosis. Nature Reviews Nephrology, 2010, 6, 151-159.	9.6	42
134	Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. European Heart Journal, 2010, 31, 261-262.	2.2	8
135	Ischemic Stroke and Secondary Prevention in Clinical Practice. Stroke, 2010, 41, 1338-1342.	2.0	62
136	Associations Between Peripheral Artery Disease and Ischemic Stroke. Stroke, 2010, 41, 2102-2107.	2.0	81
137	Promoting Cardiovascular and Cerebrovascular Health. Stroke, 2010, 41, 1079-1083.	2.0	12
138	Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal, 2010, 31, 1677-1681.	2.2	64
139	Late stent malapposition: innocent phenomenon or major risk marker? reply. European Heart Journal, 2010, 31, 260-261.	2.2	2
140	The management of combined coronary artery disease and peripheral vascular disease. European Heart Journal, 2010, 31, 1565-1572.	2.2	27
143	What Is the Future of Stroke Prevention?. Stroke, 2010, 41, S35-8.	2.0	19
144	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine, 2010, 4, 421-434.	1.4	4
145	Recent advances in cardiology. Future Cardiology, 2010, 6, 11-17.	1.2	5
146	Short-term vascular risk: time to take notice?. Nature Reviews Cardiology, 2010, 7, 409-411.	13.7	2

#	ARTICLE	IF	CITATIONS
147	Don't use aspirin for primary prevention of cardiovascular disease. BMJ: British Medical Journal, 2010, 340, c1805-c1805.	2.3	25
148	Glomerular filtration rate and the risk of stroke. BMJ: British Medical Journal, 2010, 341, c4390-c4390.	2.3	2
149	Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?. Future Cardiology, 2010, 6, 141-146.	1.2	6
150	Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 576-581.	2.8	43
151	Potential economic impact of increasing low dose aspirin usage on CVD in the US. Current Medical Research and Opinion, 2010, 26, 2365-2373.	1.9	7
152	Physicians' Attitudes toward Post-MI Aspirin Prophylaxis: Findings from an Online Questionnaire in Asia-Pacific. Postgraduate Medicine, 2010, 122, 108-117.	2.0	5
153	Aspirin for primary prevention of cardiovascular disease?. Evidence-Based Medicine, 2010, 15, 31-33.	0.6	1
154	Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2010, 33, 1193-1199.	8.6	13
155	Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on Pharmacotherapy, 2010, 11, 1459-1466.	1.8	34
156	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2010, 55, 1487-1498.	2.8	13
157	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2010, 56, 956-965.	2.8	171
158	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Journal of the American College of Cardiology, 2010, 55, 2878-2886.	2.8	96
160	Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of Clinical Lipidology, 2010, 4, 156-164.	1.5	158
161	Antiplatelet Drugs – Do We Need New Options?. Drugs, 2010, 70, 887-908.	10.9	36
162	Aspirina para diab�ticos en prevenci�n primaria: praxis sin evidencia cient�fica. Farmaceuticos De Atencion Primaria, 2010, 8, 20-21.	0.0	0
163	Hypertension 2010: what was new for the cardiologist?. Expert Opinion on Pharmacotherapy, 2010, 11, 2579-2597.	1.8	6
164	Antiplatelet therapy and vascular disease: an update. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 249-275.	2.1	16
166	Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2010, 87, 211-218.	2.8	127

#	ARTICLE	IF	CITATIONS
167	Update of Cerebral Vascular Disease: Issues for the Primary Care Physician. Disease-a-Month, 2010, 56, 40-71.	1.1	11
168	Aspirin as antiplatelet agent in diabetes. PROS-. European Journal of Internal Medicine, 2010, 21, 149-153.	2.2	8
169	Aspirin as antiplatelet agent in diabetes: Cons. European Journal of Internal Medicine, 2010, 21, 154-156.	2.2	1
170	Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)â€”A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. American Heart Journal, 2010, 159, 361-369.e4.	2.7	19
171	Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: Balancing safety and efficacy. American Heart Journal, 2010, 160, S36-S41.	2.7	6
172	Aspirin for the Primary Prevention of Stroke and Myocardial Infarction: Ineffective or Wrong Dose?. American Journal of Medicine, 2010, 123, 101-102.	1.5	10
173	Implementation Research: A Critical Component of Realizing the Benefits of Comparative Effectiveness Research. American Journal of Medicine, 2010, 123, e38-e45.	1.5	20
174	Comparison of efficacy of antiplatelet treatments for patients with claudication. Thrombosis and Haemostasis, 2010, 103, 766-773.	3.4	26
177	Early recognition and prevention of chronic kidney disease. Lancet, The, 2010, 375, 1296-1309.	13.7	494
178	Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, The, 2010, 376, 1741-1750.	13.7	1,168
179	Tratamiento integral individualizado de los factores de riesgo vascular. Medicine, 2010, 10, 4700-4707.	0.0	0
180	New antithrombotic agentsâ€”insights from clinical trials. Nature Reviews Cardiology, 2010, 7, 498-509.	13.7	45
181	Standards of Medical Care in Diabetesâ€”2010. Diabetes Care, 2010, 33, S11-S61.	8.6	2,863
182	Aspirin as Preventive Therapy in Patients With Asymptomatic Vascular Disease. JAMA - Journal of the American Medical Association, 2010, 303, 880.	7.4	9
183	Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals, 2010, 3, 1491-1506.	3.8	15
184	Platelet Activation in Essential Hypertension: Implications for Antiplatelet Treatment. American Journal of Hypertension, 2010, 23, 229-236.	2.0	65
185	The Polypill in the Prevention of Cardiovascular Diseases. Circulation, 2010, 122, 2078-2088.	1.6	152
186	Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention. Journal of the National Cancer Institute, 2010, 102, 14-25.	6.3	658

#	ARTICLE	IF	CITATIONS
187	Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nature Reviews Endocrinology, 2010, 6, 619-628.	9.6	43
188	Stroke Prevention in Atrial Fibrillation. Drugs and Aging, 2010, 27, 859-870.	2.7	8
189	Adjunctive Treatment of Chronic Periodontitis With Daily Dietary Supplementation With Omega-3 Fatty Acids and Low-Dose Aspirin. Journal of Periodontology, 2010, 81, 1635-1643.	3.4	154
190	Platelet aggregation monitoring with a newly developed quartz crystal microbalance system as an alternative to optical platelet aggregometry. Analyst, The, 2010, 135, 2930.	3.5	29
191	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 121-130.	2.2	3
192	The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk. American Journal of Cardiovascular Drugs, 2010, 10, 281-288.	2.2	37
193	Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets, 2011, 22, 188-195.	2.3	36
194	"Prevention is better than cure, but is it? Preventive medication as a risk to ordinariness?. Health, Risk and Society, 2011, 13, 653-668.	1.7	11
195	Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Annals of Medicine, 2011, 43, 531-544.	3.8	37
196	Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid. Patient, 2011, 4, 103-113.	2.7	27
197	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation, 2011, 124, 2458-2473.	1.6	1,369
198	Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology, 2011, 8, 429-441.	13.7	32
199	Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart, 2011, 97, 797-802.	2.9	114
200	Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Canadian Journal of Physiology and Pharmacology, 2011, 89, 239-244.	1.4	61
201	Risk of Upper Gastrointestinal Bleeding With Low-Dose Acetylsalicylic Acid Alone and in Combination With Clopidogrel and Other Medications. Circulation, 2011, 123, 1108-1115.	1.6	165
202	Le risque cardiovasculaire. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 9-15.	0.0	0
204	Antiplatelet Therapy in Coronary Heart Disease Prevention. Cardiology Clinics, 2011, 29, 71-85.	2.2	10
205	La aspirina no es eficaz en prevención primaria. Farmaceuticos De Atencion Primaria, 2011, 9, 65-66.	0.0	0

#	ARTICLE	IF	CITATIONS
206	Is Reclassification of Intermediate-Risk Subjects by Coronary Artery Calcium Scoring Clinically Useful?. Journal of the American College of Cardiology, 2011, 58, 1081.	2.8	1
207	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology, 2011, 57, 1920-1959.	2.8	332
208	Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2011, 58, 762-764.	2.8	10
209	Comparative Effectiveness and Cost-Effectiveness of Computed Tomography Screening for Coronary Artery Calcium in Asymptomatic Individuals. Journal of the American College of Cardiology, 2011, 58, 1690-1701.	2.8	71
210	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2550-2583.	2.8	114
211	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	2.8	2,027
212	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology, 2011, 58, 2432-2446.	2.8	700
213	Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis. Clinical Gastroenterology and Hepatology, 2011, 9, 762-768.e6.	4.4	136
214	Gastrointestinal effects of aspirin. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 385-394.	17.8	107
215	Effects of Proton Pump Inhibitors on Adverse Gastrointestinal Events in Patients Receiving Clopidogrel. Drug Safety, 2011, 34, 47-57.	3.2	36
216	Should Prophylactic Low-dose Aspirin Therapy be Continued in Peptic Ulcer Bleeding?. Drugs, 2011, 71, 1-10.	10.9	17
217	Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer. Drugs, 2011, 71, 255-261.	10.9	11
218	Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine, 2011, 364, 829-841.	27.0	2,182
219	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds â€“Gastrointestinal Adverse Effects. Drugs in R and D, 2011, 11, 277-288.	2.2	38
220	Promoting Wellness for Patients on Androgen Deprivation Therapy: Why Using Numerous Drugs for Drug Side Effects Should Not Be First-Line Treatment. Urologic Clinics of North America, 2011, 38, 303-312.	1.8	8
221	Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets, 2011, 22, 179-187.	2.3	22
222	Cost-effectiveness of oral antiplatelet agentsâ€“current and future perspectives. Nature Reviews Cardiology, 2011, 8, 580-591.	13.7	8
223	Cellular and Molecular Mechanisms Associated with Salicylate Inhibition of Intimal Hyperplasia Following Balloon Catheter-Induced Vascular Injury. , 2011, , 305-314.		0

#	ARTICLE	IF	CITATIONS
224	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal, 2011, 161, 450-461.	2.7	30
225	Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. American Heart Journal, 2011, 161, 719-725.	2.7	40
226	Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. American Heart Journal, 2011, 162, 115-124.e2.	2.7	125
227	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2011, 162, 98-105.e1.	2.7	41
228	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitusâ€“Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal, 2011, 162, 818-825.e6.	2.7	98
229	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2011, 124, 621-629.	1.5	134
230	Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake. Clinica Chimica Acta, 2011, 412, 1366-1370.	1.1	7
231	Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemporary Clinical Trials, 2011, 32, 909-915.	1.8	38
232	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2011, 27, S1-S59.	1.7	106
233	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology, 2011, 27, 208-221.	1.7	50
234	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	1.7	127
235	Antiplatelet therapy in the perioperative period. European Journal of Internal Medicine, 2011, 22, 26-31.	2.2	25
236	A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. Journal of Clinical Epidemiology, 2011, 64, 949-967.	5.0	150
238	Aspirin in the primary prevention of cardiovascular disease. Maturitas, 2011, 68, 3-4.	2.4	4
240	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	2.2	2,995
241	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. Cardiology Clinics, 2011, 29, 47-70.	2.2	19
242	Acceptance of a Polypill Approach to Prevent Cardiovascular Disease Among a Sample of U.S. Physicians. Preventive Medicine, 2011, 52, 10-15.	3.4	102
243	The Polypill in the prevention of cardiovascular disease. Preventive Medicine, 2011, 52, 16-17.	3.4	19

#	ARTICLE	IF	CITATIONS
244	Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thrombosis Research, 2011, 128, 47-53.	1.7	32
245	Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. Thrombosis Research, 2011, 128, 547-551.	1.7	14
246	Aspirin resistance and platelet turnover: A 25-year old issue. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 542-545.	2.6	19
247	European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary. Diabetes and Metabolism, 2011, 37, S27-S38.	2.9	266
248	Oral versus depot antipsychotic drugs for schizophreniaâ€”A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 2011, 127, 83-92.	2.0	397
249	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal. 2011, 32, 2851-2906.	2.2	1,394
250	Acid-NSAID/Aspirin Interaction in Peptic Ulcer Disease. Digestive Diseases, 2011, 29, 465-468.	1.9	18
252	Black soybean extract can attenuate thrombosis through inhibition of collagen-induced platelet activation. Journal of Nutritional Biochemistry, 2011, 22, 964-970.	4.2	40
254	Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, The, 2011, 377, 31-41.	13.7	1,326
255	Addressing the complexity of disparities in stillbirths. Lancet, The, 2011, 377, 1635-1636.	13.7	20
256	Science as a public enterprise: the case for open data. Lancet, The, 2011, 377, 1633-1635.	13.7	110
257	Aspirin in the prevention of cancer. Lancet, The, 2011, 377, 1649.	13.7	9
258	Aspirin in the prevention of cancer â€” Author's reply. Lancet, The, 2011, 377, 1651-1652.	13.7	2
259	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice, 2011, 17, 1-53.	2.1	387
260	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2011, , 1147-1172.		1
263	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan: Executive Summary. Endocrine Practice, 2011, 17, 287-302.	2.1	80
264	The role of aspirin in women’s health. International Journal of Women's Health, 2011, 3, 151.	2.6	3
265	Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?. Cardiovascular & Hematological Disorders Drug Targets, 2011, 11, 9-16.	0.7	2

#	ARTICLE	IF	CITATIONS
266	Diabetes and Aspirin Resistance. , 2011, , .		2
267	Pharmacologie et Thérapeutique Vasculaire. , 2011, , 687-843.		0
268	ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID. Rational Pharmacotherapy in Cardiology, 2011, 7, 492-500.	0.8	0
269	Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs. International Journal of Vascular Medicine, 2011, 2011, 1-5.	1.0	11
270	Antiplatelet combinations for prevention of atherothrombotic events. Vascular Health and Risk Management, 2011, 7, 23.	2.3	6
271	Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse. PLoS ONE, 2011, 6, e20062.	2.5	36
272	Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thrombosis and Haemostasis, 2011, 106, 491-499.	3.4	113
273	The autoimmune concept of atherosclerosis. Current Opinion in Lipidology, 2011, 22, 327-334.	2.7	86
274	Clinical practice and implications of recent diabetes trials. Current Opinion in Cardiology, 2011, 26, 288-293.	1.8	8
275	How to Stay Heart Healthy in 2011: Considerations for the Primary Prevention of Cardiovascular Disease in Women. Women's Health, 2011, 7, 433-451.	1.5	9
276	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management, 2011, 1, 615-626.	0.5	0
277	Antiplatelet Therapy in Acute Coronary Syndromes. Journal of Cardiovascular Nursing, 2011, 26, 239-249.	1.1	2
278	Overlooking Cardiovascular Risk in Patients With COPD. Chest, 2011, 140, 1385-1386.	0.8	1
279	Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists. Current Drug Targets, 2011, 12, 1805-1812.	2.1	4
280	Low-dose ASA Use for Primary Prevention of Cardiovascular Disease in Patients without Diabetes: When Should You Recommend it? A Case-Based Approach. Canadian Pharmacists Journal, 2011, 144, 278-286.e1.	0.8	0
281	Antiplatelet therapy in elderly patients. Aging Health, 2011, 7, 311-320.	0.3	2
282	Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis, 2011, 18, 431-442.	2.0	46
283	Aspirin for prevention of cancer and cardiovascular disease. British Journal of General Practice, 2011, 61, 412-415.	1.4	17

#	ARTICLE	IF	CITATIONS
284	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis. American Journal of the Medical Sciences, 2011, 341, 1-9.	1.1	42
285	Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis. British Journal of General Practice, 2011, 61, e556-e564.	1.4	9
287	Conflicting clinical environment about the management of antithrombotic agents during the perendoscopic period in Japan. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, no-no.	2.8	16
288	Antiplatelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual antiplatelet therapy. British Journal of Clinical Pharmacology, 2011, 72, 619-633.	2.4	172
289	TP receptor antagonists (TXRAs): expensive irrelevance or wonder drugs strangled at birth?. British Journal of Clinical Pharmacology, 2011, 71, 801-803.	2.4	4
290	Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Alimentary Pharmacology and Therapeutics, 2011, 34, 243-251.	3.7	27
291	Prescribing for older people in nursing homes: a review of the key issues. International Journal of Older People Nursing, 2011, 6, 45-54.	1.3	18
292	The health of European medical research. EMBO Reports, 2011, 12, 110-112.	4.5	7
293	The Role of Antiplatelets in Hypertension and Diabetes Mellitus. Journal of Clinical Hypertension, 2011, 13, 305-313.	2.0	9
294	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. Journal of Clinical Hypertension, 2011, 13, 244-251.	2.0	333
295	Atherothrombosis and the role of antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2011, 9, 325-332.	3.8	21
296	Historical perspective and future directions in platelet research. Journal of Thrombosis and Haemostasis, 2011, 9, 374-395.	3.8	80
297	Novel platelet antiaggregants and the changing landscape of stroke prevention. Lancet Neurology, The, 2011, 10, 678-680.	10.2	5
298	Management of Abdominal Aortic Aneurysms Clinical Practice Guidelines of the European Society for Vascular Surgery. European Journal of Vascular and Endovascular Surgery, 2011, 41, S1-S58.	1.5	1,204
299	Best Medical Therapy or Wishful Thinking in Carotid Disease? A Single-centre Audit in Germany. European Journal of Vascular and Endovascular Surgery, 2011, 41, 501-506.	1.5	6
300	Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin. American Journal of Cardiology, 2011, 107, 1796-1801.	1.6	149
301	The Link Between Erectile and Cardiovascular Health: The Canary in the Coal Mine. American Journal of Cardiology, 2011, 108, 599-606.	1.6	77
302	Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 2011, 32, 2922-2932.	2.2	203

#	ARTICLE	IF	CITATIONS
303	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	1.7	97
304	Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. BMJ: British Medical Journal, 2011, 343, d4264-d4264.	2.3	9
305	Effect of gender difference on platelet reactivity. Netherlands Heart Journal, 2011, 19, 451-457.	0.8	67
306	Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. American Heart Journal, 2011, 162, 166-172.e1.	2.7	38
307	Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study. Cardiovascular Drugs and Therapy, 2011, 25, 551-560.	2.6	10
308	The MAGIC Study and the Gastrointestinal Effects of Low-Dose Aspirin. Cardiovascular Drugs and Therapy, 2011, 25, 503-504.	2.6	1
309	Controversies in neurology: asymptomatic carotid stenosis—intervention or just stick to medical therapy. The argument for carotid endarterectomy. Journal of Neural Transmission, 2011, 118, 631-636.	2.8	2
312	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia, 2011, 54, 2237-2246.	6.3	55
313	Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports, 2011, 5, 86-95.	2.0	0
314	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. Current Cardiovascular Risk Reports, 2011, 5, 280-286.	2.0	0
315	Antiplatelet Agents for Stroke Prevention. Neurotherapeutics, 2011, 8, 475-487.	4.4	23
317	Update in New Medications for Primary Care. Journal of General Internal Medicine, 2011, 26, 427-432.	2.6	0
318	Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis. Journal of General Internal Medicine, 2011, 26, 1336-1344.	2.6	39
319	TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Internal and Emergency Medicine, 2011, 6, 203-212.	2.0	24
320	Current Status of Antiplatelet Agents to Prevent Stroke. Current Neurology and Neuroscience Reports, 2011, 11, 6-14.	4.2	9
321	Primary Thrombosis Prophylaxis in Antiphospholipid Antibody—Positive Patients: Where Do We Stand?. Current Rheumatology Reports, 2011, 13, 59-69.	4.7	66
322	Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Family Practice, 2011, 12, 59.	2.9	66
323	Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health, 2011, 11, 86.	2.9	25

#	ARTICLE	IF	CITATIONS
324	A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies. BMC Health Services Research, 2011, 11, 331.	2.2	62
325	Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovascular Diabetology, 2011, 10, 25.	6.8	49
326	Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. Implementation Science, 2011, 6, 65.	6.9	4
327	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 2011, 54, 1208-1216.	7.3	399
328	Aspirin in low-risk essential thrombocythemia, not so simple after all?. Leukemia Research, 2011, 35, 286-289.	0.8	13
329	Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2011, 4, 473-482.	2.9	35
330	Functional testing methods for the antiplatelet effects of aspirin. Biomarkers in Medicine, 2011, 5, 31-42.	1.4	31
331	Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. American Journal of Veterinary Research, 2011, 72, 1038-1045.	0.6	19
332	Low-dose acetylsalicylic acid and blood pressure control in drug-treated hypertensive patients. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 136-140.	2.8	5
333	Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. Expert Review of Gastroenterology and Hepatology, 2011, 5, 447-455.	3.0	4
334	Gender Differences in the Primary Prevention of Stroke with Aspirin. Women's Health, 2011, 7, 341-353.	1.5	9
335	Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. Archives of Internal Medicine, 2011, 171, 218.	3.8	45
336	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 2362-2364.	27.0	7
337	Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ: British Medical Journal, 2011, 342, d3488-d3488.	2.3	4
338	Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ: British Medical Journal, 2011, 343, d4094-d4094.	2.3	117
339	Concomitant Use of Thrombocyte Aggregation Inhibitors and Proton Pump Inhibitors (PPIs). Zeitschrift Fur Gastroenterologie, 2011, 49, 395-402.	0.5	4
341	Aspirin. Circulation, 2011, 123, 768-778.	1.6	194
342	Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. Cmaj, 2011, 183, 1835-1843.	2.0	125

#	ARTICLE	IF	CITATIONS
343	C-Reactive Protein and High-Sensitivity C-Reactive Protein: An Update for Clinicians. Postgraduate Medicine, 2011, 123, 114-119.	2.0	133
344	Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A $2\pm$ Differently for Cyclooxygenase-1 and 12-Lipoxygenase Catalysis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 435-442.	2.4	56
345	Increased risk of stroke after discontinuation of acetylsalicylic acid. Neurology, 2011, 76, 740-746.	1.1	100
346	Does Diabetes Always Confer Coronary Heart Disease Risk Equivalent to a Prior Myocardial Infarction?: Implications for prevention. Diabetes Care, 2011, 34, 782-784.	8.6	10
347	Antiplatelet Therapy for Every Diabetic Person?. Diabetes Care, 2011, 34, S150-S154.	8.6	17
348	Sex/Gender Differences in Cardiovascular Disease Prevention. Circulation, 2011, 124, 2145-2154.	1.6	777
349	Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?. Therapeutic Advances in Chronic Disease, 2011, 2, 157-160.	2.5	1
350	Migraine and cardiovascular disease in women and the role of aspirin: Subgroup analyses in the Women's Health Study. Cephalgia, 2011, 31, 1106-1115.	3.9	40
351	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Circulation, 2011, 123, 2022-2060.	1.6	321
352	Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2011, 4, 180-187.	3.9	172
353	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Circulation, 2011, 124, 2574-2609.	1.6	500
354	Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate. Diabetes Care, 2011, 34, 280-285.	8.6	39
355	Gastrointestinal Bleeding after Percutaneous Coronary Intervention. Digestion, 2011, 83, 153-160.	2.3	17
356	Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD. Nephron Clinical Practice, 2011, 118, c125-c144.	2.3	14
357	A national survey on aspirin patterns of use and persistence in community outpatients in Italy. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 695-703.	2.8	14
358	Primary Prevention for Cardiovascular Diseases: Can Statins Replace Aspirin?. Medical Principles and Practice, 2011, 20, 584-584.	2.4	1
359	Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes. Circulation, 2011, 123, 1843-1853.	1.6	147
360	Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opinion on Drug Safety, 2011, 10, 45-54.	2.4	28

#	ARTICLE	IF	CITATIONS
361	Salicylate Functions as an Efflux Pump Inducer and Promotes the Emergence of Fluoroquinolone-Resistant <i>Campylobacter jejuni</i> Mutants. <i>Applied and Environmental Microbiology</i> , 2011, 77, 7128-7133.	3.1	48
362	Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients. <i>Therapeutic Advances in Drug Safety</i> , 2011, 2, 263-270.	2.4	18
363	Aspirin about 50 years of age for the primary prevention of disease?. <i>Perspectives in Public Health</i> , 2011, 131, 64-65.	1.6	2
364	Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin. <i>Cerebrovascular Diseases</i> , 2011, 32, 22-27.	1.7	7
365	Lipoprotein(a): Medical Treatment Options for an Elusive Molecule. <i>Current Pharmaceutical Design</i> , 2011, 17, 871-876.	1.9	22
366	Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain?. <i>European Heart Journal</i> , 2011, 32, 1331-1336.	2.2	130
367	My health – whose responsibility? Healthy behaviours and prophylactic drugs. <i>Quality in Ageing and Older Adults</i> , 2011, 12, 50-55.	0.8	0
368	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. <i>BMJ Open</i> , 2011, 1, e000363-e000363.	1.9	28
369	Individual and Population Benefits of Daily Aspirin Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 268-275.	2.2	30
370	The Clinical Relevance of Response Variability to Antiplatelet Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 70-75.	2.5	17
371	Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. <i>European Heart Journal</i> , 2011, 32, 2962-2969.	2.2	36
372	Vulnerable Plaque and Inflammation: Potential Clinical Strategies. <i>Current Pharmaceutical Design</i> , 2011, 17, 4190-4209.	1.9	41
373	Standards of Medical Care in Diabetes – 2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	8.6	2,448
374	Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial. <i>Diabetes Care</i> , 2011, 34, 1277-1283.	8.6	21
375	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
376	Aspirin Treatment Increases the Risk of Cerebral Microbleeds. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 863-868.	0.5	27
377	Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. <i>BMJ: British Medical Journal</i> , 2011, 342, d2690-d2690.	2.3	161
378	Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 272-277.	0.4	83

#	ARTICLE	IF	CITATIONS
379	Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events. American Journal of Gastroenterology, 2011, 106, 741-747.	0.4	205
380	PPI plus aspirin for secondary cardiovascular disease prevention. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 543-545.	17.8	0
381	Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Expert Review of Cardiovascular Therapy, 2011, 9, 1295-1303.	1.5	0
382	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs, 2011, 16, 203-233.	2.4	1
383	Prospects for a Cardiovascular Disease Prevention Polypill. Annual Review of Public Health, 2011, 32, 23-38.	17.4	9
384	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
385	Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales. Health Education Journal, 2011, 70, 296-300.	1.2	1
386	Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bulletin of the World Health Organization, 2011, 89, 286-295.	3.3	41
387	Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews, 2011, 33, 63-87.	3.5	70
388	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation, 2011, 123, 798-813.	1.6	272
389	Laboratory signs of aspirin response in haemodialysis patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 426-431.	1.2	3
390	High Risk of Peripheral Arterial Disease in the United Kingdom: 2-Year Results of a Prospective Registry. Angiology, 2011, 62, 111-118.	1.8	13
391	Health Disparities in Endocrine Disorders: Biological, Clinical, and Nonclinical Factors—An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1579-E1639.	3.6	319
392	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq1 11d.7843 141rgBT /Ov	1.6	14
393	Stroke Prevention: Managing Modifiable Risk Factors. Stroke Research and Treatment, 2012, 2012, 1-15.	0.8	22
394	Drug Trials for Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 152-157.	3.6	35
395	Antiplatelet Therapy in Stroke Prevention. Advances in Cardiology, 2012, 47, 141-154.	2.7	7
396	Between Scylla and Charybdis: antithrombotic therapy in hematopoietic progenitor cell transplant patients. Bone Marrow Transplantation, 2012, 47, 1269-1273.	2.4	6

#	ARTICLE	IF	CITATIONS
397	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-18.	1.1	26
398	Prostanoids, Aspirin, and Related Compounds. , 2012, , 168-171.		0
399	Antithrombotic Therapy. , 2012, , 171-177.		0
400	ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. <i>Heart</i> , 2012, 98, 865-871.	2.9	25
401	Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 245-255.	2.0	22
402	Reducing the Cardiovascular Disease Burden. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 580-586.	2.2	8
403	Primary Prevention of Cardiovascular Disease. <i>InnovAiT</i> , 2012, 5, 195-203.	0.0	9
405	The aspirin controversy in primary prevention. <i>Current Opinion in Cardiology</i> , 2012, 27, 499-507.	1.8	25
406	Aspirin for Primary Prevention of Myocardial Infarction. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 1-8.	2.1	5
407	Novel Antiplatelet Activity of Protocatechuic Acid through the Inhibition of High Shear Stress-Induced Platelet Aggregation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 704-711.	2.5	52
408	Effect of Aspirin on Vascular and Nonvascular Outcomes. <i>Archives of Internal Medicine</i> , 2012, 172, 209.	3.8	252
409	The cardiovascular polypill in high-risk patients. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1234-1242.	1.8	23
410	Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1074-1081.	1.8	12
412	Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?. <i>Current Pharmaceutical Design</i> , 2012, 18, 4358-4369.	1.9	30
413	Ibuprofen, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury. <i>Arzneimittelforschung</i> , 2012, 62, 545-553.	0.4	2
414	Obesity-Driven Inflammation and Colorectal Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 5837-5853.	2.4	35
415	Hyaline Cartilage Tissue Is Formed through the Co-culture of Passaged Human Chondrocytes and Primary Bovine Chondrocytes. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 576-587.	2.5	10
416	Does aspirin increase the risk of major bleeds?. <i>Nature Reviews Cardiology</i> , 2012, 9, 495-496.	13.7	2

#	ARTICLE	IF	CITATIONS
417	Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. <i>Endoscopy</i> , 2012, 44, 114-121.	1.8	100
418	Drugs that Affect Platelet Function. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 865-883.	2.7	125
419	High Platelet Reactivity and Antiplatelet Therapy Resistance. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 200-212.	2.7	49
420	Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 4311-4325.	1.9	17
422	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	2.2	5,034
423	Underuse of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease Events in Women. <i>Journal of Women's Health</i> , 2012, 21, 379-387.	3.3	19
424	Arterial Thromboembolism. <i>Journal of Feline Medicine and Surgery</i> , 2012, 14, 459-470.	1.6	63
425	Overcoming aspirin treatment failure in diabetes. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 183-198.	6.1	9
426	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012, 2, e001925.	1.9	23
427	CVD screening in low-risk, asymptomatic adults: clinical trials needed. <i>Nature Reviews Cardiology</i> , 2012, 9, 599-604.	13.7	38
428	Use of Aspirin postdiagnosis improves survival for colon cancer patients. <i>British Journal of Cancer</i> , 2012, 106, 1564-1570.	6.4	148
429	New lipid and lipoprotein targets for the treatment of cardiometabolic diseases. <i>Journal of Lipid Research</i> , 2012, 53, 1719-1721.	4.2	7
430	Aspirin in the Primary Prevention of Myocardial Infarction. <i>Clinical Chemistry</i> , 2012, 58, 303-304.	3.2	0
431	Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease Among Intermediate-Risk Patients. <i>Circulation</i> , 2012, 125, 260-270.	1.6	22
432	Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. <i>Cancer Prevention Research</i> , 2012, 5, 164-178.	1.5	242
433	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. <i>Future Cardiology</i> , 2012, 8, 503-511.	1.2	5
434	Diabetes in Older Adults. <i>Diabetes Care</i> , 2012, 35, 2650-2664.	8.6	961
435	Knowledge, attitudes and current practice of Jordanian family physicians about prescribing aspirin in primary and secondary prevention of vascular diseases: a self-reported survey. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 9-13.	0.9	4

#	ARTICLE	IF	CITATIONS
436	Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome. Hypertension, 2012, 59, 719-725.	2.7	46
437	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vascular Health and Risk Management, 2012, 8, 77.	2.3	35
438	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry, 2012, 200, 97-106.	2.8	332
439	Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 463-471.	2.2	70
440	Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?. Therapeutic Advances in Drug Safety, 2012, 3, 213-226.	2.4	6
441	Clinical Characteristics and Prognosis of Patients with Intracranial Hemorrhage during Mechanical Ventilation. The Korean Journal of Critical Care Medicine, 2012, 27, 94.	0.2	0
442	Prophylactic aspirin and public health. Journal of Public Health, 2012, 34, 320-321.	1.8	0
443	Benefits and Risks of Aspirin Use—Reply. JAMA - Journal of the American Medical Association, 2012, 308, 1088.	7.4	1
444	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest, 2012, 141, e601S-e636S.	0.8	401
445	The risks and benefits of prophylactic aspirin in vascular disease and cancer. Clinical Investigation, 2012, 2, 1177-1184.	0.0	3
446	Aspirin: A History, A Love Story. The Consultant Pharmacist, 2012, 27, 322-329.	0.4	37
447	Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. European Heart Journal, 2012, 33, 515-522.	2.2	16
448	Pharmacogenetics of the Antiplatelet Effect of Aspirin. Current Pharmaceutical Design, 2012, 18, 5294-5308.	1.9	37
449	Antithrombotic Therapy in Peripheral Artery Disease. Chest, 2012, 141, e669S-e690S.	0.8	204
450	Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome, Transient Ischemic Attack, and Noncardioembolic Stroke in an Era of Cost Containment. Journal of Investigative Medicine, 2012, 60, 792-800.	1.6	3
451	Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future. Current Pharmaceutical Design, 2012, 18, 5215-5223.	1.9	12
452	Organized Blood Pressure Control Programs to Prevent Stroke in Australia. Stroke, 2012, 43, 1370-1375.	2.0	16
453	Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy. Stroke, 2012, 43, 1675-1677.	2.0	49

#	ARTICLE	IF	CITATIONS
454	Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents. Current Pharmaceutical Design, 2012, 18, 850-860.	1.9	3
455	Practical Implications of Nanodosimetry in Medicine. Dose-Response, 2012, 10, dose-response.1.	1.6	1
456	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	1.9	35
457	Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits. Current Pharmaceutical Biotechnology, 2012, 13, 27-36.	1.6	1
458	Platelet Turnover in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5328-5343.	1.9	20
459	New Antithrombotic Drugs. Chest, 2012, 141, e120S-e151S.	0.8	284
460	Aspirin to prevent incident cardiovascular disease: is it causing more damage than it prevents?. Clinical Practice (London, England), 2012, 9, 223-225.	0.1	0
461	Should More Patients Continue Aspirin Therapy Perioperatively?. Annals of Surgery, 2012, 255, 811-819.	4.2	163
462	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, , .		1
463	Aspirin Downregulates Angiotensin Type 1 Receptor Transcription Implications in Capillary Formation From Endothelial Cells. Journal of Cardiovascular Pharmacology, 2012, 60, 187-192.	1.9	6
464	HIV and Africa's elderly. Aids, 2012, 26, S85-S91.	2.2	39
465	Adherence junction proteins in angiogenesis. Journal of Cardiovascular Medicine, 2012, 13, 187-193.	1.5	8
466	Aspirin Reduces Cerebrovascular Events in Type 2 Diabetic Patients With Poorly Controlled Blood Pressure. Circulation Journal, 2012, 76, 1526-1532.	1.6	16
467	Primary and Secondary Prevention of Cardiovascular Disease. Chest, 2012, 141, e637S-e668S.	0.8	435
468	Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health, 2012, 8, 167-177.	0.3	13
470	Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. Annals of Internal Medicine, 2012, 156, 445.	3.9	179
471	Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation. Clinical Investigation, 2012, 2, 747-752.	0.0	1
472	Primary Prevention With Aspirin in Type 2 Diabetic Patients. Circulation Journal, 2012, 76, 1333-1334.	1.6	0

#	ARTICLE	IF	CITATIONS
473	Aspirin-exacerbated respiratory disease: Burden of disease. Allergy and Asthma Proceedings, 2012, 33, 117-121.	2.2	43
474	Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, The, 2012, 379, 1602-1612.	13.7	743
475	Management of Patients With Ulcer Bleeding. American Journal of Gastroenterology, 2012, 107, 345-360.	0.4	616
476	Benefits and Risks of Aspirin Use. JAMA - Journal of the American Medical Association, 2012, 308, 1088.	7.4	2
477	Daily Aspirin Use and Cancer Mortality in a Large US Cohort. Journal of the National Cancer Institute, 2012, 104, 1208-1217.	6.3	79
478	Cardiovascular risk. British Journal of Clinical Pharmacology, 2012, 74, 396-410.	2.4	53
479	Management of Hypertension in People with Diabetes Mellitus: Translating the 2012 Canadian Hypertension Education Program Recommendations into Practice. Canadian Journal of Diabetes, 2012, 36, 345-353.	0.8	4
480	In Vitro and In Vivo Metabolic Studies of Phospho-aspirin (MDC-22). Pharmaceutical Research, 2012, 29, 3292-3301.	3.5	2
481	Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovascular Therapeutics, 2012, 30, e41-50.	2.5	6
482	Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?. Postgraduate Medical Journal, 2012, 88, 34-37.	1.8	7
483	Renal complications of diabetes. British Medical Bulletin, 2012, 104, 113-127.	6.9	29
484	Aspirin for Primary Prevention of Cardiovascular Disease Events. Pharmacotherapy, 2012, 32, 1020-1035.	2.6	34
485	Priming effect of aspirin for tumor cells to augment cytotoxic action of cisplatin against tumor cells: implication of altered constitution of tumor microenvironment, expression of cell cycle, apoptosis, and survival regulatory molecules. Molecular and Cellular Biochemistry, 2012, 371, 43-54.	3.1	12
486	In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. Atherosclerosis, 2012, 221, 478-483.	0.8	3
487	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.8	414
488	Ischemic Stroke in Patients Receiving Aspirin. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 868-872.	1.6	8
489	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 173.	0.6	183
492	The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, S1-S95.	0.2	11

#	ARTICLE	IF	CITATIONS
493	Women and the management of acute coronary syndrome. Canadian Journal of Physiology and Pharmacology, 2012, 90, 1151-1159.	1.4	13
494	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	2.2	5,247
495	Application of 3D Statistical Methods Visualization in the Process of Formulation and Development of Modified Release Tablets with Acetylsalicylic Acid. Biotechnology and Biotechnological Equipment, 2012, 26, 3434-3436.	1.3	0
497	The 2012 SEMDSA Guideline for the Management of type 2 Diabetes. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, S1-S94.	0.2	54
498	Standards of Medical Care in Diabetes—2012. Diabetes Care, 2012, 35, S11-S63.	8.6	1,956
501	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Preventive Cardiology, 2012, 19, 585-667.	1.8	359
502	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española De Cardiología, 2012, 65, 173.e1-173.e55.	1.2	31
503	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Revista Española De Cardiología, 2012, 65, 172.e1-172.e57.	1.2	14
504	Associations between Aspirin Use and Aging Macula Disorder. Ophthalmology, 2012, 119, 112-118.	5.2	46
505	Aspirin Resistance, Platelet Turnover, and Diabetic Angiopathy: A 2011 Update. Thrombosis Research, 2012, 129, 341-344.	1.7	30
506	Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thrombosis Research, 2012, 130, 65-69.	1.7	42
507	Thromboxane Receptors Antagonists and/or Synthase Inhibitors. Handbook of Experimental Pharmacology, 2012, , 261-286.	1.8	50
508	Variability of Platelet Indices and Function: Acquired and Genetic Factors. Handbook of Experimental Pharmacology, 2012, , 395-434.	1.8	14
509	Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents. Handbook of Experimental Pharmacology, 2012, , 565-605.	1.8	9
510	Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Review of Cardiovascular Therapy, 2012, 10, 215-221.	1.5	19
511	Aspirin and Other COX-1 Inhibitors. Handbook of Experimental Pharmacology, 2012, , 137-164.	1.8	24
512	Physicians' Warnings for Unfit Drivers and the Risk of Trauma from Road Crashes. New England Journal of Medicine, 2012, 367, 1228-1236.	27.0	129
513	Hemorrhagic Complications Associated With Aspirin. JAMA - Journal of the American Medical Association, 2012, 307, 2318-20.	7.4	15

#	ARTICLE	IF	CITATIONS
514	Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes. JAMA - Journal of the American Medical Association, 2012, 307, 2286-94.	7.4	202
515	Evidence-based Use of Statins for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2012, 125, 440-446.	1.5	47
516	Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials. American Journal of Medicine, 2012, 125, 560-567.	1.5	58
517	Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology, 2012, 156, 69-75.	1.7	44
518	Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs. Journal of Clinical Epidemiology, 2012, 65, 877-886.	5.0	1
519	Prevention of damage induced by aspirin in the GI tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 153-162.	2.4	12
520	Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 125-140.	2.4	67
521	Balancing the risk and benefits of low-dose aspirin in clinical practice. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 173-184.	2.4	13
522	Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 141-151.	2.4	20
523	Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding. European Journal of Internal Medicine, 2012, 23, 227-230.	2.2	6
524	Attitudes to aspirin use in diabetes in clinical practice: a survey of health care professionals from primary and secondary care settings in the UK. Practical Diabetes, 2012, 29, 232.	0.3	0
525	Mixed methods evaluation of targeted case finding for cardiovascular disease prevention using a stepped wedged cluster RCT. BMC Public Health, 2012, 12, 908.	2.9	13
526	VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy. Chest, 2012, 141, e691S-e736S.	0.8	1,418
527	Update on pharmacology of antiplatelets, anticoagulants, and thrombolytics. Neurology, 2012, 79, S68-76.	1.1	15
528	Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer: A Retrospective Cohort Study. Journal of the American Geriatrics Society, 2012, 60, 2232-2236.	2.6	36
529	Diabetes in Older Adults: A Consensus Report. Journal of the American Geriatrics Society, 2012, 60, 2342-2356.	2.6	417
530	Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1199-1208.	3.3	4
531	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxidants and Redox Signaling, 2012, 17, 1447-1485.	5.4	57

#	ARTICLE	IF	CITATIONS
533	Gender-related differences in the management of hypertension by cardiologists: The PARITE study. Archives of Cardiovascular Diseases, 2012, 105, 271-280.	1.6	16
534	Platelet Biology and Response to Antiplatelet Therapy in Women. Journal of the American College of Cardiology, 2012, 59, 891-900.	2.8	65
535	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq0210 rgBT /Overlock 1	2.8	16
536	Relationship between acute stroke outcome, aspirin resistance, and humoral factors. Journal of the Chinese Medical Association, 2012, 75, 513-518.	1.4	12
537	Aspirin resistance and ischemic stroke outcome: Fact or fiction?. Journal of the Chinese Medical Association, 2012, 75, 549-550.	1.4	1
538	Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. American Journal of Medicine, 2012, 125, 956-962.	1.5	49
540	Cardiovascular Disease in Women. Current Problems in Cardiology, 2012, 37, 450-526.	2.4	51
541	Ischemic nephropathy. Clinical Queries Nephrology, 2012, 1, 268-278.	0.2	0
542	Antiplatelet treatment in primary and secondary stroke prevention in women. European Journal of Internal Medicine, 2012, 23, 580-585.	2.2	21
543	Complicaciones macrovasculares del paciente diab�tico. Medicine, 2012, 11, 1011-1020.	0.0	0
544	No significant association of aspirin use with cerebral microbleeds in the asymptomatic elderly. Journal of the Neurological Sciences, 2012, 319, 56-58.	0.6	16
545	Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nature Reviews Neurology, 2012, 8, 223-235.	10.1	16
547	Advances in monitoring of aspirin therapy. Platelets, 2012, 23, 526-536.	2.3	35
548	Aspirin for the primary prevention of cardiovascular diseases. Internal and Emergency Medicine, 2012, 7, 375-379.	2.0	2
549	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	1.7	224
550	Gu�a europea sobre prevenci�n de la enfermedad cardiovascular en la pr�ctica cl�nica (versi�n 2012). Revista Espan�la De Cardiolog�a, 2012, 65, 937.e1-937.e66.	1.2	30
551	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics, 2012, 1, 223-230.	0.4	3
552	Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins and Other Lipid Mediators, 2012, 98, 48-55.	1.9	7

#	ARTICLE	IF	CITATIONS
553	Aspirin for Primary Prevention of Cardiovascular Events in the Elderly. <i>Drugs and Aging</i> , 2012, 29, 251-258.	2.7	10
554	Polymorphism of the cyclooxygenase-1 gene and aspirin resistance. <i>Cytology and Genetics</i> , 2012, 46, 246-250.	0.5	0
556	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 217-224.	2.2	5
557	Dipyridamole in Antithrombotic Treatment. <i>Advances in Cardiology</i> , 2012, 47, 78-86.	2.7	20
558	Tumor strengths and frailties: Aspiring to prevent colon cancer. <i>Nature Medicine</i> , 2012, 18, 32-33.	30.7	7
559	Aspirin in primary prevention—good news and bad news. <i>Nature Reviews Cardiology</i> , 2012, 9, 262-263.	13.7	19
560	A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke. <i>Annals of Pharmacotherapy</i> , 2012, 46, 688-695.	1.9	32
562	Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. <i>BMC Public Health</i> , 2012, 12, 398.	2.9	58
563	Aspirin Therapy in Primary Prevention. <i>Archives of Internal Medicine</i> , 2012, 172, 217.	3.8	11
564	Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e31642.	2.5	17
565	Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease. <i>Thrombosis</i> , 2012, 2012, 1-7.	1.4	58
566	Aspirin: Pharmacology and Clinical Applications. <i>Thrombosis</i> , 2012, 2012, 1-15.	1.4	48
567	Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. <i>Thrombosis</i> , 2012, 2012, 1-11.	1.4	48
568	Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin. <i>Thrombosis</i> , 2012, 2012, 1-1.	1.4	3
569	Clopidogrel for Atherothrombotic Event Management in Patients with Peripheral Arterial Disease (COOPER) Study: Safety and Efficacy of Clopidogrel versus Ticlopidine in Japanese Patients. <i>Annals of Vascular Diseases</i> , 2012, 5, 364-375.	0.5	10
570	Antithrombotic and thrombolytic therapy for ischemic stroke. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2012, 23, 16-24.	0.1	0
571	Should All High-Risk Patients Receive Acetylsalicylic Acid 81 mg Daily for Primary Prevention of Cardiovascular Disease?. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 148-50.	0.1	0
572	EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 205-210.	0.8	1

#	ARTICLE	IF	CITATIONS
573	Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Journal of Pragmatic and Observational Research, 2012, 3, 1.	1.5	5
574	The Periodic Health Examination. , 2012, , 52-56.		0
575	ACETYLSALICYLIC ACID: DO WE KNOW EVERYTHING ABOUT IT AND ITS PROPER USE?. Rational Pharmacotherapy in Cardiology, 2012, 8, 708-716.	0.8	1
576	Does Low Dose Aspirin Increase Gastrointestinal Bleeding?. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2012, 59, 324.	0.4	1
577	ACETYLSALICYLIC ACID IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS. Rational Pharmacotherapy in Cardiology, 2012, 8, 237-241.	0.8	0
578	Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thrombosis and Haemostasis, 2012, 108, 140-147.	3.4	17
580	Aspirin and cancer prevention. BMJ, The, 2012, 344, e2480-e2480.	6.0	7
581	Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Archives of Medical Science, 2012, 1, 57-62.	0.9	18
582	A Sociocultural Approach to Narcissism: The Case of Modern China. European Journal of Personality, 2012, 26, 529-535.	3.1	179
583	Antiplatelet Drugs. Chest, 2012, 141, e89S-e119S.	0.8	318
584	The role of aspirin in cancer prevention. Nature Reviews Clinical Oncology, 2012, 9, 259-267.	27.6	424
585	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.8	891
586	Are sirtuins viable targets for improving healthspan and lifespan?. Nature Reviews Drug Discovery, 2012, 11, 443-461.	46.4	339
587	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	1.7	157
588	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Clinical Cardiology, 2012, 35, 722-729.	1.8	19
590	Aspirin in the primary prevention of cardiovascular disease in the Womenâ€™s Health Study: Effect of noncompliance. European Journal of Epidemiology, 2012, 27, 431-438.	5.7	13
591	NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacology, 2012, 20, 159-167.	3.9	7
592	Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria. International Journal of Clinical Pharmacy, 2012, 34, 481-489.	2.1	10

#	ARTICLE	IF	CITATIONS
593	Stroke prevention: an update. <i>Frontiers of Medicine</i> , 2012, 6, 22-34.	3.4	38
595	Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. <i>Journal of Gastroenterology</i> , 2012, 47, 770-774.	5.1	47
597	Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly. <i>International Journal of Clinical Practice</i> , 2012, 66, 2-4.	1.7	1
598	Prospective study of seasonal patterns in hemostatic factors in older men and their relation to excess winter coronary heart disease deaths. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 352-358.	3.8	12
599	Aspirin twice a day keeps new COX-1 at bay. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1217-1219.	3.8	20
600	<i>P2RY1</i> and <i>P2RY12</i> polymorphisms and on- α aspirin platelet reactivity in patients with coronary artery disease. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 473-483.	1.3	34
601	Antiplatelet Therapy for Transient Ischemic Attack. <i>Journal of Clinical Hypertension</i> , 2012, 14, 103-111.	2.0	3
602	WOMEN'S HEALTH BENEFITS OF ASPIRIN THERAPY. <i>Journal of Midwifery and Women's Health</i> , 2012, 57, 204-205.	1.3	0
603	Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). <i>BMC Neurology</i> , 2012, 12, 3.	1.8	36
604	Platelet proteomics. <i>Mass Spectrometry Reviews</i> , 2012, 31, 331-351.	5.4	43
605	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, S100-7.	4.1	5
606	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 57-68.	0.9	3
607	Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 Diabetes. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 62-70.	2.0	0
608	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 41-51.	2.4	4
609	Anticoagulation in Neurointerventions. <i>Clinical Neuroradiology</i> , 2012, 22, 3-13.	1.9	6
611	Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. <i>Cancer Causes and Control</i> , 2012, 23, 431-444.	1.8	29
612	Hemorrhage after Ischemic Stroke – Relation to Age and Previous Hemorrhage in a Nationwide Cohort of 58 868 Patients. <i>International Journal of Stroke</i> , 2013, 8, 80-86.	5.9	10
613	Assaying the efficacy of dual-antiplatelet therapy: use of a controlled-shear-rate microfluidic device with a well-defined collagen surface to track dynamic platelet adhesion. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 4823-4834.	3.7	13

#	ARTICLE	IF	CITATIONS
614	Aspirin in the Secondary Prevention of Cardiovascular Disease. New England Journal of Medicine, 2013, 368, 204-205.	27.0	22
616	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. American Heart Journal, 2013, 166, 282-289.e1.	2.7	49
618	Genetics of Coagulation: What the Cardiologist Needs to Know. Canadian Journal of Cardiology, 2013, 29, 75-88.	1.7	7
619	Handbook of Clinical Nutrition and Stroke. , 2013, , .		7
620	Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men. Journal of General Internal Medicine, 2013, 28, 1483-1491.	2.6	17
621	Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study. Journal of General Internal Medicine, 2013, 28, 216-222.	2.6	27
622	Is There Enough Evidence for Aspirin in High-Risk Groups?. Current Colorectal Cancer Reports, 2013, 9, 9-16.	0.5	1
623	The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. Journal of Cardiovascular Translational Research, 2013, 6, 388-397.	2.4	5
624	Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance. Cardiovascular Drugs and Therapy, 2013, 27, 341-357.	2.6	12
625	Follow-up of aspirin-resistant patients with end-stage kidney disease. International Urology and Nephrology, 2013, 45, 1097-1102.	1.4	9
626	Aspirin Therapy and Risk of Subdural Hematoma: Meta-analysis of Randomized Clinical Trials. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 444-448.	1.6	38
627	Treatment of NSTEMI (Non-ST Elevation Myocardial Infarction). Current Emergency and Hospital Medicine Reports, 2013, 1, 18-28.	1.5	1
628	Towards a global brief on aspirin. Lancet, The, 2013, 381, 1344-1345.	13.7	4
631	Effective, selective and specific inhibition of COX-1 may overcome the "aspirin paradox". Thrombosis Research, 2013, 132, 1-2.	1.7	6
632	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. International Journal of Cardiology, 2013, 170, 30-35.	1.7	29
633	Prevención secundaria en el paciente coronario. EMC - Tratado De Medicina, 2013, 17, 1-8.	0.0	0
635	Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, 709-716.	0.4	77
636	Is type 2 diabetes really a coronary heart disease risk equivalent?. Vascular Pharmacology, 2013, 59, 11-18.	2.1	30

#	ARTICLE	IF	CITATIONS
637	El Ácido acetilsalicílico continúa siendo objeto de investigación y debate 115 años después de su síntesis. Revista Española De Cardiología, 2013, 66, 251-254.	1.2	3
638	Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. European Heart Journal, 2013, 34, 3403-3411.	2.2	71
640	Vascular effects of nonsteroidal antiinflammatory drugs. Joint Bone Spine, 2013, 80, 358-362.	1.6	26
641	Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics, 2013, 2, 499-513.	0.4	1
643	New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thrombosis Research, 2013, 131, 320-324.	1.7	25
644	Relation of Aspirin Response to Age in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 212-216.	1.6	12
645	Management of GI emergencies: Peptic ulcer acute bleeding. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 639-647.	2.4	11
646	Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis. Revista Española De Cardiología (English Ed), 2013, 66, 251-254.	0.6	0
647	The influence of conjugates isolated from Matricaria chamomilla L. on platelets activity and cytotoxicity. International Journal of Biological Macromolecules, 2013, 61, 218-229.	7.5	44
648	Aspirin Hydrolysis in Plasma Is a Variable Function of Butyrylcholinesterase and Platelet-activating Factor Acetylhydrolase 1b2 (PAFAH1b2). Journal of Biological Chemistry, 2013, 288, 11940-11948.	3.4	34
649	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal, 2013, 34, 2444-2452.	2.2	282
650	Role of Aspirin in Cancer Prevention. Current Oncology Reports, 2013, 15, 533-540.	4.0	88
651	On the importance of global cardiovascular risk assessment in people with type 2 diabetes. Primary Care Diabetes, 2013, 7, 95-102.	1.8	21
652	Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications. Circulation, 2013, 128, 2309-2317.	1.6	80
654	Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 514-524.	2.0	23
658	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
659	Drug treatments in the secondary prevention of ischaemic stroke. Maturitas, 2013, 76, 267-271.	2.4	4
660	Perioperative management of antiplatelet therapy. British Journal of Anaesthesia, 2013, 111, i3-i17.	3.4	81

#	ARTICLE	IF	CITATIONS
661	Cardiovascular Pharmacology Core Reviews. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 505-513.	2.0	12
662	Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang. Trials, 2013, 14, 354.	1.6	16
663	Effects of a multifaceted intervention on cardiovascular risk factors in high-risk hypertensive patients: the ESCAPE trial, a pragmatic cluster randomized trial in general practice. Trials, 2013, 14, 318.	1.6	8
664	Protocol for assessing the hypotensive effect of evening administration of acetylsalicylic acid: study protocol for a randomized, cross-over controlled trial. Trials, 2013, 14, 236.	1.6	4
665	Elevated blood pressure and analgesic overuse in chronic daily headache: an outpatient clinic-based study from China. Journal of Headache and Pain, 2013, 14, 51.	6.0	8
666	Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Research and Therapy, 2013, 10, 29.	1.7	50
668	Gender Differences in Cardiovascular Therapy: Focus on Antithrombotic Therapy and Percutaneous Coronary Intervention. Drugs, 2013, 73, 1921-1933.	10.9	19
669	The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?. Clinical Investigation, 2013, 3, 447-449.	0.0	3
670	Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD. JAMA - Journal of the American Medical Association, 2013, 310, 918.	7.4	330
671	The Metabolic Syndrome. , 2013, , .		11
673	Platelet Antiaggregants in Stroke Prevention. Neurologic Clinics, 2013, 31, 633-657.	1.8	7
674	The Time Has Arrived for Sex-Specific Reporting of Research Results. Current Cardiovascular Risk Reports, 2013, 7, 427-428.	2.0	0
675	Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management. American Journal of Cardiovascular Drugs, 2013, 13, 27-35.	2.2	7
676	Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets, 2013, 24, 615-624.	2.3	35
677	Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan. Scandinavian Journal of Gastroenterology, 2013, 48, 320-325.	1.5	20
678	Effect of Low-Dose Aspirin on Functional Outcome From Cerebral Vascular Events in Women. Stroke, 2013, 44, 432-436.	2.0	19
679	Novel Antiplatelet Therapies. , 2013, , 1185-1213.		4
680	GRADE guidelines: 12. Preparing Summary of Findings tablesâ€”binary outcomes. Journal of Clinical Epidemiology, 2013, 66, 158-172.	5.0	618

#	ARTICLE	IF	CITATIONS
681	Drug Resistance and Pseudoresistance. <i>Circulation</i> , 2013, 127, 377-385.	1.6	187
682	Genetic Polymorphisms of <i>HO-1</i> and <i>COX-1</i> Are Associated With Aspirin Resistance Defined by Light Transmittance Aggregation in Chinese Han Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 513-521.	1.7	19
683	Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. <i>Cardiovascular Therapeutics</i> , 2013, 31, 45-52.	2.5	8
684	Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2013, 121, 1701-1711.	1.4	78
685	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	2.8	370
687	Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 9-18.	2.2	12
689	Discontinuation of Low-Dose Aspirin Therapy After Peptic Ulcer Bleeding Increases Risk of Death and Acute Cardiovascular Events. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 38-42.	4.4	76
690	Vascular Protection in People with Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S100-S104.	0.8	28
691	Whole-Body Magnetic Resonance Angiography (WBMRA) as a tool for driving efficiency in the cost and treatment of Claudication Co-morbidities. <i>Health Policy and Technology</i> , 2013, 2, 181-187.	2.5	4
692	Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?. <i>Cor Et Vasa</i> , 2013, 55, e190-e195.	0.1	1
693	Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. <i>Thrombosis Research</i> , 2013, 131, 198-203.	1.7	15
694	Survey response of oral and maxillofacial surgeons on invasive procedures in patients using antithrombotic medication. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2013, 42, 502-507.	1.5	18
696	Cytoreduction plus low-dose aspirin versus cyto reduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. <i>British Journal of Haematology</i> , 2013, 161, 865-871.	2.5	27
697	Antiplatelet effects of dietary nitrate in healthy volunteers: Involvement of cGMP and influence of sex. <i>Free Radical Biology and Medicine</i> , 2013, 65, 1521-1532.	2.9	97
698	Protection vasculaire chez les personnes diabétiques. <i>Canadian Journal of Diabetes</i> , 2013, 37, S474-S478.	0.8	1
699	Effect of Baseline Gastrointestinal Risk and Use of Proton Pump Inhibitors on Frequency of Discontinuation of Aspirin for Secondary Cardiovascular Prevention in United Kingdom Primary Care. <i>American Journal of Cardiology</i> , 2013, 112, 1075-1082.	1.6	15
701	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española de Cardiología</i> , 2013, 66, 880.e1-880.e64.	1.2	24
703	Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: Subanalysis from the JPAD Trial. <i>Journal of Cardiology</i> , 2013, 62, 165-170.	1.9	15

#	ARTICLE	IF	CITATIONS
704	Regular Aspirin Use and Risk of Age-Related Macular Degeneration. American Journal of Ophthalmology, 2013, 156, 213-217.e2.	3.3	8
705	Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes. American Journal of Cardiology, 2013, 112, 737-745.	1.6	33
707	Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: Methods and participant characteristics for the Heart to Health study. Contemporary Clinical Trials, 2013, 36, 394-405.	1.8	16
708	Comentarios del Comit�� Espa��ol Interdisciplinario de Prevenci��n Cardiovascular (CEIPC) a las Gu��as Europeas de Prevenci��n Cardiovascular 2012. Hipertension Y Riesgo Vascular, 2013, 30, 143-155.	0.6	22
709	Aspirin and Clopidogrel for Prevention of Ischemic Stroke. Current Neurology and Neuroscience Reports, 2013, 13, 327.	4.2	14
710	Aspirin in the Treatment and Prevention of Cardiovascular Disease: Past and Current Perspectives and Future Directions. American Journal of Medicine, 2013, 126, 373-378.	1.5	38
711	Atherothrombosis and Coronary Artery Disease. , 2013, , 653-668.		0
714	The Association of Aspirin Use With Age-Related Macular Degeneration. JAMA Internal Medicine, 2013, 173, 258.	5.1	50
715	The aspirin cardiovascular/gastrointestinal risk calculator â��a tool to aid clinicians in practice. Alimentary Pharmacology and Therapeutics, 2013, 37, 738-748.	3.7	36
716	The Indication for Antithrombotic Primary Prophylaxis and Treatment in Case of Thromboembolic Complications in Patients with Metabolic Syndrome. , 2013, , 155-164.		0
717	Standards of Medical Care in Diabetes��2013. Diabetes Care, 2013, 36, S11-S66.	8.6	3,076
719	Low-dose acetylsalicylic acid therapy monitored with ultra high performance liquid chromatography. Clinical Biochemistry, 2013, 46, 988-992.	1.9	8
720	Antiplatelet agents for chronic kidney disease. , 2013, , CD008834.		61
721	<scp>KHA��CARL</scp> Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrology, 2013, 18, 340-350.	1.6	137
722	Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: A randomized multicenter study. Pharmacological Research, 2013, 74, 7-22.	7.1	29
723	Vorapaxar prevents progression of peripheral artery disease. Nature Reviews Cardiology, 2013, 10, 367-368.	13.7	1
724	A Brief Review of 50 Years of Perioperative Thrombosis and Hemostasis Management. Seminars in Hematology, 2013, 50, 79-87.	3.4	11
725	Coronary and carotid atherosclerosis: Similarities and differences. Atherosclerosis, 2013, 227, 193-200.	0.8	131

#	ARTICLE	IF	CITATIONS
726	Combination Aspirin and Clopidogrel for Secondary Prevention of Ischemic Stroke. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 348-359.	0.9	10
727	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. Canadian Journal of Cardiology, 2013, 29, S60-S70.	1.7	11
728	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	1.5	355
729	Antithrombotic Therapy in Atrial Fibrillation. Hospital Medicine Clinics, 2013, 2, e1-e31.	0.2	0
730	Optimizing the Use of Aspirin for Cardiovascular Prevention. Drugs, 2013, 73, 803-814.	10.9	13
732	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. American Journal of Cardiovascular Drugs, 2013, 13, 233-250.	2.2	36
733	Therapeutic Angiogenesis in Critical Limb Ischemia. Angiology, 2013, 64, 466-480.	1.8	41
734	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
735	Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1335-1347.	3.3	4
736	Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding – a cohort study of the effects of proton pump inhibitor use patterns. Journal of Internal Medicine, 2013, 274, 371-380.	6.0	15
739	Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. Circulation, 2013, 128, 721-728.	1.6	132
740	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
741	Evolving management of symptomatic chronic subdural hematoma: experience of a single institution and review of the literature. Neurological Research, 2013, 35, 233-242.	1.3	39
742	Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open, 2013, 3, e002688.	1.9	18
743	Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke. European Heart Journal, 2013, 34, 2760-2767.	2.2	31
744	Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open, 2013, 3, e003044.	1.9	24
745	Medical Treatment of Peripheral Artery Disease. , 2013, , 242-258.		6
746	Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. Journal of Neurosurgery, 2013, 118, 94-103.	1.6	81

#	ARTICLE	IF	CITATIONS
747	Use of Antiplatelet Agents in Patients With Atherosclerotic Disease. <i>Postgraduate Medicine</i> , 2013, 125, 19-30.	2.0	2
748	Antithrombotic drugs and risk of hemorrhagic stroke in the general population. <i>Neurology</i> , 2013, 81, 566-574.	1.1	129
749	Development and Validation of RP-HPLC Method for Simultaneous Estimation of Aspirin and Esomeprazole Magnesium in Tablet Dosage Form. <i>Journal of Chemistry</i> , 2013, 2013, 1-5.	1.9	9
750	Correlation between Platelet Gelsolin and Platelet Activation Level in Acute Myocardial Infarction Rats and Intervention Effect of Effective Components of Chuanxiong Rhizome and Red Peony Root. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-7.	1.2	11
751	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- ∞ ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
752	Is it worth offering cardiovascular disease prevention to the elderly?. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 121-126.	1.8	10
753	The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 771-778.	1.8	16
755	Stroke Pharmacogenetics. , 2013, , 223-297.		0
756	Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding. <i>Evidence-based Nursing</i> , 2013, 16, 55-56.	0.2	0
757	Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of Myocardial Infarction: A Randomised Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-9.	1.2	50
758	Anticoagulant and antiplatelet therapy in patients with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 624-628.	2.0	15
759	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.5	4,251
760	Is aspirin still the drug of choice for management of patients with peripheral arterial disease?. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 88-95.	1.4	16
761	Global Cardiovascular Therapy. , 2013, , 75-82.		0
762	Relationship of Aspirin Use With Age-Related Macular Degeneration: Association or Causation?. <i>JAMA Internal Medicine</i> , 2013, 173, 264.	5.1	8
763	Colorectal cancer prevention: screening and the role of aspirin. <i>Colorectal Cancer</i> , 2013, 2, 429-439.	0.8	1
764	Acute right ventricular failure caused by concomitant coronary and pulmonary embolism: successful treatment with endovascular coronary and pulmonary thrombectomy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 131-136.	1.0	15
765	State-of-the-art management of acute bleeding peptic ulcer disease. <i>Saudi Journal of Gastroenterology</i> , 2013, 19, 195.	1.1	12

#	ARTICLE	IF	CITATIONS
766	The under-use of aspirin for secondary prophylaxis of vascular events. Health Education Journal, 2013, 72, 3-4.	1.2	0
767	Results From a Carotid Intima-Media Thickness Trial as a Decision Tool for Launching a Large-Scale Morbidity and Mortality Trial. Circulation: Cardiovascular Imaging, 2013, 6, 20-25.	2.6	23
768	Statins for primary prevention of cardiovascular disease. Current Opinion in Cardiology, 2013, 28, 554-560.	1.8	47
769	Platelet microRNAs. Circulation Research, 2013, 112, 576-578.	4.5	4
770	Will the epidemic of metabolic syndrome raise the prevalence of antiplatelet drug resistance?. International Journal of Applied & Basic Medical Research, 2013, 3, 75.	0.5	1
771	Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences. Journal of Medical Screening, 2013, 20, 125-148.	2.3	33
772	Advances in Our Understanding of "Resistance" to Antiplatelet Agents for Prevention of Ischemic Stroke. Stroke Research and Treatment, 2013, 2013, 1-7.	0.8	11
773	An Ensemble Topic Model for Sharing Healthcare Data and Predicting Disease Risk. , 2013, , .		12
774	Web application testing in fifteen years of WSE. , 2013, , .		1
775	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
776	Over The Counter Drugs (and Dietary Supplement) Exercise: A Team-Based Introduction to Biochemistry for Health Professional Students. Biochemistry and Molecular Biology Education, 2013, 41, 384-387.	1.2	4
777	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Future Cardiology, 2013, 9, 785-797.	1.2	4
778	Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials. Recent Results in Cancer Research, 2013, 191, 67-93.	1.8	38
779	Impact and Diagnosis of Antiplatelet Therapy Resistance in Patients Undergoing Cardiac Surgery. Drug Development Research, 2013, 74, 492-504.	2.9	1
780	Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 omeprazole 40Âmg " a randomised, phase 1, crossover study. Alimentary Pharmacology and Therapeutics, 2013, 38, 62-71.	3.7	10
781	Antithrombotic Therapy for Prevention of Various Thrombotic Diseases. Drug Development Research, 2013, 74, 568-574.	2.9	12
782	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. Journal of the American Geriatrics Society, 2013, 61, 2027-2037.	2.6	56
783	Continuous Low-Dose Aspirin Therapy in Robotic-Assisted Laparoscopic Radical Prostatectomy Does Not Increase Risk of Surgical Hemorrhage. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2013, 23, 500-505.	1.0	14

#	ARTICLE	IF	CITATIONS
784	Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 176-182.	1.9	46
785	The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 432-439.	3.7	19
786	Utility of whole-blood aggregometry for evaluating antiplatelet therapy for Kawasaki disease. <i>Pediatrics International</i> , 2013, 55, 550-554.	0.5	4
787	Management of the patient with diabetes and coronary artery disease: a contemporary review. <i>Future Cardiology</i> , 2013, 9, 387-403.	1.2	8
788	Use of antiplatelet drugs in stroke prevention: time for a rethink?. <i>Postgraduate Medical Journal</i> , 2013, 89, 309-310.	1.8	3
789	Reinitiating Aspirin Therapy for Primary Prevention of Cardiovascular Events in a Patient Post-Aspirin-Induced Upper Gastrointestinal Bleed: A Case Report and Review of Literature. <i>Annals of Pharmacotherapy</i> , 2013, 47, e8-e8.	1.9	3
790	A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	1.8	45
791	Identifying determinants of variability to tailor aspirin therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 365-379.	1.5	23
792	Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality. <i>Evidence-Based Medicine</i> , 2013, 18, e14-e14.	0.6	1
793	Are Observational Studies More Informative Than Randomized Controlled Trials in Hypertension?. <i>Hypertension</i> , 2013, 62, 470-476.	2.7	13
794	Peripheral Arterial Disease: Pathophysiology and Therapeutics. <i>Colloquium Series on Integrated Systems Physiology From Molecule To Function</i> , 2013, 4, 1-82.	0.3	0
795	Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). <i>Circulation Journal</i> , 2013, 77, 231-248.	1.6	82
796	Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1298-1304.	3.4	31
797	Clinical importance of antiplatelet drugs in cardiovascular diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 81-96.	1.7	24
798	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013, 19, 1581-1586.	1.9	1
799	Stable Angina Pectoris: Current Medical Treatment. <i>Current Pharmaceutical Design</i> , 2013, 19, 1569-1580.	1.9	7
800	Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets. <i>Current Drug Targets</i> , 2013, 14, 3-12.	2.1	27
801	Stroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1192-1197.	1.5	9

#	ARTICLE	IF	CITATIONS
802	Are we overtreating cardiovascular disease in diabetic patients?. Diabetes Management, 2013, 3, 271-275.	0.5	0
803	High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACS. Thrombosis and Haemostasis, 2013, 109, 799-807.	3.4	5
804	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Thrombosis and Haemostasis, 2013, 110, 777-784.	3.4	7
806	Effect of Low-Dose Aspirin on Primary Prevention of Cardiovascular Events in Japanese Diabetic Patients at High Risk. Circulation Journal, 2013, 77, 3023-3028.	1.6	14
807	Antiplatelet Drugs in Primary and Secondary Prevention of Atherothrombotic Events. Arquivos Brasileiros De Cardiologia, 2013, 100, e78-84.	0.8	6
808	How important is it to keep taking the aspirin?. Thrombosis and Haemostasis, 2013, 110, 1108-1109.	3.4	1
809	Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vascular Health and Risk Management, 2013, 9, 245.	2.3	10
810	A preliminary study: aspirin discontinuation before elective operations; when is the optimal timing?. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 185.	1.1	7
812	Differential Impact of Inflammation on Six Laboratory Assays Measuring Residual Arachidonic Acid-Inducible Platelet Reactivity During Dual Antiplatelet Therapy. Journal of Atherosclerosis and Thrombosis, 2013, 20, 630-645.	2.0	19
813	The Relationship between Fractional Flow Reserve, Platelet Reactivity and Platelet Leukocyte Complexes in Stable Coronary Artery Disease. PLoS ONE, 2013, 8, e83198.	2.5	5
814	Development and use of sulodexide in vascular diseases: implications for treatment. Drug Design, Development and Therapy, 2013, 8, 49.	4.3	93
815	Diabetes in Women. , 2013, , 873-882.		0
816	Vascular Pharmacology. , 2013, , 75-93.		1
817	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
818	Multivessel Disease in the Modern Era of Percutaneous Coronary Intervention. , 0, , .		0
819	ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES. Rational Pharmacotherapy in Cardiology, 2013, 9, 439-443.	0.8	0
820	Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. Journal of Multidisciplinary Healthcare, 2014, 7, 137.	2.7	62
821	The pharmacoeconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after non-cardiac surgery. South African Medical Journal, 2014, 104, 619.	0.6	28

#	ARTICLE	IF	CITATIONS
822	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 169.	2.4	135
823	The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. PLoS ONE, 2014, 9, e89072.	2.5	50
824	Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status. PLoS ONE, 2014, 9, e90286.	2.5	59
825	A Short-Term Effect of Low-Dose Aspirin on Major Hemorrhagic Risks in Primary Prevention: A Case-Crossover Design. PLoS ONE, 2014, 9, e98326.	2.5	6
826	Low-Dose Aspirin for Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. PLoS ONE, 2014, 9, e104179.	2.5	37
827	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. Medical Journal of Australia, 2014, 201, S91-6.	1.7	1
828	Evidence-based benefit of rehabilitation after stroke. , 0, , 601-614.		3
829	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 1142-1150.	3.4	49
830	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Thrombosis and Haemostasis, 2014, 112, 323-331.	3.4	11
831	Suboptimal use of gastroprotective medication in elderly antiplatelet users. Bratislava Medical Journal, 2014, 115, 643-648.	0.8	0
832	The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. Journal of Metabolic Syndrome, 2014, 03, .	0.1	0
835	Evaluation of Differences in Patient and Physician Perception of Benefit and Risks of Aspirin and Antifibrinolytic Therapy in Cardiac Surgery. Anaesthesia and Intensive Care, 2014, 42, 592-598.	0.7	3
837	Physical Activity and Exercise Engagement in Patients Diagnosed with Transient Ischemic Attack and Mild/Non-disabling Stroke: A Commentary on Current Perspectives. Rehabilitation Process and Outcome, 2014, 3, RPO.S12338.	1.6	2
838	A Randomized Controlled Trial of Aspirin and Exertional Heat Stress Activation of Platelets in Firefighters during Exertion in Thermal Protective Clothing. Prehospital Emergency Care, 2014, 18, 359-367.	1.8	24
839	Antiplatelet Therapy May Be Continued After Intracerebral Hemorrhage. Stroke, 2014, 45, 3149-3150.	2.0	22
840	Factors Influencing the Decline in Stroke Mortality. Stroke, 2014, 45, 315-353.	2.0	655
842	Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Medicine, 2014, 12, 115.	5.5	51
843	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors. JAMA - Journal of the American Medical Association, 2014, 312, 2510.	7.4	257

#	ARTICLE	IF	CITATIONS
844	Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2014, 13, 1327-1351.	2.4	260
845	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. Cancer Prevention Research, 2014, 7, 341-350.	1.5	27
846	Platelet RNA as a novel biomarker for the response to antiplatelet therapy. Future Cardiology, 2014, 10, 9-12.	1.2	5
847	Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement. Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34, 902-906.	1.0	8
848	Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization for Primary Prevention: Estimates From the Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 453-460.	2.2	189
849	Effectiveness of cilostazol in transient ischemic attack refractory to aspirin: A report of two cases. Experimental and Therapeutic Medicine, 2014, 7, 739-741.	1.8	2
850	Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thrombosis and Haemostasis, 2014, 111, 131-139.	3.4	12
851	Platelets and their chemokines in atherosclerosis—clinical applications. Frontiers in Physiology, 2014, 5, 294.	2.8	104
852	Inhibiting thrombosis without causing bleeding: can EP3 blockers fulfil the dream?. Cardiovascular Research, 2014, 101, 335-338.	3.8	4
853	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	3.7	24
855	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of Medicine, 2014, 46, 475-489.	3.8	15
856	PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. Expert Review of Cardiovascular Therapy, 2014, 12, 1251-1260.	1.5	2
857	Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiology and Drug Safety, 2014, 23, 43-50.	1.9	235
858	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
859	Drug-Induced Disorders of the Nervous System. , 2014, , 685-711.		3
860	Critical and Acute Limb Ischemia. Angiology, 2014, 65, 137-146.	1.8	41
861	Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16830-16835.	7.1	68
862	Antioxidants Use in Human Cardiovascular Disease “Where Are We? , 2014, , 1473-1478.		0

#	ARTICLE	IF	CITATIONS
863	Guidelines for the Prevention of Stroke in Women. <i>Stroke</i> , 2014, 45, 1545-1588.	2.0	754
864	Sexâ€based differences in cardiac ischaemic injury and protection: therapeutic implications. <i>British Journal of Pharmacology</i> , 2014, 171, 541-554.	5.4	69
865	Suboptimal Inhibition of Platelet Cyclooxygenase 1 by Aspirin in Systemic Lupus Erythematosus: Association With Metabolic Syndrome. <i>Arthritis Care and Research</i> , 2014, 66, 285-292.	3.4	8
866	Impact of aspirin and statins on longâ€term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. <i>European Journal of Heart Failure</i> , 2014, 16, 95-102.	7.1	10
867	Outcome of overt stroke in sickle cell anaemia, a single institution's experience. <i>British Journal of Haematology</i> , 2014, 165, 707-713.	2.5	15
868	New Ischemic Stroke and Outcomes WithâVorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2318-2326.	2.8	30
869	Evolving concepts in the primary prevention of cardiovascular disease: aspirin then and now. <i>Future Cardiology</i> , 2014, 10, 583-586.	1.2	3
870	Role of Clinical Pharmacology in the Development of Antiplatelet Drugs. <i>Clinical Therapeutics</i> , 2014, 36, 2096-2111.	2.5	8
871	2014 AHA/ACC Guideline for the Management of Patients With Nonâ€ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
872	Impact of -455G/A Polymorphism of the Î²-Fibrinogen Gene on Platelet Aggregation in Patients With Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 238-243.	1.7	0
873	Aspirin for Primary Prevention: A Challenging Decision. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	4
874	Cardiovascular disease prevention in diabetes: uncertainties and ethics. <i>Diabetes Management</i> , 2014, 4, 285-292.	0.5	0
875	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 363-371.	0.5	4
876	Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents. <i>BMC Gastroenterology</i> , 2014, 14, 172.	2.0	59
877	Aspirin for Cardioprotection and Strategies to Improve Patient Adherence. <i>Postgraduate Medicine</i> , 2014, 126, 18-28.	2.0	18
878	The Role of Aspirin in the Prevention of Cardiovascular Disease. <i>Clinical Medicine and Research</i> , 2014, 12, 147-154.	0.8	146
879	Aspirin in gastrointestinal oncology. <i>Current Opinion in Oncology</i> , 2014, 26, 441-447.	2.4	33
880	When is the use of aspirin for CVD prevention in women appropriate?. <i>Menopause</i> , 2014, 21, 103-105.	2.0	2

#	ARTICLE	IF	CITATIONS
881	Do patients with chronic kidney disease get optimal cardiovascular risk reduction?. Current Opinion in Nephrology and Hypertension, 2014, 23, 267-274.	2.0	7
882	Oral antiplatelet therapy for acute ischaemic stroke. The Cochrane Library, 2014, , CD000029.	2.8	85
883	Effects of Changing Guidelines on Prescribing Aspirin for Primary Prevention of Cardiovascular Events. Journal of the American Board of Family Medicine, 2014, 27, 78-86.	1.5	11
884	Platelet Disorders. , 2014, , 1553-1561.		1
885	Cyclooxygenase-1 Mediated Platelet Reactivity in Young Male Smokers. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 371-377.	1.7	12
886	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	2.0	173
887	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. Postgraduate Medicine, 2014, 126, 190-204.	2.0	11
888	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 2014, 130, 2354-2394.	1.6	938
889	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. European Journal of Preventive Cardiology, 2014, 21, 1531-1540.	1.8	17
890	Climacteric commentaries. Climacteric, 2014, 17, 308-316.	2.4	1
891	Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2. Cerebrovascular Diseases, 2014, 37, 296-303.	1.7	44
892	Aspirin Use and Aging Macula Disorder. JAMA Ophthalmology, 2014, 132, 9.	2.5	3
893	ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES. Acta Medica (Hradec Kralove), 2014, 57, 157-161.	0.5	2
894	The pharmacogenetics of carboxylesterases: <i>CES1</i> and <i>CES2</i> genetic variants and their clinical effect. Drug Metabolism and Drug Interactions, 2014, 29, 143-151.	0.3	79
895	Carotid Artery Stenting: Second Consensus Document of the ICCS/ISO-SPREAD Joint Committee. Cerebrovascular Diseases, 2014, 38, 77-93.	1.7	9
896	Variation in Restarting Antithrombotic Drugs at Hospital Discharge After Intracerebral Hemorrhage. Stroke, 2014, 45, 2643-2648.	2.0	55
897	When Should Aspirin Be Used for Prevention of Cardiovascular Events?. JAMA - Journal of the American Medical Association, 2014, 312, 2503.	7.4	14
898	A Comparison of Live Counseling With a Web-Based Lifestyle and Medication Intervention to Reduce Coronary Heart Disease Risk. JAMA Internal Medicine, 2014, 174, 1144.	5.1	64

#	ARTICLE	IF	CITATIONS
899	Cost-Effectiveness of Optimal Use of Acute Myocardial Infarction Treatments and Impact on Coronary Heart Disease Mortality in China. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 78-85.	2.2	32
900	Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: A population-based study (CoLaus Study). <i>Cytokine</i> , 2014, 66, 95-100.	3.2	22
901	Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine. <i>Revista Clinica Espanola</i> , 2014, 214, 209-215.	0.6	4
902	Safety of Perioperative Aspirin Therapy in Minimally Invasive Endometrial Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 636-641.	0.6	5
903	Aspirin for prevention of cardiovascular events in bipolar disorders. <i>Psychiatry Research</i> , 2014, 219, 238-239.	3.3	1
904	Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine. <i>Revista Clinica Espanola</i> , 2014, 214, 209-215.	0.5	0
905	Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. <i>Journal of Gastroenterology</i> , 2014, 49, 814-824.	5.1	46
906	Mechanisms of aspirin resistance. , 2014, 141, 69-78.		120
907	Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 190-201.	2.1	7
908	Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 4.	1.7	12
909	Aspirin in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1494-1503.	27.0	735
910	Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. <i>Stroke</i> , 2014, 45, 492-503.	2.0	63
911	Antiplatelet and Anticoagulant Agents in Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 1-14.	4.1	54
912	Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. <i>European Heart Journal</i> , 2014, 35, 837-843.	2.2	54
913	Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. <i>Clinical Research in Cardiology</i> , 2014, 103, 237-245.	3.3	16
914	Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. <i>Netherlands Heart Journal</i> , 2014, 22, 107-112.	0.8	10
915	Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 131-138.	2.1	11
916	Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 16.	1.7	10

#	ARTICLE	IF	CITATIONS
917	Antiplatelet Therapy: Targeting the TxA2 Pathway. Journal of Cardiovascular Translational Research, 2014, 7, 29-38.	2.4	72
918	Joint British Societies'™ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100, ii1-ii67.	2.9	441
919	Incident cancer risk after the start of aspirin use: Results from a Dutch population-based cohort study of low dose aspirin users. International Journal of Cancer, 2014, 135, 157-165.	5.1	20
920	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	2.7	89
921	Triflusal and Aspirin in the Secondary Prevention of Atherothrombotic Ischemic Stroke: A Very Long-Term Follow-Up. Cerebrovascular Diseases, 2014, 37, 181-187.	1.7	10
922	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
923	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal, 2014, 35, 2242-2248.	2.2	42
924	Low-Dose Aspirin and Upper Gastrointestinal Bleeding in Primary Versus Secondary Cardiovascular Prevention: A Population-Based, Nested Case-Control Study. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 70-77.	2.2	16
925	Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: a systematic review. European Journal of Preventive Cardiology, 2014, 21, 1026-1039.	1.8	49
926	An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds. Expert Opinion on Pharmacotherapy, 2014, 15, 153-157.	1.8	9
927	Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thrombosis Research, 2014, 133, 811-816.	1.7	19
928	Secondary stroke prevention. Lancet Neurology, The, 2014, 13, 178-194.	10.2	227
929	Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. European Heart Journal, 2014, 35, 2232-2241.	2.2	248
930	Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiology, 2014, 10, 291-300.	1.2	8
931	Guidelines for the Primary Prevention of Stroke. Stroke, 2014, 45, 3754-3832.	2.0	1,621
932	Drug treatment for diabetes in nursing home residents. Diabetic Medicine, 2014, 31, 570-576.	2.3	12
934	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology, 2014, 53, 275-284.	1.9	71
935	Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients. Open Forum Infectious Diseases, 2014, 1, ofu076.	0.9	29

#	ARTICLE	IF	CITATIONS
936	The Management of Acute Coronary Syndromes in Patients With Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 472-479.	1.4	7
937	Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. <i>Neurology</i> , 2014, 83, 1004-1011.	1.1	10
938	Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. <i>Hypertension Research</i> , 2014, 37, 513-518.	2.7	15
939	Antiplatelet Strategies for Secondary Prevention of Stroke and TIA. <i>Current Atherosclerosis Reports</i> , 2014, 16, 449.	4.8	9
940	Low-dose aspirin use and recurrent gout attacks. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 385-390.	0.9	50
941	The small bowel, low-dose aspirin and PPIs—should we be concerned?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 458-460.	17.8	7
942	Antiplatelet Therapy in the Management of Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 319-323.	2.3	6
943	Aspirin for Primary Cardiovascular Prevention: When is it Worth the Risks?. <i>Hospital Pharmacy</i> , 2014, 49, 502-507.	1.0	1
944	Antiplatelet therapy before, during, and after extremity revascularization. <i>Journal of Vascular Surgery</i> , 2014, 60, 1085-1091.	1.1	10
945	2014 AHA/ACC Guideline for the Management of Patients With Non- ST -Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	2.8	424
946	Functional Neural—Bone Marrow Pathways. <i>Hypertension</i> , 2014, 63, e129-39.	2.7	39
947	Epidemiological studies of CHD and the evolution of preventive cardiology. <i>Nature Reviews Cardiology</i> , 2014, 11, 276-289.	13.7	486
948	Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 360-366.	4.9	23
949	Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. <i>Annals of Medicine</i> , 2014, 46, 335-340.	3.8	2
950	Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin. <i>Gene</i> , 2014, 546, 172-176.	2.2	23
951	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A “state-of-the-art” paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	2.2	78
952	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	2.2	4,141
953	Polymorphisms in Catechol- O -Methyltransferase Modify Treatment Effects of Aspirin on Risk of Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2160-2167.	2.4	35

#	ARTICLE	IF	CITATIONS
954	Aspirin in primary prevention needs individual judgements. <i>Nature Reviews Cardiology</i> , 2014, 11, 438-440.	13.7	16
955	Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 701-707.	2.2	28
956	Aspirin, Clopidogrel, and the Surgeon. <i>Advances in Surgery</i> , 2014, 48, 211-222.	1.3	15
957	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014, 100, 1750-1756.	2.9	33
958	Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. <i>British Journal of Cancer</i> , 2014, 111, 2172-2179.	6.4	37
959	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44.		0
960	Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, e96-e138.	5.8	254
961	Polypharmacy in Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 577-590.	2.1	11
962	Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1776-1787.	3.8	61
963	2014 AHA/ACC Guideline for the Management of Patients With "ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	2.8	2,746
964	Spontaneous intracerebral hemorrhage with antiplatelets/anticoagulants/none: a comparison analysis. <i>Acta Neurochirurgica</i> , 2014, 156, 1319-1325.	1.7	9
965	Diabetes and cardiovascular disease: from evidence to clinical practice " position statement 2014 of Brazilian Diabetes Society. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 58.	2.7	19
966	Association Between Aspirin Use and Age-Related Macular Degeneration: A Meta-Analysis. , 2014, 55, 2687.		18
967	Standards of Medical Care in Diabetes"2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	8.6	3,893
968	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	2.8	150
969	Aspirin resistance as cardiovascular risk after kidney transplantation. <i>Korea Australia Rheology Journal</i> , 2014, 26, 237-241.	1.7	1
970	Neurosurgery for Extracranial Carotid Disease. , 2014, , 1-22.		0
971	A Statin a Day to Keep the Doctor Away? Comparing Aspirin and Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1238-1241.	1.9	7

#	ARTICLE	IF	CITATIONS
972	Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 354-365.	1.8	14
974	Latest developments in antithrombotic therapy in patients with lower extremity arterial disease. <i>Reviews in Vascular Medicine</i> , 2014, 2, 37-42.	0.4	2
975	Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease. <i>Journal of Vascular Surgery</i> , 2014, 59, 950-955.	1.1	19
977	Global Guideline for Type 2 Diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 1-52.	2.8	454
978	Nonsteroidal Anti-Inflammatory Drugs and the Heart. <i>Circulation</i> , 2014, 129, 907-916.	1.6	99
979	Dietary manipulation of platelet function. , 2014, 144, 97-113.		25
980	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. <i>Thrombosis Research</i> , 2014, 133, 1161-1163.	1.7	5
981	Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2014, , CD009868.		57
982	Basis for Sex-Dependent Outcomes in Acute Coronary Syndrome. <i>Canadian Journal of Cardiology</i> , 2014, 30, 713-720.	1.7	41
983	Primary Stroke Prevention. <i>Interventional Cardiology Clinics</i> , 2014, 3, 1-11.	0.4	0
984	5. Secondary Prevention of Cerebral Infarction -Most Useful Antithrombotic Therapy for Japanese Patients. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2014, 103, 115b-116a.	0.0	0
986	In noncardiac surgery, perioperative aspirin did not reduce death or MI at 30 d but increased major bleeding. <i>Annals of Internal Medicine</i> , 2014, 161, JC5.	3.9	1
987	Orally given gastroprotective capsaicin does not modify aspirin-induced platelet aggregation in healthy male volunteers (human phase I examination). <i>Acta Physiologica Hungarica</i> , 2014, 101, 429-437.	0.9	4
989	The risks of communicating sexual offender risk.. <i>Journal of Threat Assessment and Management</i> , 2014, 1, 162-178.	1.2	5
990	Stroke Prevention in Women: Synopsis of the 2014 American Heart Association/American Stroke Association Guideline. <i>Annals of Internal Medicine</i> , 2014, 160, 853.	3.9	44
991	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1041-1049.	3.4	16
992	Women Stroke Association Statement on Stroke. <i>International Journal of Stroke</i> , 2014, 9, 20-27.	5.9	3
993	Clopidogrel for Smokers and Aspirin for Nonsmokers?: Not So Fast. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 585-587.	4.7	1

#	ARTICLE	IF	CITATIONS
994	Separate prediction of intracerebral hemorrhage and ischemic stroke. <i>Neurology</i> , 2014, 82, 1804-1812.	1.1	20
995	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 182-212.	2.3	248
996	Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980â€“2009: The Minnesota Heart Survey. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	36
997	How effective are common medications: a perspective based on meta-analyses of major drugs. <i>BMC Medicine</i> , 2015, 13, 253.	5.5	77
998	Is aspirin use associated with age-related macular degeneration? A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 144-154.	1.5	15
999	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. <i>Clinical Cardiology</i> , 2015, 38, 387-394.	1.8	18
1000	Antiplatelet drugs: which targets for which treatments?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S313-S322.	3.8	47
1002	Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasisâ€” Translation From Basic Science to Clinical Medicine â€”. <i>Circulation Journal</i> , 2015, 79, 1871-1881.	1.6	26
1004	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€” 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	2.1	443
1005	American Association of Clinical Endocrinologists and American College of Endocrinology â€” Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€” 2015 â€” Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 413-437.	2.1	359
1006	GPsâ€™ perspectives on secondary cardiovascular prevention in older age: a focus group study in the Netherlands. <i>British Journal of General Practice</i> , 2015, 65, e739-e747.	1.4	18
1007	Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk. <i>Annals of Internal Medicine</i> , 2015, 163, 347-355.	3.9	139
1008	Use of Health Care System-Supplied Aspirin by Veterans With Postoperative Heart Attack or Unstable Angina. <i>American Journal of the Medical Sciences</i> , 2015, 350, 263-267.	1.1	1
1009	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. <i>Implementation Science</i> , 2015, 11, 129.	6.9	7
1010	Editorial on PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 217-219.	3.0	1
1011	Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 513.	1.6	5
1012	Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 88.	5.3	7
1013	High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2015, 14, 80.	6.8	8

#	ARTICLE	IF	CITATIONS
1014	The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 554.	1.6	57
1015	Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. <i>Thrombosis and Haemostasis</i> , 2015, 114, 498-518.	3.4	60
1016	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , 2015, 114, 876-882.	3.4	17
1017	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2015, 114, 519-529.	3.4	28
1018	Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users. <i>Medicine (United States)</i> , 2015, 94, e1047.	1.0	3
1019	The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. <i>Current Opinion in Cardiology</i> , 2015, 30, 525-535.	1.8	7
1020	Vorapaxar. <i>Cardiology in Review</i> , 2015, 23, 261-267.	1.4	8
1021	Costâ€Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	10
1022	Effect of Aspirin Supplementation on Hemodynamics in Older Firefighters. <i>Medicine and Science in Sports and Exercise</i> , 2015, 47, 2653-2659.	0.4	4
1024	Which people should take aspirin for primary prevention of cardiovascular disease?. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1043.	2.0	0
1025	State of the art paper Does aspirin-induced oxidative stress cause asthma exacerbation?. <i>Archives of Medical Science</i> , 2015, 3, 494-504.	0.9	8
1026	Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?. <i>Vascular Health and Risk Management</i> , 2015, 11, 503.	2.3	4
1027	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	4.7	40
1028	Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. <i>World Journal of Critical Care Medicine</i> , 2015, 4, 40.	1.8	30
1029	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. <i>Italian Journal of Medicine</i> , 2015, 3, 309.	0.3	1
1030	The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients. <i>Italian Journal of Medicine</i> , 2015, 9, 387.	0.3	1
1031	Diabetes and Coronary Artery Disease â€“ Pathophysiologic Insights and Therapeutic Implications. , 2015, , .		1
1032	Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 109-125.	2.0	16

#	ARTICLE	IF	CITATIONS
1033	Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?. International Journal of Molecular Sciences, 2015, 16, 14477-14489.	4.1	14
1034	The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment. Frontiers in Cardiovascular Medicine, 2015, 2, 19.	2.4	73
1035	Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. Journal of Clinical Biochemistry and Nutrition, 2015, 56, 228-239.	1.4	9
1036	New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Therapeutics and Clinical Risk Management, 2015, 11, 1449.	2.0	44
1037	Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2015, 10, e0135692.	2.5	79
1038	Testosterone Replacement Therapy and Cardiovascular Risk: A Review. World Journal of Men's Health, 2015, 33, 130.	3.3	38
1039	Secondary stroke prevention: challenges and solutions. Vascular Health and Risk Management, 2015, 11, 437.	2.3	95
1040	Upper Gastrointestinal Mucosal Injury and Symptoms in Elderly Low-Dose Aspirin Users. Gastroenterology Research and Practice, 2015, 2015, 1-7.	1.5	4
1041	Cancer after intense and prolonged antiplatelet therapies – fact or fiction?. Thrombosis and Haemostasis, 2015, 114, 1100-1103.	3.4	4
1043	Risks and benefits of antiplatelet therapies. British Journal of Cardiac Nursing, 2015, 10, 236-240.	0.1	1
1044	EVALUATION OF THE CONFORMITY OF CARDIOVASCULAR THERAPY TO CURRENT CLINICAL GUIDELINES IN THE IMPROVEMENT OF OUTCOMES IN PATIENTS AFTER STROKE (ACCORDING TO THE LIS-2 REGISTER). Rational Pharmacotherapy in Cardiology, 2015, 11, 247-252.	0.8	5
1045	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. European Heart Journal, 2015, 36, 2677-2680.	2.2	131
1046	Primary and Secondary Prevention of Ischemic Heart Disease in Women. Current Atherosclerosis Reports, 2015, 17, 38.	4.8	2
1047	Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study. PLoS ONE, 2015, 10, e0129584.	2.5	20
1048	Pharmacological Treatment and Current Management of Peripheral Artery Disease. Circulation Research, 2015, 116, 1579-1598.	4.5	87
1049	Head Position in the Early Phase of Acute Ischemic Stroke: An International Survey of Current Practice. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1564-1569.	1.6	13
1050	Severe Bleeding after Percutaneous Transhepatic Drainage of the Biliary System: Effect of Antithrombotic Agents – Analysis of 34 606 Cases from a Japanese Nationwide Administrative Database. Radiology, 2015, 274, 605-613.	7.3	34
1051	Coronary Artery Calcium Improves Risk Assessment in Adults With a Family History of Premature Coronary Heart Disease. Circulation: Cardiovascular Imaging, 2015, 8, e003186.	2.6	49

#	ARTICLE	IF	CITATIONS
1052	Construction and validation of a model to predict nonadherence to guidelines for prescribing antiplatelet therapy to hypertensive patients. <i>Current Medical Research and Opinion</i> , 2015, 31, 883-889.	1.9	8
1053	Global burden of CVD: focus on secondary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2015, 201, S1-S7.	1.7	219
1054	Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Socrates) Trial: Rationale and Design. <i>International Journal of Stroke</i> , 2015, 10, 1304-1308.	5.9	28
1055	The Efficacy and Safety of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD): Protocol of a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. <i>International Journal of Stroke</i> , 2015, 10, 123-127.	5.9	12
1056	Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling. <i>Frontiers of Medicine</i> , 2015, 9, 444-456.	3.4	15
1057	Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2424-2447.	1.6	239
1058	Aspirin for primary prevention of cardiovascular disease. <i>Thrombosis Journal</i> , 2015, 13, 38.	2.1	26
1059	Platelet Reactivity: Is There a Role to Switch?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 278-284.	3.1	4
1060	Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 541-551.	2.2	24
1061	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2122-2133.	2.4	16
1062	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2015, 38, S49-S57.	8.6	224
1063	Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 906-912.e2.	4.4	207
1064	Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. <i>Cerebrovascular Diseases</i> , 2015, 39, 13-22.	1.7	7,982
1065	Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2015, 80, 101-110.	2.9	44
1066	Prospective Evaluation of Blood Coagulability and Effect of Treatment in Patients with Stroke Using Rotational Thromboelastometry. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 304-311.	1.6	9
1067	Stroke Prevention - Medical and Lifestyle Measures. <i>European Neurology</i> , 2015, 73, 150-157.	1.4	117
1069	New Approaches to Inhibiting Platelets and Coagulation. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 373-397.	9.4	44
1070	How do we manage serious gastrointestinal adverse events associated with anti-thrombotic therapy?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 5-8.	3.0	5

#	ARTICLE	IF	CITATIONS
1071	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
1072	Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. Journal of Gastroenterology, 2015, 50, 626-637.	5.1	24
1073	Advances in non-invasive drug delivery for atherosclerotic heart disease. Expert Opinion on Drug Delivery, 2015, 12, 1135-1147.	5.0	20
1074	Recurrent Stroke while on Antiplatelet Therapy. Neurologic Clinics, 2015, 33, 475-489.	1.8	15
1075	The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. Thrombosis Research, 2015, 135, 217-225.	1.7	28
1076	The Role of the Cardiologist in the Primary Prevention of Cardiovascular Disease With Aspirin—. Journal of the American College of Cardiology, 2015, 65, 122-124.	2.8	2
1077	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2015, 65, 111-121.	2.8	63
1078	Antithrombotic therapy after left atrial appendage closure. Expert Review of Cardiovascular Therapy, 2015, 13, 105-109.	1.5	10
1079	Determination of Aspirin Using Functionalized Cadmium-Tellurium Quantum Dots as a Fluorescence Probe. Analytical Letters, 2015, 48, 1117-1127.	1.8	13
1080	Aspirin underuse, non-compliance or cessation: Definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease. International Journal of Cardiology, 2015, 182, 148-154.	1.7	10
1081	Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 87-95.	2.2	98
1082	A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study. BMJ Open, 2015, 5, e006694-e006694.	1.9	4
1083	Regional, age and sex differences in baseline characteristics of patients enrolled in the <scp>T</scp>rial <scp>E</scp>valuating <scp>C</scp>ardiovascular <scp>O</scp>utcomes with <scp>S</scp>itagliptin (<scp>TECOS</scp>). Diabetes, Obesity and Metabolism, 2015, 17, 395-402.	4.4	37
1084	Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin. Journal of Gastroenterology, 2015, 50, 1041-1046.	5.1	31
1086	The harms of low-dose aspirin prophylaxis are overstated. Annals of Oncology, 2015, 26, 441-442.	1.2	4
1087	Albumin to globulin ratio, a predictor or a misleader?. Annals of Oncology, 2015, 26, 443-444.	1.2	14
1088	Lipid Management. , 2015, , .		1
1089	Quality of Diabetes Care at Outpatient Clinic, Sultan Qaboos University Hospital. Oman Medical Journal, 2015, 30, 48-54.	1.0	4

#	ARTICLE	IF	CITATIONS
1090	A decade of individual participant data meta-analyses: A review of current practice. <i>Contemporary Clinical Trials</i> , 2015, 45, 76-83.	1.8	97
1091	Aspirin and statin use and the subsequent development of depression in men and women: Results from a longitudinal population-based study. <i>Journal of Affective Disorders</i> , 2015, 182, 126-131.	4.1	31
1092	Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose Acetylsalicylic Acid. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2321-2328.	1.6	4
1093	The role of platelets in the recruitment of leukocytes during vascular disease. <i>Platelets</i> , 2015, 26, 507-520.	2.3	146
1094	Effects of Perioperative Acetyl Salicylic Acid on Clinical Outcomes in Patients Undergoing Craniotomy for Brain Tumor. <i>World Neurosurgery</i> , 2015, 84, 41-47.	1.3	27
1095	Suitability of antiplatelet therapy in hypertensive patients. <i>Journal of Human Hypertension</i> , 2015, 29, 40-45.	2.2	5
1096	Reply to the letter to the editor "The harms of low-dose aspirin prophylaxis are overstated"™ by P. Elwood and G. Morgan. <i>Annals of Oncology</i> , 2015, 26, 442-443.	1.2	1
1097	Hydrogen Sulfide Levels and Nuclear Factor-erythroid 2-Related Factor 2 (NRF2) Activity Are Attenuated in the Setting of Critical Limb Ischemia (CLI). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	51
1098	Polypharmacy in the Aging Patient. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 170.	7.4	113
1099	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	2.2	175
1100	Lower Mortality Rate in Elderly Patients With Community-Onset Pneumonia on Treatment With Aspirin. <i>Journal of the American Heart Association</i> , 2015, 4, e001595.	3.7	78
1102	The Elderly Spine Surgery Patient: Pre- and Intraoperative Management of Drug Therapy. <i>Drugs and Aging</i> , 2015, 32, 601-609.	2.7	10
1103	Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. <i>American Heart Journal</i> , 2015, 170, 173-179.e1.	2.7	3
1104	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 74-85.	2.8	105
1105	Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	44
1106	Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 981-989.	2.4	147
1107	Screening for Carotid Artery Stenosis. <i>Seminars in Roentgenology</i> , 2015, 50, 127-138.	0.6	4
1108	Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. <i>American Journal of Gastroenterology</i> , 2015, 110, 684-689.	0.4	65

#	ARTICLE	IF	CITATIONS
1109	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. <i>Blood Reviews</i> , 2015, 29, 335-343.	5.7	24
1110	Aspirin Use Among Adults in the U.S.. <i>American Journal of Preventive Medicine</i> , 2015, 48, 501-508.	3.0	94
1111	Use of Low-Dose Aspirin as Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults (from the National Health Interview Survey, 2012). <i>American Journal of Cardiology</i> , 2015, 115, 895-900.	1.6	27
1112	Dual antiplatelet therapy in patients with a long coronary artery lesion over 30mm: Determinants and impact on prognosis. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 235-243.	1.6	6
1113	Optimizing anti-platelet management in the type II diabetic with CAD: Focus on newer therapies. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S69-S75.	0.1	0
1114	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.4	4
1115	Digital Health Interventions for the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 469-480.	3.0	293
1116	A brief review on high on-aspirin residual platelet reactivity. <i>Vascular Pharmacology</i> , 2015, 67-69, 6-9.	2.1	26
1117	Adult Patientsâ€™ Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study. <i>Journal of General Internal Medicine</i> , 2015, 30, 1618-1626.	2.6	41
1118	Secondary Prevention of Heart Disease in Women: Gaps in Care/Gaps in Knowledgeâ€”Where Do We Need to Focus Our Attention. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	0
1119	Management of Coronary Artery Calcium and Coronary CTA Findings. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 18.	0.6	22
1120	Integrated Preclinical Cardiovascular Prevention: A New Paradigm to Face Growing Challenges of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 163-170.	2.2	6
1121	Evaluation of Aspirin Use for Primary Prevention in Diabetic Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 150-151.	1.9	1
1122	Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?. <i>Medical Principles and Practice</i> , 2015, 24, 198-198.	2.4	1
1123	Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis â€“ an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. <i>BMC Medicine</i> , 2015, 13, 55.	5.5	165
1124	Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 8.	2.7	8
1125	Pregabalin for chronic pain: does one medication fit all?. <i>Current Medical Research and Opinion</i> , 2015, 31, 1403-1411.	1.9	9
1126	Antiplatelet drug resistance: Molecular insights and clinical implications. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 21-27.	1.9	32

#	ARTICLE	IF	CITATIONS
1127	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. Postgraduate Medical Journal, 2015, 91, 284-290.	1.8	1
1128	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension. Clinical Hypertension, 2015, 21, 2.	2.0	30
1129	A possible new focus for stroke treatment — migrating stem cells. Expert Opinion on Biological Therapy, 2015, 15, 949-958.	3.1	39
1130	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
1131	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. European Journal of Epidemiology, 2015, 30, 5-18.	5.7	53
1132	Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology, 2015, 6, 142-156.	2.5	13
1133	Preventing Cardiovascular Disease in Patients with Diabetes: Use of Aspirin for Primary Prevention. Current Cardiology Reports, 2015, 17, 566.	2.9	4
1135	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	13.7	59
1136	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. BMJ, The, 2015, 350, h1088-h1088.	6.0	51
1137	Statins and Aspirin: Do They Really Work in Women?. American Journal of Cardiovascular Drugs, 2015, 15, 151-162.	2.2	1
1138	Current State and Novel Approaches of Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1327-1338.	2.4	62
1139	Balancing the Risks and Benefits of Dual Platelet Inhibition. New England Journal of Medicine, 2015, 372, 1854-1856.	27.0	13
1140	Anti-platelet therapy and endoscopic procedures: eyes wide shut?. Endoscopy International Open, 2015, 3, E179-E180.	1.8	3
1141	Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. American Journal of Health-System Pharmacy, 2015, 72, 1623-1629.	1.0	11
1142	Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open, 2015, 5, e007111-e007111.	1.9	74
1144	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. Current Cardiology Reports, 2015, 17, 64.	2.9	1
1145	Polypill: Progress and Challenges to Global Use—Update on the Trials and Policy Implementation. Current Cardiology Reports, 2015, 17, 121.	2.9	10
1147	Optimal Duration of Dual Antiplatelet Therapy After Coronary Stent Implantation. American Journal of Cardiology, 2015, 116, 1631-1636.	1.6	1

#	ARTICLE	IF	CITATIONS
1148	Prevention and Control of Cardiovascular Diseases: What Works?. , 2015, , 207-217.		0
1149	Aspirin and multiple sclerosis. BMC Medicine, 2015, 13, 153.	5.5	20
1150	Antiplatelet therapy and exodontia. Journal of the American Dental Association, 2015, 146, 851-856.	1.5	14
1151	Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy, 2015, 47, 997-1004.	1.8	45
1152	Intracranial Hemorrhage After Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 413-420.	2.2	12
1153	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. Circulation, 2015, 132, 691-718.	1.6	303
1154	Prospective analysis of risk for bleeding after endoscopic biopsy without cessation of antithrombotics in <scp>J</scp>apan. Digestive Endoscopy, 2015, 27, 458-464.	2.3	25
1155	Enteric Coating Can Lead to Reduced Antiplatelet Effect of Lowâ€Dose Acetylsalicylic Acid. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 212-215.	2.5	24
1156	Medical and Invasive Management of Coronary Artery Disease in Patients on Anticoagulants. , 2015, , 163-174.		0
1157	Incidence, Predictors, and Impact ofÂPost-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	2.8	344
1158	Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A₂± Activity and Its Role in Human Platelet Activation. Biochemistry, 2015, 54, 5578-5588.	2.5	14
1159	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	1.8	30
1160	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	8.6	346
1161	Prevention of Cardiovascular Diseases. , 2015, , .		1
1162	Controversies in Cardiology. , 2015, , .		0
1163	Long-Term Use of Cardiovascular Drugs. Journal of the American College of Cardiology, 2015, 66, 1273-1285.	2.8	111
1164	Coronary artery disease in the military patient. Journal of the Royal Army Medical Corps, 2015, 161, 211-222.	0.8	10
1165	Suppressive effect of citalopram on plasma concentrations of thromboxane B₂. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 615-620.	1.2	5

#	ARTICLE	IF	CITATIONS
1166	Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 603-611.	1.7	3
1167	Older people with diabetes “avoiding hospitalization. Diabetes Management, 2015, 5, 311-326.	0.5	2
1168	Diagnosis and Treatment of Intracranial Stenoses. Clinical Neuroradiology, 2015, 25, 307-316.	1.9	10
1169	Aspirin dosing in cardiovascular disease prevention and management: an update. Journal of Thrombosis and Thrombolysis, 2015, 40, 499-511.	2.1	7
1172	Cardiac Complications in Patients Undergoing Major Noncardiac Surgery. New England Journal of Medicine, 2015, 373, 2258-2269.	27.0	322
1173	Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes. Current Diabetes Reports, 2015, 15, 85.	4.2	12
1174	Short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO, dual-therapy stent: what we plan to learn from REDUCE. Future Cardiology, 2015, 11, 17-20.	1.2	2
1175	Pathophysiologic, Rather than Laboratory-defined Resistance Drives Aspirin Failure in Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 745-750.	1.6	9
1176	Aspirin for Primary Prevention: What’s a Clinician to Do?. Journal of General Internal Medicine, 2015, 30, 147-149.	2.6	1
1177	A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?. American Journal of Cardiovascular Drugs, 2015, 15, 113-133.	2.2	41
1178	Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes/Metabolism Research and Reviews, 2015, 31, 402-410.	4.0	82
1179	Dental extractions and risk of bleeding in patients taking single and dual antiplatelet treatment. British Journal of Oral and Maxillofacial Surgery, 2015, 53, 39-43.	0.8	48
1180	Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry. Atherosclerosis, 2015, 238, 119-125.	0.8	11
1181	Impact of Pharmacologic Interventions on Peripheral Artery Disease. Progress in Cardiovascular Diseases, 2015, 57, 510-520.	3.1	7
1182	Interpreting Health Benefits and Risks. , 2015, , .		4
1183	Screening and Treatment by the Primary Care Provider of Common Diabetes Complications. Medical Clinics of North America, 2015, 99, 201-219.	2.5	16
1184	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2015, 43, 7-12.	0.4	1
1185	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. American Journal of Medicine, 2015, 128, 137-143.	1.5	7

#	ARTICLE	IF	CITATIONS
1186	The Mediterranean Diet, its Components, and Cardiovascular Disease. American Journal of Medicine, 2015, 128, 229-238.	1.5	629
1187	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 422-432.	2.4	169
1188	Do Clinicians Recommend Aspirin to Patients for Primary Prevention of Cardiovascular Disease?. Journal of General Internal Medicine, 2015, 30, 155-160.	2.6	12
1189	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	1.3	49
1190	Antiplatelet Therapy for Peripheral Arterial Disease and Critical Limb Ischemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 144-156.	2.0	17
1191	Cardiovascular Disease and Chronic Kidney Disease. , 2015, , 181-198.		2
1192	Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology, 2015, 26, 47-57.	1.2	303
1193	Hyperaggregability and impaired nitric oxide production in platelets from postmenopausal women. Maturitas, 2015, 80, 75-81.	2.4	3
1194	Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8Âyears follow-up of NID-2 study. Acta Diabetologica, 2015, 52, 239-247.	2.5	9
1195	Comentarios del ComitÃ© EspaÃ±ol Interdisciplinario de PrevenciÃ³n Cardiovascular (CEIPC) a las GuÃas Europeas de PrevenciÃ³n Cardiovascular 2012. NeurologÃa, 2016, 31, 195-207.	0.7	0
1196	Why we should not skip aspirin in cardiovascular prevention. Hamostaseologie, 2016, 36, 33-43.	1.9	14
1197	Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation. Chinese Medical Journal, 2016, 129, 2861-2867.	2.3	3
1198	Aspirin use for primary prevention in elderly patients. Monaldi Archives for Chest Disease, 2016, 84, 728.	0.6	1
1199	Frequency and Predictors of Non-Compliance to Aspirin Therapy in Post Myocardial Infarction Patients. Global Journal of Health Science, 2016, 9, 217.	0.2	1
1200	Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. International Journal of Nanomedicine, 2016, Volume 11, 3265-3276.	6.7	30
1201	Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterology Research and Practice, 2016, 2016, 1-8.	1.5	11
1202	Initiation and maintenance of statins and aspirin after acute coronary syndromes (ANZACS-QI 11). Journal of Primary Health Care, 2016, 8, 238.	0.6	12
1203	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis â€” Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	3.4	24

#	ARTICLE	IF	CITATIONS
1204	Coronary thrombosis in diabetes: Are we doing enough?. Diabetes and Vascular Disease Research, 2016, 13, 445-448.	2.0	0
1205	Primary prevention of cardiovascular disease. Tenri Medical Bulletin, 2016, 19, 90-94.	0.1	0
1206	Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Services Research, 2016, 16, 185.	2.2	10
1208	Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. Thrombosis and Haemostasis, 2016, 116, 356-368.	3.4	14
1209	Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS ONE, 2016, 11, e0160046.	2.5	137
1210	Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study. PLoS ONE, 2016, 11, e0147635.	2.5	14
1211	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS ONE, 2016, 11, e0152402.	2.5	124
1212	The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials. Frontiers in Pharmacology, 2016, 7, 440.	3.5	21
1213	Preventing Cardiovascular Disease in Patients With Diabetes. Journal of Cardiovascular Nursing, 2016, 31, 198-200.	1.1	2
1214	Preoperative Cardiac Evaluation and Management of the Patient Undergoing Major Vascular Surgery. International Anesthesiology Clinics, 2016, 54, 1-32.	0.8	16
1215	Clinical implications of low-dose aspirin on vasospastic angina patients without significant coronary artery stenosis; a propensity score-matched analysis. International Journal of Cardiology, 2016, 221, 161-166.	1.7	20
1216	Platelets in cancer metastasis: To help the "evil" to do evil. International Journal of Cancer, 2016, 138, 2078-2087.	5.1	165
1217	To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2439-2447.	1.6	5
1219	Choosing and using non-steroidal anti-inflammatory drugs in haemophilia. Haemophilia, 2016, 22, 179-187.	2.1	18
1220	Topical diclofenac does not affect the antiplatelet properties of aspirin as compared to the intermediate effects of oral diclofenac: A prospective, randomized, complete crossover study. Journal of Clinical Pharmacology, 2016, 56, 422-428.	2.0	4
1221	The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease. Cardiovascular Therapeutics, 2016, 34, 115-124.	2.5	16
1222	A long-term risk-benefit analysis of low-dose aspirin in primary prevention. European Journal of Clinical Investigation, 2016, 46, 130-140.	3.4	2
1223	Effect of aspirin on models of retinal pigment epithelium pathology. Clinical and Experimental Ophthalmology, 2016, 44, 610-617.	2.6	1

#	ARTICLE	IF	CITATIONS
1224	General practitionersâ€™ insight into deprescribing for the multimorbid older individual: a qualitative study. <i>International Journal of Clinical Practice</i> , 2016, 70, 261-276.	1.7	48
1225	Randomized controlled trial comparing impact on platelet reactivity of twiceâ€daily with onceâ€daily aspirin in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2016, 33, 224-230.	2.3	51
1226	How good is aspirin for patients with acute brain ischaemia?. <i>Nature Reviews Neurology</i> , 2016, 12, 434-435.	10.1	0
1227	Cardiovascular effects of cyclooxygenaseâ€2 inhibitors: a mechanistic and clinical perspective. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 957-964.	2.4	109
1228	Lowâ€dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4<scp>VLU</scp>). <i>Journal of Advanced Nursing</i> , 2016, 72, 669-679.	3.3	7
1229	The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 277-282.	5.6	17
1230	Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. <i>Journal of Nutritional Biochemistry</i> , 2016, 35, 58-65.	4.2	21
1231	Refining prognostication of thrombosis in <scp>ET</scp>. <i>American Journal of Hematology</i> , 2016, 91, 361-363.	4.1	8
1232	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016, 5, 204800401665251.	0.7	6
1234	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
1236	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. <i>Heart</i> , 2016, 102, 1883-1889.	2.9	45
1237	Stroke at the beginning of the XXist century. <i>Presse Medicale</i> , 2016, 45, e389-e390.	1.9	4
1238	When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding. <i>Techniques in Gastrointestinal Endoscopy</i> , 2016, 18, 177-186.	0.3	0
1239	HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. <i>Atherosclerosis</i> , 2016, 255, 128-139.	0.8	76
1242	Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2016, 14, 10.	1.5	26
1243	History, Evolution, and Importance of Emergency Endovascular Treatment of Acute Ischemic Stroke. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 42.	4.2	16
1244	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	3.2	12
1245	Reduced mucosal side-effects of acetylsalicylic acid after conjugation with tris-hydroxymethyl-aminomethane. Synthesis and biological evaluation of a new anti-inflammatory compound. <i>European Journal of Pharmacology</i> , 2016, 781, 181-189.	3.5	6

#	ARTICLE	IF	CITATIONS
1246	Preventive effect of a novel diosgenin derivative on arterial and venous thrombosis in vivo. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3364-3369.	2.2	21
1247	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	2.2	5,370
1248	Use of anti-platelet agents after traumatic intracranial hemorrhage. Clinical Neurology and Neurosurgery, 2016, 140, 85-90.	1.4	7
1249	Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet, The, 2016, 388, 365-375.	13.7	321
1250	The benefits of aspirin in early secondary stroke prevention. Lancet, The, 2016, 388, 312-314.	13.7	14
1251	Antiplatelet therapy – a summary for the general physicians. Clinical Medicine, 2016, 16, 152-160.	1.9	36
1252	ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding. American Journal of Gastroenterology, 2016, 111, 459-474.	0.4	377
1253	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy, 2016, 48, 385-402.	1.8	170
1254	The metabolic vascular syndrome - guide to an individualized treatment. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 5-17.	5.7	29
1255	Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model. Pharmacological Research, 2016, 107, 415-425.	7.1	37
1256	Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). Cardiology, 2016, 134, 11-18.	1.4	8
1257	Factors Influencing Physician Counseling on Cardiovascular Risk. Journal of Primary Care and Community Health, 2016, 7, 65-70.	2.1	1
1258	Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?. Kidney International, 2016, 89, 981-983.	5.2	23
1259	Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill. Current Hypertension Reports, 2016, 18, 40.	3.5	16
1260	An update on management of the patient presenting with non-ST-elevation acute coronary syndromes. Hospital Practice (1995), 2016, 44, 173-178.	1.0	1
1261	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 35-43.	27.0	424
1262	Primary Prevention of Cardiovascular Disease in Older Adults. Canadian Journal of Cardiology, 2016, 32, 1074-1081.	1.7	15
1263	Stratifying cardiovascular risk in diabetes: The role of diabetes-related clinical characteristics and imaging. Journal of Diabetes and Its Complications, 2016, 30, 1408-1415.	2.3	11

#	ARTICLE	IF	CITATIONS
1264	The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. British Journal of Cancer, 2016, 114, 1053-1059.	6.4	23
1265	Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2016, 1, 341.	6.1	65
1267	Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 2605-2613.	13.7	587
1268	Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors. Stroke, 2016, 47, 1605-1611.	2.0	27
1269	High-on-Aspirin Residual Platelet Reactivity Evaluated Using the Multiplate® Point-of-Care Device. Acta Marisiensis - Seria Medica, 2016, 62, 101-105.	0.3	0
1270	Aspirin in the Treatment and Prevention of Cardiovascular Disease: Need for Individual Clinical Judgments. , 2016, , 153-171.		0
1271	Aspirin and the Prevention of Colorectal Cancer. , 2016, , 219-240.		0
1272	Low-Dose Aspirin in the Cardiovascular System. , 2016, , 133-142.		0
1274	Clinical practice guideline on thromboprophylaxis and management of anticoagulant and antiplatelet drugs in neurosurgical and neurocritical patients. Revista Española De Anestesiología Y Reanimación (English Edition), 2016, 63, 406-418.	0.1	0
1276	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation, 2016, 134, 1419-1429.	1.6	183
1277	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 2016, 91, 1413-1447.	3.0	10
1278	Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation, 2016, 134, 1579-1594.	1.6	107
1280	Accidenti vascolari cerebrali nella donna. EMC - Neurologia, 2016, 16, 1-12.	0.0	0
1281	Bleeding Complications in Patients Undergoing Percutaneous Spinal Cord Stimulator Trials and Implantations. Pain Medicine, 2016, 17, 2076-2081.	1.9	17
1282	Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. New England Journal of Medicine, 2016, 375, 1197-1198.	27.0	9
1283	Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. International Journal of Cardiology, 2016, 220, 328-332.	1.7	26
1284	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Current Cardiology Reports, 2016, 18, 81.	2.9	54
1285	Standards of care for type 2 diabetes in China. Diabetes/Metabolism Research and Reviews, 2016, 32, 442-458.	4.0	236

#	ARTICLE	IF	CITATIONS
1286	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 16-35.	2.8	491
1287	Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00221.	2.4	1
1288	Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. <i>Annals of Neurology</i> , 2016, 79, 560-568.	5.3	35
1289	Perioperative cardiac protection for noncardiac surgery. <i>Anaesthesia</i> , 2016, 71, 29-39.	3.8	12
1290	The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 500-512.	4.7	13
1291	NSAIDs and Aspirin. , 2016, , .		6
1292	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System. , 2016, , 61-89.		1
1293	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
1294	Dielectric permittivity change detects the process of blood coagulation: Comparative study of dielectric coagulometry with rotational thromboelastometry. <i>Thrombosis Research</i> , 2016, 145, 3-11.	1.7	6
1295	Aspirin and Cancer. <i>Journal of the American College of Cardiology</i> , 2016, 68, 967-976.	2.8	209
1296	Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery. <i>Journal of Clinical Anesthesia</i> , 2016, 35, 163-169.	1.6	15
1297	The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. <i>Molecular and Cellular Biochemistry</i> , 2016, 420, 85-94.	3.1	25
1299	Antiplatelet therapy for preventing stroke in people with atrial fibrillation. <i>The Cochrane Library</i> , 2016, , .	2.8	0
1300	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 791-801.	1.6	16
1301	Future of the Prevention and Treatment of Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 1067-1072.	1.6	37
1302	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 325-350.	1.6	7
1303	Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 164.	1.7	9
1304	Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. <i>The Cochrane Library</i> , 2016, 9, CD003333.	2.8	11

#	ARTICLE	IF	CITATIONS
1305	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.8	415
1306	Aspirin inhibits the production of proangiogenic 15 <i>-S</i> -HETE by platelet cyclooxygenase-1. <i>FASEB Journal</i> , 2016, 30, 4256-4266.	0.5	44
1307	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , The, 2016, 388, 2532-2561.	13.7	1,399
1309	Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. <i>British Journal of Surgery</i> , 2016, 103, 1626-1633.	0.3	57
1310	Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors. <i>Cardiovascular Therapeutics</i> , 2016, 34, 423-430.	2.5	7
1311	Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men. <i>International Journal of Clinical Practice</i> , 2016, 70, 898-906.	1.7	9
1313	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. <i>Contemporary Clinical Trials</i> , 2016, 51, 56-64.	1.8	129
1314	Effects of Aspirin on Endothelial Function and Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 83.	3.5	37
1315	Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2016, 164, 777.	3.9	80
1316	Stroke prevention. <i>Presse Medicale</i> , 2016, 45, e457-e471.	1.9	23
1318	Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2016, 164, 826.	3.9	188
1319	Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2016, 164, 836.	3.9	721
1320	Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2016, 164, 804.	3.9	197
1321	Aspirin for Disease Prevention: Public Policy or Personal Choice?. <i>Annals of Internal Medicine</i> , 2016, 164, 846.	3.9	4
1322	Aspirin Use in Women: Current Perspectives and Future Directions. <i>Current Atherosclerosis Reports</i> , 2016, 18, 74.	4.8	8
1323	Risk of Cerebral Infarction in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study (MID) Tj ETQq1 1 0.784314 rgBT/11/Overlook	2.0	11
1324	How to translate clinical trial results into gain in healthy life expectancy for individual patients. <i>BMJ</i> , The, 2016, 352, i1548.	6.0	44
1325	Clot Formation in the Presence of Acetylsalicylic Acid Leads to Increased Lysis Rates Regardless of the Chosen Thrombolysis Strategy. <i>Journal of Vascular Research</i> , 2016, 53, 128-137.	1.4	2

#	ARTICLE	IF	CITATIONS
1326	Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study. <i>BMJ Open</i> , 2016, 6, e010458.	1.9	12
1327	Assessment of platelet function in patients with stroke using multiple electrode platelet aggregometry: a prospective observational study. <i>BMC Neurology</i> , 2016, 16, 254.	1.8	10
1330	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 779-791.	1.5	3
1331	Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1195.	5.1	58
1332	Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , 2016, 151, 271-277.	1.3	59
1333	Risk of Vascular Thrombotic Events Following Discontinuation of Antithrombotics After Peptic Ulcer Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e40-e44.	2.2	12
1334	Effects of low-dose aspirin in subjects with dyslipidemia. <i>Lipids in Health and Disease</i> , 2016, 15, 106.	3.0	5
1335	Acute coronary syndromes in women and men. <i>Nature Reviews Cardiology</i> , 2016, 13, 471-480.	13.7	90
1338	Low-dose aspirin mitigates acute radiation-induced genitourinary toxicity in patients with prostate adenocarcinoma. <i>Journal of Radiation Oncology</i> , 2016, 5, 71-78.	0.7	2
1339	Does modern medicine increase life-expectancy: Quest for the Moon Rabbit?. <i>Indian Heart Journal</i> , 2016, 68, 19-27.	0.5	32
1340	Anti-myocardial ischemia effect of <i>Syringa pinnatifolia</i> Hemsl. by inhibiting expression of cyclooxygenase-1 and -2 in myocardial tissues of mice. <i>Journal of Ethnopharmacology</i> , 2016, 187, 259-268.	4.1	37
1341	The lack of aspirin resistance in patients with coronary artery disease. <i>Journal of Translational Medicine</i> , 2016, 14, 74.	4.4	9
1342	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
1343	Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. <i>Atherosclerosis</i> , 2016, 251, 177-182.	0.8	39
1344	Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. <i>New England Journal of Medicine</i> , 2016, 374, 2367-2376.	27.0	78
1345	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	683
1346	Acute Myocardial Infarction in Women. <i>Circulation</i> , 2016, 133, 916-947.	1.6	858
1347	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26

#	ARTICLE	IF	CITATIONS
1349	Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. <i>Cerebrovascular Diseases</i> , 2016, 41, 226-232.	1.7	4
1350	A Central Role for Monocyte-Platelet Interactions in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 245-261.	2.0	22
1351	Polypill treatments for cardiovascular diseases. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1-6.	5.0	33
1352	Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial. <i>Contemporary Clinical Trials</i> , 2016, 46, 60-66.	1.8	37
1353	Current therapies and investigational drugs for peripheral arterial disease. <i>Hypertension Research</i> , 2016, 39, 183-191.	2.7	40
1354	Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1029-1036.	1.8	2
1355	Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 27-34.	0.5	45
1356	Chronic Stable Angina. <i>New England Journal of Medicine</i> , 2016, 374, 1167-1176.	27.0	67
1357	Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42	0.4	0
1358	Protease receptor antagonism to target blood platelet therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 72-81.	4.7	10
1359	Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1289-1297.	1.8	13
1360	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2016, , 992-1013.		0
1361	Indications for Carotid Endarterectomy in Patients with Asymptomatic and Symptomatic Carotid Stenosis. , 2016, , 1181-1191.		0
1362	Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. <i>Heart</i> , 2016, 102, 783-789.	2.9	27
1363	Indicaciones y duraci3n de las combinaciones de antiagregantes. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 29-34.	0.0	0
1364	Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 495-504.	3.1	16
1365	Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. <i>Current Cardiology Reports</i> , 2016, 18, 25.	2.9	36
1366	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. <i>Drugs</i> , 2016, 76, 459-483.	10.9	150

#	ARTICLE	IF	CITATIONS
1367	Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. <i>Drugs</i> , 2016, 76, 533-549.	10.9	59
1368	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. <i>Gut</i> , 2016, 65, 374-389.	12.1	225
1369	When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 26.	0.9	2
1370	Intracranial Hemorrhage Risk in the Era of Antithrombotic Therapies for Ischemic Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 29.	0.9	15
1371	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. <i>Drugs and Aging</i> , 2016, 33, 233-248.	2.7	6
1373	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. <i>Expert Review of Hematology</i> , 2016, 9, 223-225.	2.2	6
1374	Guía de práctica clínica sobre trombopprofilaxis y manejo de los fármacos anticoagulantes y antiagregantes en pacientes neuroquirúrgicos y neurocríticos. <i>Revista Española De Anestesiología Y Reanimación</i> , 2016, 63, 406-418.	0.3	2
1375	Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 483-494.	3.1	27
1376	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2016, 39, S60-S71.	8.6	237
1377	Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. <i>European Journal of Vascular and Endovascular Surgery</i> , 2016, 51, 336-342.	1.5	36
1378	Preoperative antiplatelet and statin treatment was not associated with reduced myocardial infarction after high-risk vascular operations in the Vascular Quality Initiative. <i>Journal of Vascular Surgery</i> , 2016, 63, 182-189.e2.	1.1	18
1379	Aspirin in the prevention of cardiovascular events in patients with diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 180-190.	2.0	5
1380	Effective universal health coverage and improved 1-year survival after acute myocardial infarction: the Chilean experience. <i>Health Policy and Planning</i> , 2016, 31, 700-705.	2.7	16
1381	Aspirin resistance and other aspirin-related concerns. <i>Neurological Sciences</i> , 2016, 37, 181-189.	1.9	32
1382	Preventing a First Stroke. , 2016, , 280-291.		1
1383	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , 2016, 12, 45-58.	1.2	17
1384	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334.	4.9	3
1385	Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. <i>Archives of Gerontology and Geriatrics</i> , 2016, 62, 103-111.	3.0	14

#	ARTICLE	IF	CITATIONS
1387	Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. <i>Seminars in Oncology</i> , 2016, 43, 65-77.	2.2	72
1388	Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. <i>Platelets</i> , 2016, 27, 196-202.	2.3	10
1389	Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. <i>Vascular Pharmacology</i> , 2016, 78, 1-9.	2.1	60
1390	Non-instrumented extradural lumbar spine surgery under low-dose acetylsalicylic acid: a comparative risk analysis study. <i>European Spine Journal</i> , 2016, 25, 732-739.	2.2	33
1391	Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 173-190.	1.0	16
1392	Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. <i>Diabetic Medicine</i> , 2017, 34, 316-327.	2.3	44
1393	Oral Antiplatelet Therapy in Coronary Disease. <i>American Journal of Therapeutics</i> , 2017, 24, e744-e750.	0.9	2
1394	Bleeding risk of endoscopic ultrasound-guided fine-needle aspiration in patients undergoing antithrombotic therapy. <i>Digestive Endoscopy</i> , 2017, 29, 91-96.	2.3	25
1395	Is there a "therapeutic window"™ for antiplatelet therapy?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 18-20.	3.0	1
1396	Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular. <i>Medicina Clínica</i> , 2017, 148, 139.e1-139.e15.	0.6	6
1397	Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. <i>Preventive Medicine Reports</i> , 2017, 5, 183-186.	1.8	92
1398	The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices. <i>Neuromodulation</i> , 2017, 20, 51-62.	0.8	66
1399	Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. <i>Current Problems in Cardiology</i> , 2017, 42, 146-164.	2.4	51
1400	Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. <i>British Journal of Cancer</i> , 2017, 116, 405-413.	6.4	34
1401	Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 972-977.	1.6	20
1402	Drug Therapy for Stable Angina Pectoris. <i>Drugs</i> , 2017, 77, 265-284.	10.9	32
1403	Secondary prophylactic treatment and long-term prognosis after <scp>TIA</scp> and different subtypes of stroke. A 25-year follow-up hospital-based observational study. <i>Brain and Behavior</i> , 2017, 7, e00603.	2.2	8
1405	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 301-310.	10.2	174

#	ARTICLE	IF	CITATIONS
1406	Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 519-527.	2.1	10
1407	No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 251-260.	2.2	1
1408	The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. <i>Cancer Treatment Reviews</i> , 2017, 55, 120-127.	7.7	30
1409	Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. <i>Pharmacological Research</i> , 2017, 119, 36-47.	7.1	48
1410	Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis. <i>Maturitas</i> , 2017, 100, 1-7.	2.4	16
1411	Acquired Disorders of Platelet Function. , 2017, , 951-973.		1
1412	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 139.e1-139.e15.	0.2	2
1413	Association of Antithrombotic Drug Use With Subdural Hematoma Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 836.	7.4	121
1414	Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	84
1415	Stroke Risk Factors, Genetics, and Prevention. <i>Circulation Research</i> , 2017, 120, 472-495.	4.5	920
1416	A novel indication of platonin, a therapeutic immunomodulating medicine, on neuroprotection against ischemic stroke in mice. <i>Scientific Reports</i> , 2017, 7, 42277.	3.3	9
1417	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017, 103, 546-562.	2.9	5
1418	Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. <i>Heart</i> , 2017, 103, 871-884.	2.9	4
1419	Aspirin (single dose) for perineal pain in the early postpartum period. <i>The Cochrane Library</i> , 2017, 2, CD012129.	2.8	9
1420	Brain and Spine Surgery in the Elderly. , 2017, , .		7
1421	Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. <i>The Cochrane Library</i> , 2017, 2017, CD009868.	2.8	49
1422	Usefulness of a systematic screening of carotid atherosclerosis in asymptomatic people with type 2 diabetes for cardiovascular risk reclassification. <i>Annales D'Endocrinologie</i> , 2017, 78, 14-19.	1.4	8
1423	Antiplatelet Therapy in Cerebrovascular Disorders. , 2017, , 1373-1380.		2

#	ARTICLE	IF	CITATIONS
1425	Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 69, 298-304.	1.9	5
1426	Pharmacogenomics of Antiplatelet Drugs. , 2017, , 1325-1340.		0
1427	Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study. <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 105-114.	1.1	11
1428	Epidemiology of Cardio-Oncology. , 2017, , 1-14.		1
1429	Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review. <i>Current Problems in Cardiology</i> , 2017, 42, 266-305.	2.4	14
1430	Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. <i>Medical Decision Making</i> , 2017, 37, 802-814.	2.4	24
1431	Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants. <i>Journal of Hypertension</i> , 2017, 35, S33-S40.	0.5	5
1432	Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2017, 99, 91-98.	3.0	105
1433	Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 875-888.	3.1	11
1434	Safety and feasibility of liver resection with continued antiplatelet therapy using aspirin. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 375-381.	2.6	10
1435	Regional Anesthesia and Anticoagulation. , 2017, , 139-148.		0
1436	Suspected aspirin resistance in individual healthy adult warmblood horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, e16-e22.	1.3	4
1437	Management of venous thromboembolism in myeloproliferative neoplasms. <i>Current Opinion in Hematology</i> , 2017, 24, 108-114.	2.5	9
1438	How does the multifaceted plant hormone salicylic acid combat disease in plants and are similar mechanisms utilized in humans?. <i>BMC Biology</i> , 2017, 15, 23.	3.8	171
1439	Sex differences in cardiovascular disease – Impact on care and outcomes. <i>Frontiers in Neuroendocrinology</i> , 2017, 46, 46-70.	5.2	179
1440	The polypill in cardiovascular prevention. <i>Journal of Hypertension</i> , 2017, 35, 1546-1553.	0.5	48
1441	Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 328-334.	1.8	15
1442	Systematic Review and Meta-analysis of Dual Versus Single Antiplatelet Therapy in Carotid Interventions. <i>European Journal of Vascular and Endovascular Surgery</i> , 2017, 53, 53-67.	1.5	43

#	ARTICLE	IF	CITATIONS
1443	MACULAR DEGENERATION AND ASPIRIN USE. Retina, 2017, 37, 1630-1635.	1.7	10
1444	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. European Journal of Preventive Cardiology, 2017, 24, 88-100.	1.8	45
1445	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. European Journal of Preventive Cardiology, 2017, 24, 61-70.	1.8	20
1446	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. European Journal of Preventive Cardiology, 2017, 24, 52-60.	1.8	41
1447	Assessing and Modifying Coronary Artery Disease Risk in Women. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 51.	0.9	5
1449	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation, 2017, 135, 2534-2555.	1.6	136
1450	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 331-339.	2.2	8
1451	Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis, 2017, 263, 343-351.	0.8	118
1452	Oral antiplatelet therapy: impact for transfusion medicine. Vox Sanguinis, 2017, 112, 511-517.	1.5	11
1453	Polypill is not just for cardiovascular disease. BMJ: British Medical Journal, 2017, 357, j2733.	2.3	1
1454	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the <scp>REACH</scp> Registry. Clinical Cardiology, 2017, 40, 710-718.	1.8	33
1455	The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy. European Journal of Internal Medicine, 2017, 44, 62-66.	2.2	16
1456	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. European Journal of Internal Medicine, 2017, 42, 1-15.	2.2	11
1457	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. European Journal of Heart Failure, 2017, 19, 1089-1094.	7.1	3
1458	Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2128-2136.	1.6	5
1459	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Canadian Journal of Cardiology, 2017, 33, 965-976.	1.7	89
1460	Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet, The, 2017, 390, 490-499.	13.7	290
1461	Effect of Antithrombotic Therapy and Long Endoscopic Submucosal Dissection Procedure Time on Early and Delayed Postoperative Bleeding. Digestion, 2017, 96, 21-28.	2.3	18

#	ARTICLE	IF	CITATIONS
1462	Cost-effectiveness of Maintaining Daily Intake of Oat Î²-Glucan for Coronary Heart Disease Primary Prevention. <i>Clinical Therapeutics</i> , 2017, 39, 804-818.e3.	2.5	12
1463	Incidence of intracranial bleeds in new users of low-dose aspirin: a cohort study using The Health Improvement Network. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1055-1064.	3.8	10
1464	Bleeding Risk Related to Upper Gastrointestinal Endoscopic Biopsy in Patients Receiving Antithrombotic Therapy: A Multicenter Prospective Observational Study. <i>Current Therapeutic Research</i> , 2017, 84, 32-36.	1.2	8
1465	How to measure the net benefit of treatment?. <i>Therapie</i> , 2017, 72, 51-61.	1.0	3
1466	Do Women Really Respond Differently to Antiplatelet Therapies?. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1560-1563.	2.8	4
1467	Neuroanesthesiology Update. <i>Journal of Neurosurgical Anesthesiology</i> , 2017, 29, 97-131.	1.2	1
1468	Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate. <i>Anesthesia and Analgesia</i> , 2017, 124, 1091-1098.	2.2	11
1469	Gender differences in the effects of cardiovascular drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 163-182.	3.0	204
1470	The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 561-572.	2.4	21
1471	Role of Coronary Calcium for Risk Stratification and Prognostication. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 8.	0.9	4
1472	Acute Lower Gastrointestinal Bleeding. <i>New England Journal of Medicine</i> , 2017, 376, 1054-1063.	27.0	97
1473	Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 951-961.	1.8	23
1474	Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 9.	1.0	10
1475	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	1.7	24
1476	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , The, 2017, 389, 1799-1808.	13.7	174
1477	Continuous Aspirin Use Does Not Increase Bleeding Risk of Split-Thickness Skin Transplantation Repair to Chronic Wounds. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 316-319.	1.2	3
1478	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	1.7	84
1479	Effect of antiplatelet therapy on aneurysmal sac expansion associated with type II endoleaks after endovascular aneurysm repair. <i>Journal of Vascular Surgery</i> , 2017, 66, 396-403.	1.1	18

#	ARTICLE	IF	CITATIONS
1480	Aspirin in Older Adults. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 511-513.	2.0	3
1481	Potent P2Y ₁₂ Inhibitors in Men Versus Women. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
1482	Mortality in patients who discontinue low-dose acetylsalicylic acid therapy after upper gastrointestinal bleeding. Pharmacoepidemiology and Drug Safety, 2017, 26, 215-222.	1.9	5
1483	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. Interventional Cardiology Clinics, 2017, 6, 119-129.	0.4	2
1484	Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!. European Journal of Heart Failure, 2017, 19, 1086-1088.	7.1	6
1485	Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1040, 136-143.	2.3	35
1486	Update in the Management of Cerebrovascular Accidents. Hospital Medicine Clinics, 2017, 6, 176-192.	0.2	3
1487	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	5.1	77
1488	Vascular Diseases for the Non-Specialist. , 2017, , .		3
1489	9. Cardiovascular Disease and Risk Management. Diabetes Care, 2017, 40, S75-S87.	8.6	203
1490	A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. American Heart Journal, 2017, 185, 17-25.	2.7	16
1491	Antiviral activity of aspirin against <scp>RNA</scp> viruses of the respiratory tractâ€”an in vitro study. Influenza and Other Respiratory Viruses, 2017, 11, 85-92.	3.4	63
1492	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. American Journal of Cardiology, 2017, 119, 881-885.	1.6	29
1493	Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart, 2017, 4, e000651.	2.3	49
1494	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Nonâ€”ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 2048-2090.	2.8	146
1495	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	2.8	140
1496	Use and Misuse of Aspirin in Primary Cardiovascular Prevention. Clinical Medicine Insights: Cardiology, 2017, 11, 117954681770214.	1.8	3
1497	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA - Journal of the American Medical Association, 2017, 318, 1260.	7.4	35

#	ARTICLE	IF	CITATIONS
1498	Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3207-3212.	1.8	1
1499	Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network. <i>International Journal of Cardiology</i> , 2017, 248, 376-381.	1.7	4
1500	Low-dose aspirin and risk of intracranial bleeds. <i>Neurology</i> , 2017, 89, 2280-2287.	1.1	36
1501	Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis. <i>Blood</i> , 2017, 130, 2171-2179.	1.4	125
1502	How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 219, 1-9.	1.1	13
1503	Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. <i>Circulation</i> , 2017, 136, 1183-1192.	1.6	128
1504	Prevalence and characteristics of antiplatelet therapy without overt occlusive vascular disease among hospitalized older patients. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1335-1337.	1.5	0
1505	Bleeding and Neurologic Complications in 58,000 Interventional Pain Procedures. <i>Regional Anesthesia and Pain Medicine</i> , 2017, 42, 782-787.	2.3	1
1506	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1083-1124.	5.4	92
1507	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
1508	Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 551-567.	0.2	3
1509	Primary prevention aspirin use in high-risk patients: A pharmacist intervention and comparison of risk stratification tools. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 585-590.	1.5	2
1510	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-“ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	71
1511	Reducing the Global Burden of Cardiovascular Disease, Part 2. <i>Circulation Research</i> , 2017, 121, 695-710.	4.5	256
1512	Antithrombotics: Antiplatelet Drugs. , 2017, , 301-306.		0
1513	Using Absolute Event Rates to See What Works in Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1376-1378.	2.8	5
1514	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	1.7	503
1515	Prevalence of Preventive Cardiovascular Medication Use In Nursing Home Residents. Room for Deprescribing? The SHELTER Study. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1037-1042.	2.5	9

#	ARTICLE	IF	CITATIONS
1516	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 2480-2487.	2.0	19
1517	The critical care literature 2016. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1547-1554.	1.6	0
1518	Appropriateness of antiplatelet therapy for primary and secondary cardiovascular and cerebrovascular prevention in acutely hospitalized older people. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2528-2540.	2.4	17
1519	Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?. <i>Lupus</i> , 2017, 26, 1351-1367.	1.6	7
1520	A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. <i>American Journal of Hematology</i> , 2017, 92, 1131-1136.	4.1	57
1521	Acute Management of Hemostasis in Patients With Neurological Injury. <i>Transfusion Medicine Reviews</i> , 2017, 31, 236-244.	2.0	7
1522	Antiplatelet Resumption after Antiplatelet-Related Intracerebral Hemorrhage: A Retrospective Hospital-Based Study. <i>World Neurosurgery</i> , 2017, 106, 85-91.	1.3	20
1523	<i>Helicobacter pylori</i> infection and atherosclerosis: is there a causal relationship?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 2293-2301.	2.9	31
1524	Prevention of Cerebral Small Vessel Disease. <i>Seminars in Neurology</i> , 2017, 37, 316-325.	1.4	1
1525	Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence. <i>Seminars in Neurology</i> , 2017, 37, 366-375.	1.4	0
1526	Preoperative Aspirin Does Not Increase Transfusion or Reoperation in Isolated Valve Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1618-1623.	1.3	7
1527	Aspirin for primary stroke prevention in elderly patients with vascular risk factors. <i>Journal of General and Family Medicine</i> , 2017, 18, 331-335.	0.8	8
1528	Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets. <i>Neurology</i> , 2017, 89, 936-943.	1.1	34
1529	Assigning Functions to Medical Technologies. <i>Philosophy and Technology</i> , 2017, 30, 321-338.	4.3	1
1530	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	2.8	125
1531	Interventional and surgical occlusion of the left atrial appendage. <i>Nature Reviews Cardiology</i> , 2017, 14, 727-743.	13.7	35
1532	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e1-e9.	0.4	17
1533	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14

#	ARTICLE	IF	CITATIONS
1535	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1082.	0.6	189
1536	Aspirin and the prevention of venous thromboembolism following total joint arthroplasty. Bone and Joint Journal, 2017, 99-B, 1420-1430.	4.4	80
1537	Assessment and management of peripheral arterial disease. Practice Nursing, 2017, 28, 465-470.	0.1	0
1538	Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Current Atherosclerosis Reports, 2017, 19, 56.	4.8	16
1539	Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?. Stroke, 2017, 48, 3408-3412.	2.0	18
1540	Sex-biased eicosanoid biology: Impact for sex differences in inflammation and consequences for pharmacotherapy. Biochemical Pharmacology, 2017, 145, 1-11.	4.4	51
1541	Postoperative atrial fibrillation: Target for stroke prevention?. European Stroke Journal, 2017, 2, 222-228.	5.5	6
1542	Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea. JAMA - Journal of the American Medical Association, 2017, 318, 156.	7.4	287
1543	Cardiac Society of Australia and New Zealand Position Statement: Coronary Artery Calcium Scoring. Heart Lung and Circulation, 2017, 26, 1239-1251.	0.4	29
1544	Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. Revista Portuguesa De Cardiologia, 2017, 36, 551-567.	0.5	12
1545	Do antiplatelet drugs increase the risk of bleeding after tooth extraction? A case-crossover study. International Journal of Oral and Maxillofacial Surgery, 2017, 46, 1475-1478.	1.5	7
1546	A case report of intracranial hemorrhage after spinal anesthesia. JA Clinical Reports, 2017, 3, 11.	0.7	6
1547	Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia. Annals of Internal Medicine, 2017, 167, 170.	3.9	42
1549	Endocrine Considerations in Critical Limb Ischemia. , 2017, , 543-560.		1
1550	Utilidad de un policomprimido cardiovascular en el tratamiento de pacientes en prevención secundaria en España: un estudio de coste-efectividad. Revista Espanola De Cardiologia, 2017, 70, 42-49.	1.2	28
1551	Anesthesia for the Older Patient. , 2017, , 91-100.		0
1552	Strategies to limit immune-activation in HIV patients. Expert Review of Anti-Infective Therapy, 2017, 15, 43-54.	4.4	24
1553	Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration. Clinical Drug Investigation, 2017, 37, 187-193.	2.2	6

#	ARTICLE	IF	CITATIONS
1554	No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 46-52.	4.4	72
1555	Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 42-49.	0.6	13
1556	Low-dose aspirin and rupture of abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2017, 65, 616-625.e4.	1.1	32
1557	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	3.8	17
1558	Clinical outcomes associated with periprocedural discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1168-1175.	1.7	8
1559	Percutaneous Treatment of Cardiovascular Diseases in Women. , 2017, , .		0
1560	Perioperative Aspirin in Cardiac and Noncardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1060-1070.	1.3	5
1561	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6.	4.1	45
1562	Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 10-15.	0.8	28
1563	Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. <i>European Journal of Internal Medicine</i> , 2017, 39, 63-68.	2.2	8
1564	Personality Makes a Difference: Attachment Orientation Moderates Theory of Planned Behavior Prediction of Cardiac Medication Adherence. <i>Journal of Personality</i> , 2017, 85, 867-879.	3.2	9
1565	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 135, 659-670.	1.6	119
1566	Stroke. <i>Lancet</i> , 2017, 389, 641-654.	13.7	887
1567	Pharmacological secondary prevention in patients with mesenteric artery atherosclerosis and arterial embolism. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 105-109.	2.4	4
1568	ASPRE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly. <i>International Journal of Stroke</i> , 2017, 12, 108-113.	5.9	32
1569	Should This Patient Receive Aspirin?. <i>Annals of Internal Medicine</i> , 2017, 167, 786.	3.9	3
1570	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD005158.	2.8	50
1571	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). <i>Regional Anesthesia and Pain Medicine</i> , 2017, 43, 1.	2.3	117

#	ARTICLE	IF	CITATIONS
1572	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. <i>Cardiovascular Research</i> , 2017, 113, e61-e63.	3.8	6
1573	Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1486-1497.	3.4	18
1574	Upper Gastrointestinal Complications and Cardiovascular/Gastrointestinal Risk Calculator in Patients with Myocardial Infarction Treated with Aspirin. <i>Chinese Medical Journal</i> , 2017, 130, 1909-1913.	2.3	2
1575	Outcomes of Geriatric Trauma Patients on Preinjury Anticoagulation: A Multicenter Study. <i>American Surgeon</i> , 2017, 83, 527-535.	0.8	16
1576	Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk – a randomised, controlled trial. <i>Archives of Medical Science</i> , 2018, 14, 773-780.	0.9	11
1577	Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest. <i>Biosensors</i> , 2017, 7, 30.	4.7	40
1578	Salvianolic Acid Exerts Cardioprotection through Promoting Angiogenesis in Animal Models of Acute Myocardial Infarction: Preclinical Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	51
1579	Regional anesthesia and antithrombotic agents: instructions for use. <i>Minerva Anestesiologica</i> , 2017, 83, 321 - 335.	1.0	4
1580	Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. <i>Medical Journal of Australia</i> , 2017, 207, 357-361.	1.7	25
1581	Rivaroxaban plus aspirin for secondary prevention. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 124-124.	0.3	0
1582	Antiplatelet treatment in the primary prophylaxis of cardiovascular disease in patients with arterial hypertension. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2017, 2, 133-136.	0.1	2
1583	Preeclampsia and cardiovascular disease: interconnected paths that enable detection of the subclinical stages of obstetric and cardiovascular diseases. <i>Integrated Blood Pressure Control</i> , 2017, Volume 10, 17-23.	1.2	24
1584	Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2937-2945.	4.3	6
1585	The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. <i>PLoS ONE</i> , 2017, 12, e0170775.	2.5	23
1586	Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults – a systematic review. <i>BMC Geriatrics</i> , 2017, 17, 225.	2.7	10
1587	New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. <i>BMC Cancer</i> , 2017, 17, 637.	2.6	33
1588	Flavonolignans inhibit the arachidonic acid pathway in blood platelets. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 396.	3.7	25
1590	Antithrombotic Therapy: Focus on the Elderly. <i>Cardiovascular Innovations and Applications</i> , 2017, 2, .	0.3	1

#	ARTICLE	IF	CITATIONS
1591	Gastro-protective potential of Artemisia parviflora on aspirin induced gastric ulcers in albino rabbits. African Journal of Pharmacy and Pharmacology, 2017, 11, 561-566.	0.3	1
1592	Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 684-690.	0.9	2
1593	Aspirin for Prevention of Cardiovascular Disease. Preventing Chronic Disease, 2017, 14, E77.	3.4	1
1594	Licochalcone A Prevents Platelet Activation and Thrombus Formation through the Inhibition of PLC β 2-PKC, Akt, and MAPK Pathways. International Journal of Molecular Sciences, 2017, 18, 1500.	4.1	45
1595	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. Korean Journal of Anesthesiology, 2017, 70, 13.	2.5	17
1596	Long-term prognosis in patients continuing taking antithrombotics after peptic ulcer bleeding. World Journal of Gastroenterology, 2017, 23, 723.	3.3	8
1597	Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study. Journal of Preventive Medicine and Public Health, 2017, 50, 165-176.	1.9	0
1598	Antiplatelet therapy following ischaemic stroke – “Continue or change pre-existing therapy?”. European Stroke Journal, 2017, 2, 31-36.	5.5	2
1599	Advances in Antiplatelet Agents. , 2017, , 556-599.		1
1600	Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. Circulation Journal, 2017, 81, 511-519.	1.6	8
1601	Aspirin Before Elective Surgery – “Stop or Continue?”. Deutsches Ärztblatt International, 2017, 114, 473-480.	0.9	12
1602	Evidence for periprocedural antiplatelet therapy, heparinization and bridging of coumarin therapy in carotid revascularization. Journal of Cardiovascular Surgery, 2017, 58, 143-151.	0.6	4
1603	The Concept of the Polypill in the Prevention of Cardiovascular Disease. Annals of Global Health, 2018, 80, 24.	2.0	23
1604	Low-Dose Aspirin for Prevention of Cardiovascular Risk in Bereavement: Results from a Feasibility Study. Psychotherapy and Psychosomatics, 2018, 87, 112-113.	8.8	9
1605	External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients. Stroke, 2018, 49, 601-606.	2.0	13
1606	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. International Journal of Diabetes in Developing Countries, 2018, 38, 1-115.	0.8	85
1607	Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. Journal of Arthroplasty, 2018, 33, S131-S135.	3.1	63
1608	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Current Atherosclerosis Reports, 2018, 20, 15.	4.8	5

#	ARTICLE	IF	CITATIONS
1609	Rivaroxaban in peripheral artery disease: The new kid on the block?. Journal of Vascular Surgery, 2018, 67, 985-986.	1.1	4
1610	Mucus reduction promotes acetyl salicylic acid-induced small intestinal mucosal injury in rats. Biochemical and Biophysical Research Communications, 2018, 498, 228-233.	2.1	8
1611	Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiology and Therapy, 2018, 7, 15-24.	2.6	21
1612	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	2.2	106
1614	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney International, 2018, 93, 1165-1174.	5.2	21
1615	Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets, 2018, 29, 425-430.	2.3	19
1616	Interventions for lower extremity peripheral artery disease. Nature Reviews Cardiology, 2018, 15, 332-350.	13.7	69
1617	Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 407-413.	2.0	2
1618	Optimal pharmacological therapy in ST-elevation myocardial infarctionâ€”aÂreview. Netherlands Heart Journal, 2018, 26, 296-310.	0.8	12
1619	Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events. PharmacoEconomics - Open, 2018, 2, 371-380.	1.8	5
1621	Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in Highâ€Risk Patients for Cardiovascular Disease. Clinical Pharmacology and Therapeutics, 2018, 104, 111-119.	4.7	7
1622	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	2.4	158
1623	Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. Journal of Thrombosis and Haemostasis, 2018, 16, 1198-1210.	3.8	38
1624	Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes, 2018, 42, S162-S169.	0.8	44
1625	Establishing a Safe Administration of ASA in Cardiovascular Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity with Skin and/or Respiratory Involvement. International Archives of Allergy and Immunology, 2018, 175, 237-245.	2.1	11
1626	Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease. Canadian Journal of Cardiology, 2018, 34, 390-399.	1.7	28
1627	Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke. Neurology, 2018, 90, e683-e689.	1.1	31
1628	The Value of Helicobacter Eradication in Long-term Aspirin Users. Journal of the National Cancer Institute, 2018, 110, 690-691.	6.3	0

#	ARTICLE	IF	CITATIONS
1629	Rivaroxaban with or without aspirin for prevention of cardiovascular disease. <i>Coronary Artery Disease</i> , 2018, 29, 361-365.	0.7	0
1630	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 33-50.	2.5	30
1631	Stroke Prevention in the Very Elderly. <i>Stroke</i> , 2018, 49, 796-802.	2.0	32
1633	A Reanalysis of the RIVUR Trial Using a Risk Classification System. <i>Journal of Urology</i> , 2018, 199, 1608-1614.	0.4	34
1634	Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS. Herz, 2018, 43, 11-19.	1.1	2
1635	Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). <i>Atherosclerosis</i> , 2018, 269, 42-49.	0.8	7
1636	Preoperative Antiplatelet and Statin Use Does Not Affect Outcomes after Carotid Endarterectomy. <i>Annals of Vascular Surgery</i> , 2018, 46, 43-52.	0.9	7
1639	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
1640	Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer. <i>Gastroenterology</i> , 2018, 154, 849-860.e1.	1.3	31
1641	Epidural Hematoma Following Interlaminar Epidural Injection in Patient Taking Aspirin. <i>Regional Anesthesia and Pain Medicine</i> , 2018, 43, 1.	2.3	7
1642	Influence of pre-analytical time and temperature conditions on serum thromboxane B2 levels. <i>Thrombosis Research</i> , 2018, 163, 1-5.	1.7	5
1643	Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. <i>Gut</i> , 2018, 67, 405-417.	12.1	132
1644	ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. <i>American Heart Journal</i> , 2018, 198, 135-144.	2.7	78
1645	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. <i>Autoimmunity Reviews</i> , 2018, 17, 703-708.	5.8	76
1646	The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 162.	1.6	18
1647	Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. <i>International Journal of Cardiology</i> , 2018, 263, 118-124.	1.7	13
1648	Coronary Artery Disease in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2015-2040.	2.8	175
1649	DASH, the data and specimen hub of the National Institute of Child Health and Human Development. <i>Scientific Data</i> , 2018, 5, 180046.	5.3	9

#	ARTICLE	IF	CITATIONS
1650	In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCCACS (Improving Care for Cardiovascular Disease in China—Acute Coronary Syndrome) Project. Journal of the American Heart Association, 2018, 7, .	3.7	13
1651	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. International Journal of Cardiology, 2018, 259, 20-25.	1.7	18
1652	Update of Antiplatelet Therapy in Patients Without Known Cardiovascular Disease. Serbian Journal of Experimental and Clinical Research, 2018, 19, 383-388.	0.1	0
1653	Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events. Medical Decision Making, 2018, 38, 427-438.	2.4	10
1654	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2018, 258, 59-67.	1.7	14
1655	A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study. BMJ Open, 2018, 8, e013063.	1.9	1
1656	Chronic Medications and Maxillofacial Surgery. , 2018, , 161-181.		0
1657	Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 158-165.	3.0	6
1658	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. Current Problems in Cardiology, 2018, 43, 68-110.	2.4	22
1659	A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery. Annals of Surgery, 2018, 267, 1-10.	4.2	77
1660	Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?. Cor Et Vasa, 2018, 60, e165-e168.	0.1	10
1661	Axillobifemoral Bypasses: Reappraisal of an Extra-Anatomic Bypass by Analysis of Results and Prognostic Factors. World Journal of Surgery, 2018, 42, 283-294.	1.6	3
1662	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
1663	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
1664	Cardiovascular Screening and Primary Prevention in Older Adults. Clinics in Geriatric Medicine, 2018, 34, 81-93.	2.6	1
1665	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
1666	Why women are not small men. Maturitas, 2018, 107, A3-A4.	2.4	3
1667	Aspirin Use and Mortality in Two Contemporary US Cohorts. Epidemiology, 2018, 29, 126-133.	2.7	7

#	ARTICLE	IF	CITATIONS
1669	Editor's Choice "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	1.5	734
1670	Editor's Choice "Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 3-81.	1.5	934
1672	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. International Journal of Stroke, 2018, 13, 420-443.	5.9	175
1673	Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?. Diabetes and Metabolism, 2018, 44, 217-225.	2.9	13
1674	Coaching Patients Saves Lives and Money. American Journal of Medicine, 2018, 131, 415-421.e1.	1.5	17
1675	Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension, 2018, 12, 128-134.	2.3	2
1676	Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. International Journal of Cardiology, 2018, 252, 96-100.	1.7	10
1677	Continued Use of a Single Antiplatelet Agent Does Not Increase the Risk of Delayed Bleeding After Colorectal Endoscopic Submucosal Dissection. Digestive Diseases and Sciences, 2018, 63, 218-227.	2.3	26
1678	9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes"2018". Diabetes Care, 2018, 41, S86-S104.	8.6	461
1679	The aspirin in reducing events in the elderly trial: Statistical analysis plan. International Journal of Stroke, 2018, 13, 335-338.	5.9	44
1680	Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats. Digestive Diseases and Sciences, 2018, 63, 72-80.	2.3	2
1681	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clinical Genitourinary Cancer, 2018, 16, 226-234.	1.9	14
1682	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
1683	Secondary prevention shifts into second gear. Lancet, The, 2018, 391, 181-182.	13.7	1
1684	Aspirin use and endometrial cancer risk and survival. Gynecologic Oncology, 2018, 148, 222-232.	1.4	34
1685	The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea-rationale and methodology of the SNORE-ASA study. Contemporary Clinical Trials, 2018, 64, 101-111.	1.8	12
1686	Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction. Medicine (United States), 2018, 97, e13010.	1.0	7
1687	Factors Associated with Inadequate Management of Antiplatelet Agents in Perioperative Period of Non-Cardiac Surgeries. Arquivos Brasileiros De Cardiologia, 2018, 111, 596-604.	0.8	3

#	ARTICLE	IF	CITATIONS
1689	Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration. , 2018, , 433-441.		0
1690	Should dexamethasone be standard in the prophylaxis of pain flare after palliative radiotherapy for bone metastases?â€”a debate. Annals of Palliative Medicine, 2018, 7, 279-283.	1.2	9
1691	Cardiovascular events after discontinuation of low-dose aspirin. Journal of Thoracic Disease, 2018, 10, 75-78.	1.4	1
1692	An Antithrombotic Strategy by Targeting Phospholipase D in Human Platelets. Journal of Clinical Medicine, 2018, 7, 440.	2.4	6
1693	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	1.7	45
1694	Screening for Atherosclerotic Cardiovascular Disease in Asymptomatic Individuals. , 2018, , 459-478.		2
1696	ANTIPLATELET ADEQUACY OF CYCLOPENTYL TRIAZOLOPYRIMIDINE VERSUS CLOPIDOGREL IN-PATIENTS WITH CORONARY HEART DISEASE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 536.	0.3	4
1697	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. Annals of Internal Medicine, 2018, 168, 640-650.	3.9	66
1698	DOCTORâ€™S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT. Rational Pharmacotherapy in Cardiology, 2018, 14, 235-243.	0.8	2
1699	Current Perspectives Regarding Stem Cell-based Therapy for Ischemic Stroke. Current Pharmaceutical Design, 2018, 24, 3332-3340.	1.9	12
1700	Patrones de prescripci3n de medicamentos para la diabetes mellitus tipo 2 en cinco departamentos de Colombia, en 2014. Revista Facultad Nacional De Salud Publica, 2018, 36, 58-65.	0.2	1
1701	Indication and prescription of antiplatelet agents in the elderly population. Sang Thrombose Vaisseaux, 2018, 30, 217-226.	0.1	0
1702	Thrombotic antiphospholipid syndrome. Lupus, 2018, 27, 21-27.	1.6	3
1703	Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology, 2018, 14, 443-453.	1.2	6
1704	Preoperative Management of Medications. Anesthesiology Clinics, 2018, 36, 663-675.	1.4	5
1705	Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?. Journal of the American Heart Association, 2018, 7, e010996.	3.7	1
1706	Antiplatelet agents in uncertain clinical scenariosâ€”a bleeding nightmare. Cardiovascular Diagnosis and Therapy, 2018, 8, 647-662.	1.7	7
1707	Impact of a medication therapy management service offered to patients in treatment of breast cancer. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	8

#	ARTICLE	IF	CITATIONS
1708	Gastroduodenal ulcer bleeding in elderly patients on low dose aspirin therapy. World Journal of Gastroenterology, 2018, 24, 3908-3918.	3.3	10
1709	Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE, 2018, 13, e0203957.	2.5	31
1710	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	2.4	20
1711	Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. Ageing Research Reviews, 2018, 48, 51-78.	10.9	23
1712	Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. Clinical Interventions in Aging, 2018, Volume 13, 1675-1690.	2.9	5
1713	Aspirin and diabetes mellitus in primary prevention: the Endless Conundrum. Annals of Translational Medicine, 2018, 6, 218-218.	1.7	5
1714	Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy?. Current Neurology and Neuroscience Reports, 2018, 18, 80.	4.2	36
1716	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. Expert Opinion on Pharmacotherapy, 2018, 19, 1857-1865.	1.8	16
1717	Diabetes and Platelet Response to Low-dose Aspirin. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4599-4608.	3.6	8
1718	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	2.0	39
1719	Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin. Ecancermedicalscience, 2018, 12, 813.	1.1	4
1720	Linalyl acetate prevents hypertension-related ischemic injury. PLoS ONE, 2018, 13, e0198082.	2.5	20
1721	Use of the cardiovascular polypill 40 mg in secondary cardiovascular prevention. Clínica E Investigaci3n En Arteriosclerosis (English Edition), 2018, 30, 240-247.	0.2	0
1723	Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1102-1111.	0.9	1
1724	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation—The Fushimi AF Registry —. Circulation Journal, 2018, 82, 2983-2991.	1.6	16
1725	Association of Computed Tomographic Leg Muscle Characteristics With Lower Limb and Cardiovascular Events in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2018, 7, e009943.	3.7	18
1726	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	1.7	195
1727	Antiplatelet agents in perioperative noncardiac surgeries: to maintain or to suspend?. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1887-1895.	2.0	7

#	ARTICLE	IF	CITATIONS
1728	Guidelineâ€Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, e009885.	3.7	21
1729	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 683-697.	2.4	19
1730	OBSOLETE: Peripheral Arterial Disease. , 2018, , .		0
1731	Updated American Heart Association/American College of Cardiology; European Society of Hypertension/European Society of Cardiology Guidelines. , 2018, , 459-468.		1
1732	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1499-1508.	27.0	392
1733	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1509-1518.	27.0	770
1734	Gender Differences in Ischemic Cardiomyopathy. Current Atherosclerosis Reports, 2018, 20, 50.	4.8	21
1735	Mutation of TGFÎ²-RII eliminates NSAID cancer chemoprevention. Oncotarget, 2018, 9, 12554-12561.	1.8	10
1736	Acute Coronary Syndrome. , 2018, , 147-161.		2
1737	Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?. Blood, 2018, 132, 2619-2628.	1.4	47
1738	Comparing Long-term Mortality After Carotid Endarterectomy vs Carotid Stenting Using a Novel Instrumental Variable Method for Risk Adjustment in Observational Time-to-Event Data. JAMA Network Open, 2018, 1, e181676.	5.9	27
1739	Contrast Enhanced Ultrasound (CEUS) Is Not Able to Identify Vulnerable Plaques in Asymptomatic Carotid Atherosclerotic Disease. European Journal of Vascular and Endovascular Surgery, 2018, 56, 632-642.	1.5	16
1740	When are the cardiovascular and stroke risks too high? Pharmacotherapy for stroke prophylaxis. Expert Opinion on Pharmacotherapy, 2018, 19, 1427-1440.	1.8	2
1741	Pre-Procedural Thrombolysis in Myocardial Infarction Flow in Patients with ST-Segment Elevation Myocardial Infarction. International Heart Journal, 2018, 59, 920-925.	1.0	14
1742	Novel aspects of antiplatelet therapy in cardiovascular disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	2.3	41
1743	The Vascular Endothelium. , 2018, , 5-10.		2
1744	Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 509-518.	10.2	72
1745	Antithrombotic Therapy for PeripheralÂArtery Disease. Journal of the American College of Cardiology, 2018, 71, 2450-2467.	2.8	43

#	ARTICLE	IF	CITATIONS
1746	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Critical Pathways in Cardiology, 2018, 17, 53-68.	0.5	2
1747	Diabetes and Cardiovascular Disease. , 2018, , 823-838.		0
1748	Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation. American Journal of Transplantation, 2018, 18, 2924-2933.	4.7	61
1749	Reducing risk of spinal haematoma from spinal and epidural pain procedures. Scandinavian Journal of Pain, 2018, 18, 129-150.	1.3	14
1750	Preeclampsia and the cardiovascular system: An update. Trends in Cardiovascular Medicine, 2018, 28, 505-513.	4.9	43
1751	Development of a standardized definition for clinically significant bleeding in the Aspirin in Reducing Events in the Elderly (ASPREE) trial. Contemporary Clinical Trials Communications, 2018, 11, 30-36.	1.1	14
1752	Can aspirin help?. ELife, 2018, 7, .	6.0	2
1754	Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy. JAMA - Journal of the American Medical Association, 2018, 319, 2507.	7.4	36
1755	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. International Journal of Cardiology, 2018, 270, 54-59.	1.7	24
1756	12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study. PLoS ONE, 2018, 13, e0195543.	2.5	12
1757	Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016. Future Cardiology, 2018, 14, 277-282.	1.2	6
1758	Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2018, 28, 351-361.	1.4	6
1759	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
1760	Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection, 2018, , .	0.1	5
1761	Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose. Current Treatment Options in Neurology, 2018, 20, 32.	1.8	4
1762	Reconfiguring Cardiac Rehabilitation to Achieve Panvascular Prevention: New Care Models for a New World. Canadian Journal of Cardiology, 2018, 34, S231-S239.	1.7	12
1763	Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. Journal of Thrombosis and Haemostasis, 2018, 16, 1953-1963.	3.8	13
1764	Medical Therapies. , 2018, , 357-372.		0

#	ARTICLE	IF	CITATIONS
1766	Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. JAMA - Journal of the American Medical Association, 2018, 320, 593.	7.4	8
1767	Signalling through Src family kinase isoforms is not redundant in models of thrombo-inflammatory vascular disease. Journal of Cellular and Molecular Medicine, 2018, 22, 4317-4327.	3.6	9
1768	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. International Journal of Cardiology, 2018, 269, 292-297.	1.7	14
1769	Serious hemorrhages after ischemic stroke or TIA - Incidence, mortality, and predictors. PLoS ONE, 2018, 13, e0195324.	2.5	4
1770	Inhibition of the development of N-nitrosomethylbenzylamine-induced esophageal tumors in rats by strawberries and aspirin, alone and in combination. Journal of Berry Research, 2018, 8, 137-146.	1.4	14
1771	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. Journal of the Formosan Medical Association, 2018, 117, 766-790.	1.7	44
1772	Aspirin for Primary Prevention in Patients with Type 2 Diabetes. Endocrine Practice, 2018, 24, 925-927.	2.1	1
1773	Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, The, 2018, 392, 387-399.	13.7	273
1774	Weight-adjusted aspirin for cardiovascular prevention. Lancet, The, 2018, 392, 361-362.	13.7	7
1775	Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2). British Journal of Surgery, 2018, 105, 1591-1597.	0.3	20
1776	Uso de la polipiridina cardiovascular 40 mg en prevenci3n cardiovascular secundaria. Cl3nica E Investigaci3n En Arteriosclerosis, 2018, 30, 240-247.	0.8	0
1777	Measures of Drug Prescribing at Care Transitions in an Internal Medicine Unit. Journal of Clinical Pharmacology, 2018, 58, 1171-1183.	2.0	5
1778	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
1779	Aspirin: the miracle drug?. Clinical and Translational Gastroenterology, 2018, 9, e153.	2.5	0
1780	Advances in thermoanalytical techniques. Journal of Thermal Analysis and Calorimetry, 2018, 134, 1299-1306.	3.6	12
1781	Platelet receptor-mediated mechanosensing and thrombosis. , 2018, , 285-304.		0
1782	Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 392, 1036-1046.	13.7	619
1783	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine, 2018, 379, 1529-1539.	27.0	823

#	ARTICLE	IF	CITATIONS
1784	Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes—Why Is It Not Used in Clinical Practice?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1528-1534.	3.4	4
1785	Bioactive lipid metabolism in platelet “first responder” and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 439-454.	5.9	14
1786	Carotid Artery Disease in Patients with Cancer. , 2018, , 117-134.		0
1787	Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1426-1436.	1.7	10
1788	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies — Part 2. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 893-915.	2.4	8
1789	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.1	25
1790	Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
1792	Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. <i>Diabetes Care</i> , 2018, 41, 1757-1764.	8.6	17
1793	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	6.2	30
1794	Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. <i>Stroke</i> , 2018, 49, 1639-1646.	2.0	16
1795	Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 255-263.	2.6	44
1796	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. <i>Alzheimer's and Dementia</i> , 2018, 14, 1171-1183.	0.8	468
1797	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1277-1286.	2.9	14
1798	Polyphenols: Anti-Platelet Nutraceutical?. <i>Current Pharmaceutical Design</i> , 2018, 24, 146-157.	1.9	14
1799	Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 127-138.	3.0	14
1800	Aspirin for primary prevention of stroke in traumatic cerebrovascular injury: association with increased risk of transfusion. <i>Journal of Neurosurgery</i> , 2019, 130, 1520-1527.	1.6	4
1801	Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. <i>European Heart Journal</i> , 2019, 40, 1466-1471.	2.2	22
1802	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537

#	ARTICLE	IF	CITATIONS
1803	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	1.4	402
1804	Aerobic exercise interventions reduce blood pressure in patients after stroke or transient ischaemic attack: a systematic review and meta-analysis. British Journal of Sports Medicine, 2019, 53, 1515-1525.	6.7	43
1805	Aspirin for the primary prevention of cardiovascular disease: latest evidence. Expert Review of Cardiovascular Therapy, 2019, 17, 633-643.	1.5	20
1806	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clinical Hypertension, 2019, 25, 20.	2.0	193
1807	A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. American Journal of Medicine, 2019, 132, 1295-1304.e3.	1.5	16
1808	Antithrombotics and bleeding risk: paradoxical findings. Lancet Neurology, The, 2019, 18, 905-906.	10.2	0
1809	Aspirin and Primary Prevention in Patients with Diabetesâ€”A Critical Evaluation of Available Randomized Trials and Meta-Analyses. Thrombosis and Haemostasis, 2019, 119, 1573-1582.	3.4	6
1810	The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies. Ophthalmology, 2019, 126, 1647-1656.	5.2	13
1811	The Metabolites of the Dietary Flavonoid Quercetin Possess Potent Antithrombotic Activity, and Interact with Aspirin to Enhance Antiplatelet Effects. TH Open, 2019, 03, e244-e258.	1.4	37
1812	Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease. Journal of the American College of Cardiology, 2019, 74, 786-803.	2.8	40
1813	An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy, 2019, 17, 561-573.	1.5	2
1814	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Therapeutic Advances in Hematology, 2019, 10, 204062071986147.	2.5	3
1815	The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries. Gastroenterology Research and Practice, 2019, 2019, 1-7.	1.5	8
1816	Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-32.	4.0	369
1817	Variability in aspirin efficacy: all in the genes?. European Heart Journal, 2019, 40, 3393-3396.	2.2	3
1818	Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset. Journal of the American Heart Association, 2019, 8, e012652.	3.7	29
1819	Arachidonic Acid Metabolism and Kidney Inflammation. International Journal of Molecular Sciences, 2019, 20, 3683.	4.1	191
1820	Number needed to treat: A primer for neurointerventionalists. Interventional Neuroradiology, 2019, 25, 613-618.	1.1	19

#	ARTICLE	IF	CITATIONS
1821	Observational study of the medical management of patients with peripheral artery disease. British Journal of Surgery, 2019, 106, 1168-1177.	0.3	49
1822	Les patients inclus dans COMPASS sont-ils ceux de notre pratique ?. Archives of Cardiovascular Diseases Supplements, 2019, 11, S20-S27.	0.0	0
1823	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). European Journal of Cardiovascular Nursing, 2019, 18, 534-544.	0.9	26
1824	Coronary Computed Tomography Angiography as the Investigation of Choice for Stable Chest Pain—Reply. JAMA Cardiology, 2019, 4, 948.	6.1	0
1825	Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. Journal of the American College of Cardiology, 2019, 73, 3281-3291.	2.8	36
1826	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	1.3	108
1827	The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy. Renal Failure, 2019, 41, 623-628.	2.1	3
1828	Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 283-291.	2.2	8
1829	Estándares SEA 2019 para el control global del riesgo cardiovascular. Clínica E Investigación En Arteriosclerosis, 2019, 31, 1-43.	0.8	8
1830	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal, 2019, 40, 3757-3767.	2.2	211
1831	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety, 2019, 18, 1171-1189.	2.4	23
1832	Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain. Journal of the American College of Cardiology, 2019, 74, 2058-2070.	2.8	99
1833	Study on molecular mechanisms of nattokinase in pharmacological action based on label-free liquid chromatography-tandem mass spectrometry. Food Science and Nutrition, 2019, 7, 3185-3193.	3.4	5
1834	Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Medicine, 2019, 17, 198.	5.5	71
1835	Aspirin for Primary Prevention of Cardiovascular Disease. Journal of Lipid and Atherosclerosis, 2019, 8, 162.	3.5	2
1836	Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. International Forum of Allergy and Rhinology, 2019, 9, 1409-1419.	2.8	38
1837	Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. Journal of Thrombosis and Thrombolysis, 2019, 48, 554-562.	2.1	26
1838	Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. The Lancet Global Health, 2019, 7, e1346-e1358.	6.3	30

#	ARTICLE	IF	CITATIONS
1839	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862.	8.1	47
1840	Aspirin in primary prevention: the triumph of clinical judgement over complex equations. Internal and Emergency Medicine, 2019, 14, 1217-1231.	2.0	4
1841	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	7.1	15
1842	The effect of low-dose aspirin on colorectal cancer prevention and gastrointestinal bleeding according to bodyweight and body mass index: Analysis of UK primary care data. International Journal of Cardiology, 2019, 297, 135-139.	1.7	4
1843	Microvesicles from patients with acute coronary syndrome enhance platelet aggregation. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 507-512.	1.2	1
1844	Platelets Are at the Nexus of Vascular Diseases. Frontiers in Cardiovascular Medicine, 2019, 6, 132.	2.4	48
1845	Drug trends among non-institutionalized Canadians and the impact of data collection changes in the Canadian Health Measures Survey 2007 to 2015. PLoS ONE, 2019, 14, e0214718.	2.5	7
1846	<p>The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1129-1140.	2.0	9
1847	Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities. Frontiers in Cardiovascular Medicine, 2019, 6, 141.	2.4	123
1848	Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line. Open Medicine (Poland), 2019, 14, 552-560.	1.3	6
1849	Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors. International Journal of Stroke, 2021, 16, 719-726.	5.9	6
1850	Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence. Current Diabetes Reports, 2019, 19, 107.	4.2	5
1851	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation, 2019, 140, 1115-1124.	1.6	33
1852	Aspirin for Primary Prevention. JAMA - Journal of the American Medical Association, 2019, 321, 253.	7.4	12
1853	Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events. JAMA - Journal of the American Medical Association, 2019, 321, 277.	7.4	399
1854	Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?. European Heart Journal, 2019, 40, 3754-3756.	2.2	2
1855	Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?. Internal Medicine Journal, 2019, 49, 133-134.	0.8	1
1856	Prescription of Aspirin and Statins in Primary Prevention. Primary Care - Clinics in Office Practice, 2019, 46, 13-25.	1.6	3

#	ARTICLE	IF	CITATIONS
1859	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. <i>Circulation Research</i> , 2019, 124, 416-425.	4.5	29
1860	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. <i>Mayo Clinic Proceedings</i> , 2019, 94, 287-308.	3.0	49
1861	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	3.4	8
1862	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
1863	Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention. <i>Annals of Pharmacotherapy</i> , 2019, 53, 738-745.	1.9	0
1864	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. <i>American Journal of Medicine</i> , 2019, 132, e569-e580.	1.5	18
1866	Neuroprotection in Cerebrovascular Disease. <i>Springer Protocols</i> , 2019, , 175-280.	0.3	0
1867	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	1.1	841
1868	Genetic variation at the coronary artery disease risk locus <i>GUCY1A3</i> modifies cardiovascular disease prevention effects of aspirin. <i>European Heart Journal</i> , 2019, 40, 3385-3392.	2.2	25
1869	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1534-1544.	1.8	87
1870	Role of aspirin in primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 675-686.	13.7	97
1871	Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 336-344.	2.1	9
1872	Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. <i>American Heart Journal</i> , 2019, 214, 77-87.	2.7	26
1873	Synthesis of Substituted Farnesyl Acetone Derivatives and their Inhibitory Activity against Platelet Aggregation. <i>Bulletin of the Korean Chemical Society</i> , 2019, 40, 602-605.	1.9	0
1874	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	1.5	741
1875	Aspirin for Primary Prevention of Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2915-2929.	2.8	89
1876	Treatment Approaches to Lacunar Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2055-2078.	1.6	28
1877	Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. <i>EBioMedicine</i> , 2019, 44, 28-40.	6.1	37

#	ARTICLE	IF	CITATIONS
1878	The Year in Vascular Anesthesia: Selected Highlights From 2018. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2826-2832.	1.3	0
1879	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. Archives of Cardiovascular Diseases Supplements, 2019, 11, S28-S39.	0.0	0
1881	The influence of microbial isoflavonoid specific metabolites on platelets and transition metals iron and copper. Phytomedicine, 2019, 62, 152974.	5.3	3
1882	How I treat polycythemia vera. Blood, 2019, 134, 341-352.	1.4	54
1883	Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 70.	6.8	46
1884	Antiplatelet Therapy After Noncardioembolic Stroke. Stroke, 2019, 50, 1812-1818.	2.0	25
1885	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. Cardiology Research and Practice, 2019, 2019, 1-7.	1.1	5
1886	Antiplatelet Drug Management. , 2019, , 51-60.		1
1887	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, The, 2019, 393, 2613-2623.	13.7	134
1888	The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet, The, 2019, 393, 2155-2167.	13.7	140
1890	Tetraâ€PEG Based Hydrogel Sealants for In Vivo Visceral Hemostasis. Advanced Materials, 2019, 31, e1901580.	21.0	208
1891	Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study. Family Practice, 2019, 36, 706-712.	1.9	30
1892	Antithrombotic dose: Some observations from published clinical trials. British Journal of Clinical Pharmacology, 2019, 85, 2194-2197.	2.4	1
1893	â€œDoctor, Should I Keep Taking an Aspirin a Day?â€ New England Journal of Medicine, 2019, 380, 1967-1970.	27.0	17
1895	Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease. JAMA Neurology, 2019, 76, 906.	9.0	53
1896	Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefitâ€A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2019, 45, 478-489.	2.7	22
1897	The Effect of Aspirin on Preventing Vascular Access Dysfunction in Incident Hemodialysis Patients: A Prospective Cohort Study in Korean Clinical Research Centers for End-Stage Renal Disease (CRC for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
1899	The effects of secondary prevention after coronary revascularization in Taiwan. PLoS ONE, 2019, 14, e0215811.	2.5	4

#	ARTICLE	IF	CITATIONS
1900	Aspirin for primary prevention: Is this the end of the road?. Indian Heart Journal, 2019, 71, 113-117.	0.5	8
1902	Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. Annals of Medicine, 2019, 51, 182-192.	3.8	12
1903	Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI. New England Journal of Medicine, 2019, 380, 1580-1581.	27.0	14
1904	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e596-e646.	1.6	1,789
1905	Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. Stroke, 2019, 50, 947-953.	2.0	26
1907	Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs. Journal of Community Health, 2019, 44, 561-568.	3.8	11
1908	Comparative efficacy and safety of multiple antiplatelet therapies for secondary prevention of ischemic stroke or transient ischemic attack: A network meta-analysis. Journal of the Neurological Sciences, 2019, 399, 199-206.	0.6	7
1909	Aspirin use in central retinal arterial occlusion to prevent ischaemic stroke: a retrospective cohort study in Taiwan. BMJ Open, 2019, 9, e025455.	1.9	12
1910	Injectable colloidal hydrogel with mesoporous silica nanoparticles for sustained co-release of microRNA-222 and aspirin to achieve innervated bone regeneration in rat mandibular defects. Journal of Materials Chemistry B, 2019, 7, 2722-2735.	5.8	70
1911	External applicability of the COMPASS trial: the Western Denmark Heart Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 192-199.	3.0	12
1912	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1520-1574.	3.6	305
1913	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
1914	Acquired Disorders of Platelet Function. , 2019, , 905-920.		2
1915	Acetylsalicylic acid on primary prevention of cardiovascular diseases. European Journal of Preventive Cardiology, 2019, 26, 743-745.	1.8	0
1916	Engaging <sc>GP</sc> s and primary care patients in research: implications of the <sc>ASPREE</sc> trial for future studies. Medical Journal of Australia, 2019, 210, 159-160.	1.7	0
1918	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 217-224.	2.1	6
1919	The Role of Platelets in Diabetes Mellitus. , 2019, , 469-503.		9
1920	Novel Antiplatelet Therapies. , 2019, , 991-1015.		1

#	ARTICLE	IF	CITATIONS
1921	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. , 2019, , 1067-1077.		0
1922	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 74, e177-e232.	2.8	1,038
1923	Driver see, driver crash: Associations between televised stock car races™ audience size and the incidence of speed-related motor vehicle collisions in the United States. Baylor University Medical Center Proceedings, 2019, 32, 37-42.	0.5	1
1924	No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non-steroidal anti-inflammatory drugs. Diabetes, Obesity and Metabolism, 2019, 21, 1978-1984.	4.4	4
1925	Initial management for acute lower gastrointestinal bleeding. World Journal of Gastroenterology, 2019, 25, 69-84.	3.3	44
1926	Aspirin for the primary prevention of cardiovascular disease in the elderly. BMJ Evidence-Based Medicine, 2019, 24, 143-144.	3.5	3
1927	Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies. Biochemical Pharmacology, 2019, 163, 119-127.	4.4	5
1928	Gastrointestinal Hemorrhage in Patients with Acute Ischemic Stroke: Should Endoscopy Be Within the Scope of Practice?. Digestive Diseases and Sciences, 2019, 64, 1395-1396.	2.3	1
1929	No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA. Clinical Orthopaedics and Related Research, 2019, 477, 396-402.	1.5	27
1930	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. European Journal of Preventive Cardiology, 2019, 26, 820-823.	1.8	8
1931	Complications Associated with Neuraxial Blockade. , 2019, , 21-41.		0
1932	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. International Journal of Cardiology, 2019, 286, 198-207.	1.7	23
1933	General Aspects of Primary Cancer Prevention. Digestive Diseases, 2019, 37, 406-415.	1.9	15
1934	Results of the ASCEND study: time to abandon aspirin for the primary prevention of cardiovascular disease in people with diabetes. Practical Diabetes, 2019, 36, 4.	0.3	1
1935	Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention. Annals of Internal Medicine, 2019, 171, 529.	3.9	16
1936	Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 170, 357.	3.9	23
1937	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2019. Diabetes Care, 2019, 42, S103-S123.	8.6	676
1938	High dose versus low dose Aspirin after Percutaneous Coronary Intervention in Coronary Artery Disease. Nepalese Heart Journal, 2019, 16, 59-62.	0.1	2

#	ARTICLE	IF	CITATIONS
1939	Medical therapeutics: mortality effects, uncertainty, and informed consent. Porto Biomedical Journal, 2019, 4, e35.	1.0	1
1940	Prolong antiplatelet therapy. Where we stand?. Hellenic Journal of Cardiology, 2019, 60, 269-270.	1.0	0
1941	Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits. BMC Geriatrics, 2019, 19, 366.	2.7	0
1942	Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI. Therapie, 2019, 74, 459-468.	1.0	5
1943	Gender-based differences in platelet function and platelet reactivity to P2Y12 inhibitors. PLoS ONE, 2019, 14, e0225771.	2.5	39
1944	Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLoS ONE, 2019, 14, e0224580.	2.5	3
1945	Invited correspondence on: "Aspirin for patients undergoing major lung resections: hazardous or harmless?" Journal of Thoracic Disease, 2019, 11, E194-E195.	1.4	0
1946	Aspirin for primary prevention of CVD in CKD: where do we stand?. British Journal of General Practice, 2019, 69, 590-591.	1.4	5
1947	Omitting aspirin in PCI patients: Myth or reality?. Cardiovascular Drugs and Therapy, 2019, 33, 711-724.	2.6	4
1948	Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension, 2019, 37, 1301-1307.	0.5	8
1949	A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes. Journal of Diabetes Research, 2019, 2019, 1-6.	2.3	3
1950	Impact of long-term therapy with acetylsalicylic acid on immature platelet count. Journal of Cardiovascular Medicine, 2019, 20, 306-312.	1.5	3
1951	Impact of gastric endoscopic submucosal dissection in elderly patients. Medicine (United States), 2019, 98, e14842.	1.0	7
1952	Preoperative Management of Antithrombotics in Arthroplasty. Journal of the American Academy of Orthopaedic Surgeons, The, 2019, 27, 878-886.	2.5	11
1953	COMPASS for Vascular Surgeons. Current Opinion in Cardiology, 2019, 34, 178-184.	1.8	7
1954	Diabetes and Cardiovascular Disease: an Update. Current Diabetes Reports, 2019, 19, 161.	4.2	53
1955	Firefighting Induces Acute Inflammatory Responses that are not Relieved by Aspirin in Older Firefighters. Journal of Occupational and Environmental Medicine, 2019, 61, 617-622.	1.7	11
1956	Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel. Medicine (United States), 2019, 98, e14685.	1.0	7

#	ARTICLE	IF	CITATIONS
1957	Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study. <i>Journal of the American Heart Association</i> , 2019, 8, e013404.	3.7	12
1958	Antithrombotic Management After Intracranial Hemorrhage. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 88.	0.9	2
1959	Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy. <i>BMC Nephrology</i> , 2019, 20, 442.	1.8	7
1960	Not all head injured patients on antiplatelet drugs need platelets: Integrating platelet reactivity testing into platelet transfusion guidelines. <i>Injury</i> , 2019, 50, 73-78.	1.7	10
1961	Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat. <i>FASEB Journal</i> , 2019, 33, 1510-1521.	0.5	8
1962	Incidence of Upper and Lower Gastrointestinal Bleeding in New Users of Low-Dose Aspirin. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 887-895.e6.	4.4	27
1963	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 299-311.	2.2	13
1964	The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!. <i>European Heart Journal</i> , 2019, 40, 618-620.	2.2	10
1965	Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019, 40, 607-617.	2.2	124
1966	A farewell to aspirin in primary prevention?. <i>Nature Reviews Cardiology</i> , 2019, 16, 76-77.	13.7	3
1967	Prospects for the Primary Prevention of Myocardial Infarction and Stroke. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 207-214.	2.0	38
1968	Cerebrovascular Disease. <i>Medical Clinics of North America</i> , 2019, 103, 295-308.	2.5	124
1969	Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015. <i>Diabetic Medicine</i> , 2019, 36, 878-887.	2.3	5
1970	Quality of Life for 19,114 participants in the ASPREE (ASpirin in Reducing Events in the Elderly) study and their association with sociodemographic and modifiable lifestyle risk factors. <i>Quality of Life Research</i> , 2019, 28, 935-946.	3.1	21
1971	Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 57, 199-211.	1.5	29
1972	Carotid Artery-Related Perioperative Stroke Following Anterior Cervical Spine Surgery: A Series of 3 Cases and Literature Review. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 458-463.	1.6	3
1973	The Psychological Risk of Minimal Risk Activities: A Pre- and Posttest Study Using the Self-Assessment Manikin. <i>Journal of Empirical Research on Human Research Ethics</i> , 2019, 14, 15-22.	1.3	8
1974	Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 528-537.	2.0	8

#	ARTICLE	IF	CITATIONS
1975	Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 6, 23-31.	4.0	10
1976	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019, 40, 336-344.	2.2	26
1977	The SCOT-HEART Trial. What we observed and what we learned. <i>Journal of Cardiovascular Computed Tomography</i> , 2019, 13, 54-58.	1.3	14
1978	Critical limb ischemia: Current and novel therapeutic strategies. <i>Journal of Cellular Physiology</i> , 2019, 234, 14445-14459.	4.1	19
1979	Post-thoracic Surgery Patient Management and Complications. , 2019, , 953-968.		0
1980	Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. <i>Atherosclerosis</i> , 2019, 282, 11-18.	0.8	70
1981	Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2019, 50, 773-778.	2.0	74
1982	Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. <i>International Journal of Cardiology</i> , 2019, 275, 171-178.	1.7	16
1983	Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 157-163.	2.7	14
1984	The first 3500+ years of aspirin history from its roots – A concise summary. <i>Vascular Pharmacology</i> , 2019, 113, 1-8.	2.1	132
1985	Endoscopy Is Relatively Safe in Patients with Acute Ischemic Stroke and Gastrointestinal Hemorrhage. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1588-1598.	2.3	7
1986	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.1	0
1987	Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 746-749.	1.8	6
1988	Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery. <i>Journal of Anesthesia</i> , 2019, 33, 90-95.	1.7	6
1989	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	13.7	73
1990	Intravesical lidocaine decreases autonomic dysreflexia when administered prior to catheter change. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 557-561.	1.4	7
1991	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
1992	Anticoagulation in the Perioperative Period. , 2019, , 721-733.		0

#	ARTICLE	IF	CITATIONS
1993	The transtelephonic electrocardiogram-based triage is an independent predictor of decreased hospital mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 216-222.	2.7	6
1994	Safety of elective laparoscopic cholecystectomy in patients with antiplatelet therapy: Lessons from more than 800 operations in a single tertiary referral institution. <i>Asian Journal of Endoscopic Surgery</i> , 2020, 13, 33-38.	0.9	8
1995	A broken paradigm? What education needs to learn from evidence-based medicine. <i>Journal of Education Policy</i> , 2020, 35, 648-664.	2.8	31
1996	Myocardial injury after non-cardiac surgery: diagnosis and management. <i>European Heart Journal</i> , 2020, 41, 3083-3091.	2.2	110
1997	Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 182-188.	0.8	0
1998	Letter to the Editor. <i>Clinical Infectious Diseases</i> , 2020, 70, 355-356.	5.8	0
1999	Weight as an assay-independent predictor of poor response to enteric aspirin in cardiovascular patients. <i>Platelets</i> , 2020, 31, 530-535.	2.3	11
2000	Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. <i>Global Heart</i> , 2019, 14, 303.	2.3	9
2001	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <i>Atherosclerosis</i> , 2020, 293, 94-100.	0.8	109
2002	Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 443-451.	4.7	4
2003	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 57-68.	3.0	13
2004	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	13.7	89
2005	Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. <i>Journal of Orthopaedic Science</i> , 2020, 25, 156-160.	1.1	7
2006	Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 522-532.	1.0	28
2007	Comparison of anticoagulants and risk factors for bleeding following endoscopic sphincterotomy among anticoagulant users: Results from a large multicenter retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 37-42.	2.8	6
2008	Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 37-46.	2.0	9
2009	Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. <i>Heart and Vessels</i> , 2020, 35, 170-176.	1.2	5
2010	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210

#	ARTICLE	IF	CITATIONS
2011	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
2012	Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 3-6.	2.0	17
2013	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	2.2	55
2014	Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 251-257.	1.2	16
2015	Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study. <i>Journal of Neurosurgery</i> , 2020, 132, 1529-1538.	1.6	21
2016	Angiographically visible coronary artery collateral circulation improves prognosis in patients presenting with acute ST segmentâ€elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 528-533.	1.7	8
2017	Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. <i>Journal of Arthroplasty</i> , 2020, 35, 886-892.	3.1	44
2018	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108008.	2.8	18
2019	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
2020	Aspirin antiplatelet effects are associated with body weight. <i>Vascular Pharmacology</i> , 2020, 125-126, 106635.	2.1	9
2021	Dual versus Single Antiplatelet Therapy in Carotid Artery Endarterectomy: Direct Comparison of Complications Related to Antiplatelet Therapy. <i>World Neurosurgery</i> , 2020, 135, e598-e609.	1.3	8
2022	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Riskâ€”A Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 199-206.	3.4	5
2023	Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 123-127.	1.0	3
2024	Aspirin for the Primary Prevention of Cardiovascular Disease. <i>Cardiology in Review</i> , 2020, 28, 98-106.	1.4	4
2025	A comparison of contemporary versus older studies of aspirin for primary prevention. <i>Family Practice</i> , 2020, 37, 290-296.	1.9	10
2026	Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. <i>Drugs and Aging</i> , 2020, 37, 43-55.	2.7	8
2027	Review of the top 5 cardiology studies of 2017-18. <i>Canadian Pharmacists Journal</i> , 2020, 153, 32-36.	0.8	2
2028	The role of aspirin in the prevention of ovarian, endometrial and cervical cancers. <i>Women's Health</i> , 2020, 16, 174550652096171.	1.5	6

#	ARTICLE	IF	CITATIONS
2029	Clinical profile and drug therapy of outpatients with arterial hypertension. Rational Pharmacotherapy in Cardiology, 2020, 16, 206-212.	0.8	0
2030	Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis. Cardiovascular Drugs and Therapy, 2021, 35, 871-873.	2.6	1
2031	The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease. ReumatologĀa ClĀnica (English Edition), 2020, 16, 311-312.	0.3	0
2032	Aspirin might reduce the incidence of breast cancer. Medicine (United States), 2020, 99, e21917.	1.0	16
2033	The long journey of individualizing antiplatelet therapy after acute coronary syndromes. European Heart Journal, 2020, 41, 3546-3548.	2.2	6
2034	Current state and future perspective of cardiovascular medicines derived from natural products. , 2020, 216, 107698.		41
2035	Management of Acute Ischemic Stroke. Critical Care Medicine, 2020, 48, 1654-1663.	0.9	316
2037	STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial. European Stroke Journal, 2020, 5, 414-422.	5.5	5
2038	Treatment of intracerebral hemorrhage: Current approaches and future directions. Journal of the Neurological Sciences, 2020, 416, 117020.	0.6	27
2039	Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia. International Journal of Molecular Sciences, 2020, 21, 4983.	4.1	10
2040	Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12056.	3.7	23
2041	Management of Antiphospholipid Syndrome. Biomedicines, 2020, 8, 508.	3.2	17
2042	Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Annals of Hematology, 2020, 100, 2015-2022.	1.8	16
2043	Risks of adverse events for users of protonĀpump inhibitors plus aspirin or clopidogrel in patients with aspirinĀrelated ulcer bleeding. Journal of Gastroenterology and Hepatology (Australia), 2020, 36, 1828-1835.	2.8	3
2044	In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding. Annals of Internal Medicine, 2020, 173, JC27.	3.9	0
2045	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. European Heart Journal Supplements, 2020, 22, L166-L169.	0.1	4
2046	VEGF-A in Cardiomyocytes and Heart Diseases. International Journal of Molecular Sciences, 2020, 21, 5294.	4.1	121
2047	Aspirin and low-dose rivaroxaban Āthe dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	1.5	1

#	ARTICLE	IF	CITATIONS
2048	Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study. PLoS ONE, 2020, 15, e0237022.	2.5	15
2049	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. Future Cardiology, 2020, 16, 597-611.	1.2	0
2050	Novel Approaches to Fine-Tune Therapeutic Targeting of Platelets in Atherosclerosis: A Critical Appraisal. Thrombosis and Haemostasis, 2020, 120, 1492-1504.	3.4	6
2051	Aspirin (single dose) for perineal pain in the early postpartum period. The Cochrane Library, 2020, 2020, CD012129.	2.8	4
2052	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries, 2020, 40, 1-122.	0.8	16
2053	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?. Drugs, 2020, 80, 1383-1396.	10.9	93
2054	Aspirin use for cardiovascular disease prevention in the uninsured population. SAGE Open Medicine, 2020, 8, 205031212093822.	1.8	3
2055	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology, 2020, 191, 171-193.	2.5	38
2056	Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. FASEB Journal, 2020, 34, 10027-10040.	0.5	10
2057	Dental implant surgery and risk of bleeding in patients on antithrombotic medications: A review of the literature. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 130, 522-532.	0.4	9
2058	Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. Visceral Medicine, 2020, 36, 264-273.	1.3	3
2059	Inappropriate use of antiplatelet agents for primary prevention in nursing homes: An Italian multicenter observational study. Geriatrics and Gerontology International, 2020, 20, 828-832.	1.5	3
2060	Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2020, 9, e017109.	3.7	8
2061	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. Journal of the American College of Cardiology, 2020, 76, 2252-2266.	2.8	52
2062	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2020. Diabetes Care, 2020, 43, S111-S134.	8.6	421
2063	Prescription prevalence of low dose aspirin in primary prevention in the Spanish population, trends over time and associated factors. Medicina Clínica (English Edition), 2020, 155, 104-111.	0.2	0
2064	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	1.7	313
2065	All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study. BMJ Open, 2020, 10, e030034.	1.9	6

#	ARTICLE	IF	CITATIONS
2066	Resistance to Antiplatelet Therapy Is Associated With Symptoms of Cerebral Ischemia in Carotid Artery Disease. <i>Vascular and Endovascular Surgery</i> , 2020, 54, 712-717.	0.7	7
2067	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. <i>Circulation</i> , 2020, 142, 1579-1590.	1.6	28
2068	Anticoagulation and antiplatelet therapy in patients with prosthetic heart valves. <i>Journal of Cardiac Surgery</i> , 2020, 35, 3521-3529.	0.7	4
2069	The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases. <i>Rheumatology</i> , 2020, 59, 3593-3602.	1.9	2
2070	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1838-1847.	27.0	1,010
2071	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies. <i>EBioMedicine</i> , 2020, 60, 102978.	6.1	22
2072	The Role of Aspirin After High-Risk Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2020, 9, 489-498.	0.4	1
2073	Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5840.	2.6	5
2075	Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?. <i>Journal of European CME</i> , 2020, 9, 1836866.	1.6	3
2076	Evaluating the safety of early surgery for ruptured intracranial aneurysms in patients with long-term aspirin use: a propensity score matching study. <i>Chinese Neurosurgical Journal</i> , 2020, 6, 37.	0.9	2
2077	Risk-Benefit Events Associated with the Use of Aspirin for Primary Prevention of Cardiovascular Disorders. , 2020, , .		0
2079	2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease. <i>Chinese Medical Journal</i> , 2020, 133, 1221-1223.	2.3	7
2080	Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. <i>Lancet, The</i> , 2020, 395, 1487-1495.	13.7	104
2081	Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2020, 153, 153-160.	0.8	1
2082	Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events. <i>Cmaj</i> , 2020, 192, E302-E311.	2.0	13
2083	An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). <i>Medicine (United States)</i> , 2020, 99, e20307.	1.0	0
2084	Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. <i>Life Sciences</i> , 2020, 253, 117720.	4.3	4
2085	Platelet Responses in Cardiovascular Disease: Sex-Related Differences in Nutritional and Pharmacological Interventions. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-16.	2.5	7

#	ARTICLE	IF	CITATIONS
2086	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	2.4	82
2087	Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma. <i>Internal and Emergency Medicine</i> , 2020, 15, 1169-1181.	2.0	7
2088	Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. <i>Current Cardiology Reports</i> , 2020, 22, 48.	2.9	5
2089	A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden. <i>PLoS Medicine</i> , 2020, 17, e1003135.	8.4	10
2090	Antiplatelet properties of Pim kinase inhibition are mediated through disruption of thromboxane A2 receptor signaling. <i>Haematologica</i> , 2021, 106, 1968-1978.	3.5	7
2091	Who needs acetylsalicylic acid? Some order after many studies. <i>European Heart Journal Supplements</i> , 2020, 22, E37-E39.	0.1	1
2092	JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2020, 84, 831-865.	1.6	197
2093	Structural modification of aspirin to design a new potential cyclooxygenase (COX-2) inhibitors. In <i>Silico Pharmacology</i> , 2020, 8, 1.	3.3	25
2094	Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2020, 14, 175394472091207.	2.1	6
2095	Rationale and Design of the Aspirin Dosing "A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020, 5, 598.	6.1	59
2096	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 413-421.	2.3	9
2097	Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019. <i>Circulation</i> , 2020, 141, 1541-1553.	1.6	107
2098	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1340-1351.	2.4	56
2099	Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. <i>JRSM Cardiovascular Disease</i> , 2020, 9, 204800402090700.	0.7	1
2100	Refining prediction of major bleeding on antiplatelet treatment after transient ischaemic attack or ischaemic stroke. <i>European Stroke Journal</i> , 2020, 5, 130-137.	5.5	1
2101	Shear-Induced Platelet Activation is Sensitive to Age and Calcium Availability: A Comparison of Adult and Cord Blood. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 575-590.	2.1	2
2102	Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?. <i>Current Atherosclerosis Reports</i> , 2020, 22, 34.	4.8	1
2103	Impact of Antithrombotic Agents on Postpancreatectomy Hemorrhage: Results from a Retrospective Multicenter Study. <i>Journal of the American College of Surgeons</i> , 2020, 231, 460-469e1.	0.5	9

#	ARTICLE	IF	CITATIONS
2104	Platelets as therapeutic targets to prevent atherosclerosis. <i>Atherosclerosis</i> , 2020, 307, 97-108.	0.8	47
2105	Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care*. <i>Critical Care Medicine</i> , 2020, 48, 985-992.	0.9	5
2106	Low density lipoprotein cholesterol values and outcome of stroke patients: influence of previous aspirin therapy. <i>Neurological Research</i> , 2020, 42, 267-274.	1.3	0
2107	Number Needed to Treat with Vertebral Augmentation to Save a Life. <i>American Journal of Neuroradiology</i> , 2020, 41, 178-182.	2.4	23
2108	Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 181-187.	3.6	63
2109	New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 15, 873-880.	0.8	0
2110	Symptomatic and asymptomatic intracranial atherosclerotic stenosis: 3 yearsâ€™ prospective study. <i>Journal of Neurology</i> , 2020, 267, 1687-1698.	3.6	9
2111	Ischemic Heart Disease: An Update. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 195-207.	4.6	40
2112	Incidence and Predictors of Aspirin Discontinuation in Older Adult Veteran Nursing Home Residents at End of Life. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 725-735.	2.6	10
2113	Pathophysiology of chronic peripheral ischemia: new perspectives. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062231989446.	2.5	13
2114	Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 337-343.	2.1	11
2115	Aspirin in Primary Prevention: Needs Individual Clinical Judgments. <i>American Journal of Medicine</i> , 2020, 133, 774-776.	1.5	3
2116	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	13.7	87
2117	Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104584.	1.6	8
2118	The emergent phenomenon of aspirin resistance: insights from genetic association studies. <i>Pharmacogenomics</i> , 2020, 21, 125-140.	1.3	19
2119	Aspirin moderates the association between cardiovascular risk, brain white matter hyperintensity total lesion volume and processing speed in normal ageing. <i>Maturitas</i> , 2020, 133, 49-53.	2.4	4
2120	Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990â€“2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1201-1213.	1.8	26
2121	Aspirin Reduces the Potentiating Effect of CD40L on Platelet Aggregation via Inhibition of Myosin Light Chain. <i>Journal of the American Heart Association</i> , 2020, 9, e013396.	3.7	9

#	ARTICLE	IF	CITATIONS
2122	Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2020, 72, 2130-2138.	1.1	11
2123	Chronic subdural haematoma in antithrombotic cohorts: characteristics, surgical outcomes, and recurrence. <i>British Journal of Neurosurgery</i> , 2020, 34, 408-415.	0.8	12
2124	Vascular vantage point. <i>Journal of Vascular Surgery</i> , 2020, 71, 1449.	1.1	0
2125	Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 928.	2.4	9
2126	Synthetic Ruthenium Complex TQ-6 Potently Recovers Cerebral Ischemic Stroke: Attenuation of Microglia and Platelet Activation. <i>Journal of Clinical Medicine</i> , 2020, 9, 996.	2.4	7
2127	Choosing antithrombotics for atrial fibrillation in primary care. <i>British Journal of General Practice</i> , 2020, 70, 102-103.	1.4	1
2128	Consumption of Diet Soda Sweetened with Sucralose and Acesulfameâ€Potassium Alters Inflammatory Transcriptome Pathways in Females with Overweight and Obesity. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1901166.	3.3	15
2129	An Assessment of Patients Factors Effect on Prescriber Adherence to Ischemic Stroke Secondary Prevention Guidelines. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2021, 16, 97-102.	0.8	2
2130	Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. <i>Blood Reviews</i> , 2021, 45, 100694.	5.7	87
2131	Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 218-224.	3.0	12
2132	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. <i>Future Cardiology</i> , 2021, 17, 175-182.	1.2	1
2133	Selecting an Optimal Antiplatelet Agent for Secondary Stroke Prevention. <i>Neurology: Clinical Practice</i> , 2021, 11, e121-e128.	1.6	3
2134	Clinical practice for antiplatelet and anticoagulant therapy in neurosurgery: data from an Italian survey and summary of current recommendations â€“ part I, antiplatelet therapy. <i>Neurosurgical Review</i> , 2021, 44, 485-493.	2.4	13
2135	The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1221-1229.	1.7	0
2136	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 125-140.	3.0	31
2137	Aspirin for Primary Prevention of Coronary Artery Disease. <i>Current Problems in Cardiology</i> , 2021, 46, 100553.	2.4	6
2138	Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis. <i>European Journal of Internal Medicine</i> , 2021, 83, 14-20.	2.2	3
2139	Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2021, 6, 179.	6.1	55

#	ARTICLE	IF	CITATIONS
2140	Intracerebral haemorrhage, microbleeds and antithrombotic drugs. <i>Revue Neurologique</i> , 2021, 177, 11-22.	1.5	3
2141	Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. <i>Gut</i> , 2021, 70, 717-724.	12.1	54
2142	A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. <i>International Journal of Cancer</i> , 2021, 148, 1323-1330.	5.1	9
2143	Cleaning Up the MESS: Can Machine Learning Be Used to Predict Lower Extremity Amputation after Trauma-Associated Arterial Injury?. <i>Journal of the American College of Surgeons</i> , 2021, 232, 102-113e4.	0.5	7
2144	Cardiovascular risk prediction tools made relevant for GPs and patients. <i>Heart</i> , 2021, 107, 332-340.	2.9	5
2145	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. <i>Journal of Palliative Medicine</i> , 2021, 24, 273-284.	1.1	5
2146	Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. <i>American Journal of Cardiology</i> , 2021, 141, 38-48.	1.6	12
2147	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). <i>European Journal of Internal Medicine</i> , 2021, 85, 1-13.	2.2	31
2148	The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: AAWork Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 827-844.	2.9	69
2149	P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials. <i>Thrombosis Research</i> , 2021, 198, 115-121.	1.7	2
2150	Polypill with or without Aspirin in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 216-228.	27.0	163
2151	Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Hepatology Communications</i> , 2021, 5, 133-143.	4.3	39
2152	Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. <i>Vascular Pharmacology</i> , 2021, 136, 106819.	2.1	5
2153	Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. <i>Clinical and Translational Science</i> , 2021, 14, 645-655.	3.1	7
2154	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
2155	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2021</i>. <i>Diabetes Care</i> , 2021, 44, S125-S150.	8.6	359
2156	Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases. <i>American Journal of Preventive Medicine</i> , 2021, 60, 513-519.	3.0	7
2157	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	4.3	40

#	ARTICLE	IF	CITATIONS
2158	The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach. American Journal of Cardiovascular Drugs, 2021, 21, 139-151.	2.2	6
2159	Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. European Respiratory Journal, 2021, 57, 2002795.	6.7	9
2160	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
2161	Determinants of ST-segment elevation myocardial infarction as clinical presentation of acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2021, 51, 1026-1035.	2.1	5
2162	Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. Cardiovascular Drugs and Therapy, 2021, 35, 539-547.	2.6	4
2163	A review of diagnosis, etiology, assessment, and management of patients with myocardial infarction in the absence of obstructive coronary artery disease. Hospital Practice (1995), 2021, 49, 12-21.	1.0	3
2164	Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations. Expert Opinion on Pharmacotherapy, 2021, 22, 83-91.	1.8	7
2165	Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies. Journal of Public Health, 2021, 43, 308-315.	1.8	6
2166	Cardiovascular Medications. , 2021, , 597-642.		1
2167	Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade—why it could be a novel paradigm?. , 2021, , 167-191.		0
2168	Effects of low-dose aspirin on the osseointegration process in rats. International Journal of Implant Dentistry, 2021, 7, 3.	2.7	1
2169	The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2022, 36, 263-269.	2.6	1
2170	Neurological complications of cardiovascular drugs. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 319-344.	1.8	1
2171	Risk-Stratified Venous Thromboembolism Prophylaxis after Total Joint Arthroplasty: Low Molecular Weight Heparins and Sequential Aspirin vs Aggressive Chemoprophylaxis. Orthopaedic Surgery, 2021, 13, 260-266.	1.8	2
2172	Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence. Advances in Experimental Medicine and Biology, 2021, 1286, 145-161.	1.6	7
2173	Intracerebral Haemorrhage. , 2021, , 127-159.		0
2174	Cardiovascular Diseases Prevention Across Populations During Urbanization in China: A Nationwide Population-Based Study. SSRN Electronic Journal, 0, , .	0.4	0
2175	Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients?. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110145.	1.7	4

#	ARTICLE	IF	CITATIONS
2177	Vascular disease prevention and screening in women. , 2021, , 297-306.		0
2178	Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110069.	2.7	7
2179	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovascular Research, 2021, 117, 2001-2015.	3.8	55
2180	New horizons: managing antithrombotic dilemmas in patients with cerebral amyloid angiopathy. Age and Ageing, 2021, 50, 347-355.	1.6	10
2181	Cerebrovascular diseases and personalized prevention. Profilakticheskaya Meditsina, 2021, 24, 76.	0.6	3
2182	Resuming aspirin in patients with non-variceal upper gastrointestinal bleeding: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 344-353.	0.6	2
2183	Cerebrovascular disease—what is the role of dual antiplatelet therapy for the prevention and treatment of ischemic stroke?. , 2021, , 91-110.		1
2184	Low-Dose Aspirin Use Among African American Older Adults. Journal of the American Board of Family Medicine, 2021, 34, 132-143.	1.5	4
2186	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. European Heart Journal, 2021, 42, 561-562.	2.2	2
2187	Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea. Yonsei Medical Journal, 2021, 62, 577.	2.2	3
2188	Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study. BMJ Open, 2021, 11, e041715.	1.9	4
2189	Aspirin in the Modern Era of Cardiovascular Disease Prevention. Methodist DeBakey Cardiovascular Journal, 2021, 17, 36-47.	1.0	10
2190	Aspirin in people with dementia, long-term benefits, and harms: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 943-954.	1.9	13
2191	Association of Mortality with Antiplatelet Treatment in Patients with Stent Placement or Angioplasty: A Population-Based Nested Case-Control Study. Yonsei Medical Journal, 2021, 62, 75.	2.2	0
2192	Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. Journal of Racial and Ethnic Health Disparities, 2022, 9, 538-545.	3.2	4
2194	The Total Thrombus Formation (T-TAS) platelet (PL) assay, a novel test that evaluates whole blood platelet thrombus formation under physiological conditions. Platelets, 2022, 33, 273-277.	2.3	4
2195	Medical therapy for cardiovascular and limb-related risk reduction in critical limb ischemia. Vascular Medicine, 2021, 26, 210-224.	1.5	8
2196	Author Response: AAN Position Statement: Ethical Issues in Clinical Research in Neurology. Neurology, 2021, 96, 409-409.	1.1	0

#	ARTICLE	IF	CITATIONS
2197	Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go. <i>European Respiratory Journal</i> , 2021, 57, 2003778.	6.7	2
2198	Effects and Issues of Diet Fat on Cardiovascular Metabolism. , 0, , .		0
2199	Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 957-965.	1.5	3
2200	Combination of Panax notoginseng saponins and aspirin potentiates platelet inhibition with alleviated gastric injury via modulating arachidonic acid metabolism. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111165.	5.6	31
2201	Clinicians'™ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study. <i>BMJ Open</i> , 2021, 11, e042261.	1.9	6
2202	Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among <scp>U.S.</scp> Adults Aged 50 or Older, 2011-2018. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1272-1282.	2.6	19
2203	“To take or not to take an aspirin?” The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease. <i>Kidney International</i> , 2021, 99, 308-310.	5.2	2
2204	Thrombocytopenia and Clinical Outcomes in Intracerebral Hemorrhage. <i>Stroke</i> , 2021, 52, 611-619.	2.0	6
2205	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	2.2	29
2206	Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e019184.	3.7	11
2207	Antithrombotic strategies in elderly patients with acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 232-245.	1.6	2
2208	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 459-468.	2.2	5
2209	Safety of antithrombotic therapy in East Asian patients. <i>Internal and Emergency Medicine</i> , 2021, 16, 1443-1450.	2.0	7
2210	Diabetes and Stroke. <i>Journal of Korean Diabetes</i> , 2021, 22, 26-37.	0.3	1
2211	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2021, 33, 85-107.	0.2	4
2212	Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105581.	1.6	7
2213	Cancer Prevention in Patients with GERD and Barrett's Esophagus” Medicine. <i>Foregut</i> , 2021, 1, 50-62.	0.5	1
2214	Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease and low bodyweight: results from KNOW-CKD study. <i>Scientific Reports</i> , 2021, 11, 6691.	3.3	8

#	ARTICLE	IF	CITATIONS
2215	Risk factors and prognostic impact of post-discharge bleeding after endovascular therapy for peripheral artery disease. <i>Vascular Medicine</i> , 2021, 26, 281-287.	1.5	1
2216	Association Between Aspirin Use and Decreased Risk of Pneumonia in Patients With Cardio-Cerebra-Vascular Ischemic Disease: A Population-Based Cohort Study. <i>Frontiers in Public Health</i> , 2021, 9, 625834.	2.7	2
2217	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	16.0	80
2218	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq1 1 0.784314 rgBT /Overloc	4.6	79
2219	PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. <i>BMJ Open</i> , 2021, 11, e041845.	1.9	14
2220	Comentario del CEIPV a la actualizaci3n de las Gu3as Europeas de Prevenci3n Vascular en la Pr3ctica Cl3nica. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 85-107.	0.8	1
2221	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021, 42, 2765-2775.	2.2	119
2222	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 424-431.	4.7	7
2223	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	2.4	3
2224	Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials. <i>Journal of Hypertension</i> , 2021, 39, 1689-1696.	0.5	1
2225	Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 1721.	2.4	2
2226	Antithrombotic Management of Elderly Patients With CoronaryArteryDisease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 723-738.	2.9	22
2227	The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 246-258.	1.5	2
2228	An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). <i>Medical Journal of Australia</i> , 2021, 214, 420-427.	1.7	7
2229	Overview of Aspirin and Platelet Biology. <i>American Journal of Cardiology</i> , 2021, 144, S2-S9.	1.6	22
2230	Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4354.	4.1	10
2231	Dairy consumption and mortality after myocardial infarction: a prospective analysis in the Alpha Omega Cohort. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 59-69.	4.7	15
2232	Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2021, 144, S15-S22.	1.6	16

#	ARTICLE	IF	CITATIONS
2233	Chronic Coronary Syndromes in Women. Mayo Clinic Proceedings, 2021, 96, 1058-1070.	3.0	6
2234	Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease. American Journal of Cardiology, 2021, 145, 1-11.	1.6	22
2235	Prevalence and Effect of Cerebral Small Vessel Disease in Stroke Patients With Aspirin Treatment Failure—A Hospital-Based Stroke Secondary Prevention Registry. Frontiers in Neurology, 2021, 12, 645444.	2.4	2
2236	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. European Cardiology Review, 2021, 16, e14.	2.2	4
2237	Diagnosis and Management of Stable Angina. JAMA - Journal of the American Medical Association, 2021, 325, 1765.	7.4	44
2238	Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. Journal of Clinical Medicine, 2021, 10, 2419.	2.4	40
2239	Aspirin at 120: Retiring, recombining, or repurposing?. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12516.	2.3	6
2240	Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2847.	1.4	3
2241	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology, 2021, , .	1.8	3
2242	Contemporary outcomes of traumatic popliteal artery injury repair from the popliteal scoring assessment for vascular extremity injury in trauma study. Journal of Vascular Surgery, 2021, 74, 1573-1580.e2.	1.1	11
2243	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology, 2021, 26, 4449.	1.4	63
2244	Troponin Elevation After Ischemic Stroke and Future Cardiovascular Risk: Is the Heart in the Right Place?. Journal of the American Heart Association, 2021, 10, e021474.	3.7	3
2245	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	1.5	3
2246	Serum Albumin, Body Mass Index, and Preceding Xa and P2Y12 Inhibitors Predict Prognosis of Recurrent Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105681.	1.6	3
2247	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction. Therapeutics and Clinical Risk Management, 2021, Volume 17, 441-452.	2.0	1
2248	Antiplatelet therapy for secondary prevention of cardiovascular disease: challenging the certainties. Lancet, The, 2021, 397, 2443-2444.	13.7	6
2249	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. Future Cardiology, 2021, 17, 521-534.	1.2	3
2250	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	27.0	145

#	ARTICLE	IF	CITATIONS
2251	Antiplatelet regimens for Asian patients with ischemic stroke or transient ischemic attack: a systematic review and network meta- analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 753-753.	1.7	4
2252	COVID-19 vaccines: effectiveness and number needed to treat. <i>Lancet Microbe</i> , The, 2021, 2, e281.	7.3	4
2253	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.8	9
2254	Antiplatelet therapy increases symptomatic ICH risk after thrombolysis and thrombectomy. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 500-508.	2.1	3
2255	Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018. <i>JAMA Network Open</i> , 2021, 4, e218380.	5.9	17
2256	Diabetes mellitus, platelet function and acetylsalicylic acid. <i>Mã~Å¼narodnij EndokrinologÃ~Änij Å½urnal</i> , 2021, 17, 250-257.	0.4	0
2257	Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review. <i>American Journal of Health-System Pharmacy</i> , 2021, , .	1.0	0
2259	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. <i>European Cardiology Review</i> , 2021, 16, e26.	2.2	7
2260	Optimal Medical Management of Asymptomatic Carotid Stenosis. <i>Stroke</i> , 2021, 52, 2191-2198.	2.0	17
2261	Prevention of Non-Cardiogenic Ischemic Stroke: Towards Personalized Stroke Care. , 0, , 133-148.		1
2263	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1671-1690.	2.6	5
2264	The Effects of Aspirin With Combined Compound Danshen Dropping Pills on Hemorheology and Blood Lipids in Middle-Aged and Elderly Patients With CHD: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 664841.	2.7	3
2265	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 800-814.	2.7	12
2266	Use of Preventive Aspirin Among Older US Adults With and Without Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2112210.	5.9	16
2267	Towards individualised secondary prevention after intracerebral haemorrhage. <i>Lancet Neurology</i> , The, 2021, 20, 411-413.	10.2	0
2268	Low Dose Aspirin in high-risk pregnancies: The volatile effect of acetylsalicylic acid on the inhibition of platelets uncovered by G. Bornâ€™s light transmission aggregometry. <i>Journal of Reproductive Immunology</i> , 2021, 145, 103320.	1.9	3
2269	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â€™2018. <i>Scientific Reports</i> , 2021, 11, 13603.	3.3	8
2270	Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. <i>Lancet</i> , The, 2021, 397, 2487-2496.	13.7	162

#	ARTICLE	IF	CITATIONS
2271	Contemporary Medical Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2021, 128, 1868-1884.	4.5	53
2272	Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. <i>Blood</i> , 2021, 138, 2269-2277.	1.4	13
2273	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2720.	2.4	5
2274	Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. <i>Ecancermedicalscience</i> , 2021, 15, 1258.	1.1	20
2275	A Twin-Herbal Combination was found to have Cardio-Vascular Protection Effects after repeated RCTs on four groups of patients with Different Disease Background A Cross-Biostatistical Study. <i>Journal of Cardiovascular Medicine and Cardiology</i> , 0, , 063-068.	0.1	0
2276	De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
2277	An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. <i>Trials</i> , 2021, 22, 452.	1.6	6
2278	Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. <i>TH Open</i> , 2021, 05, e230-e238.	1.4	4
2279	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECTâ€CVD) study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14597.	1.7	2
2280	Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e048719.	1.9	8
2281	Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Caseâ€Control Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 671835.	3.5	4
2282	Beyond COVID-19: respiratory infection and cardiovascular events. <i>British Journal of General Practice</i> , 2021, 71, 342-343.	1.4	1
2283	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7942.	4.1	20
2284	Platelet Reactivity Testing for Aspirin Patients Who Sustain Traumatic Intracranial Hemorrhage. <i>Journal of Surgical Research</i> , 2021, 263, 186-192.	1.6	1
2285	Drug therapy of arterial hypertension: assessment of the physiciansâ€™ basic knowledge. Final results of the PHYSTARH project. <i>Systemic Hypertension</i> , 2021, 18, 80-87.	0.6	2
2286	Combination of Xuesaitong and Aspirin Based on the Antiplatelet Effect and Gastrointestinal Injury: Study Protocol for a Randomized Controlled Noninferiority Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-7.	1.2	1
2287	CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. <i>Cardiovascular Diabetology</i> , 2021, 20, 154.	6.8	111
2288	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	2.0	1,123

#	ARTICLE	IF	CITATIONS
2289	Clinical efficacy of aspirin combination treatment in the treatment of coronary heart disease and its effect on inflammatory factors: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 8858-8868.	1.2	2
2290	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
2291	Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 297-301.	1.9	2
2292	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021, 144, 512-523.	1.6	25
2293	Can an individualized adherence education program delivered by nurses improve therapeutic adherence in elderly people with acute myocardial infarction?: A randomized controlled study. <i>International Journal of Nursing Studies</i> , 2021, 120, 103975.	5.6	8
2294	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. <i>Netherlands Heart Journal</i> , 2022, 30, 25-37.	0.8	3
2295	Differences in cerebral small vessel disease magnetic resonance imaging markers between lacunar stroke and non-Lobar intracerebral hemorrhage. <i>European Stroke Journal</i> , 2021, 6, 239698732110317.	5.5	3
2296	Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000719.	2.7	9
2297	Ischemic Stroke. <i>American Journal of Medicine</i> , 2021, 134, 1457-1464.	1.5	247
2298	Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1953-1960.	1.8	10
2299	Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations Taking Low-Dose Aspirin. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105917.	1.6	6
2300	Aspirin Use and Risk of Subdural Hematoma: Updated Meta-Analysis of Randomized Trials. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105911.	1.6	2
2301	Association of clinical trial participation after myocardial infarction with socioeconomic status, clinical characteristics, and outcomes. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	3
2302	A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke. <i>Current Cardiology Reports</i> , 2021, 23, 145.	2.9	2
2303	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	1.8	220
2304	Aspirin does not increase the need for haemostatic interventions in blunt liver and spleen injuries. <i>Injury</i> , 2021, 52, 2594-2600.	1.7	2
2305	Caloric Restriction Mimetics in Nutrition and Clinical Trials. <i>Frontiers in Nutrition</i> , 2021, 8, 717343.	3.7	52
2306	Safety and efficacy of acetylsalicylic acid in the secondary prevention of cardiovascular diseases in combination with comorbid diseases. COVID-19 treatment options. <i>Meditinskiy Sovet</i> , 2021, , 8-16.	0.5	0

#	ARTICLE	IF	CITATIONS
2307	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e020330.	3.7	4
2308	Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. <i>Clinical Epidemiology</i> , 2021, Volume 13, 813-823.	3.0	9
2311	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 408-416.	0.7	3
2312	Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1169-1176.	1.9	7
2313	Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. <i>Stroke</i> , 2021, 52, 2809-2816.	2.0	11
2315	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. <i>JAMA Neurology</i> , 2021, 78, 1179.	9.0	25
2316	Eurasian Guidelines for the diagnostics and management of stable coronary artery disease (2020-2021). <i>Eurasian Heart Journal</i> , 2021, , 54-93.	0.8	1
2317	Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. <i>Scientific Reports</i> , 2021, 11, 19367.	3.3	10
2319	Multiparameter phenotyping of platelet reactivity for stratification of human cohorts. <i>Blood Advances</i> , 2021, 5, 4017-4030.	5.2	14
2320	Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 720113.	2.4	5
2323	Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model. <i>IJC Heart and Vasculature</i> , 2021, 36, 100851.	1.1	2
2324	Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2021, 52, 3258-3265.	2.0	5
2325	Stroke Prevention with Extracranial Carotid Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 161.	2.9	2
2326	Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 160-166.	5.0	1
2327	Risk Factors and Prevention. , 2022, , 187-206.e6.		0
2328	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2022, , 912-931.e4.		1
2329	Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110070.	2.1	2
2330	The Returns to Nursing: Evidence from a Parental-Leave Program. <i>Review of Economic Studies</i> , 2021, 88, 2308-2343.	5.4	11

#	ARTICLE	IF	CITATIONS
2331	Cardiovascular preventive pharmacotherapy stratified by predicted cardiovascular risk: a national data linkage study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1905-1913.	1.8	6
2332	The role of aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1949-1952.	1.8	1
2333	An Update on Aspirin for Cardioprevention: Implications for Patient Care. , 2021, 70, S1-S10.		0
2334	Updates on Aspirin in Primary Prevention of Cardiovascular Disease Create New Clinical and Policy Challenges. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2335	A New Score for Predicting Acute Gastrointestinal Bleeding in Patients Administered Oral Antiplatelet Drugs. <i>Frontiers in Pharmacology</i> , 2020, 11, 571605.	3.5	9
2336	Platelet physiology and pharmacology—relevant considerations for patient care. , 2021, , 15-45.		0
2338	Aspirin in the Prevention of Cardiovascular Disease and Cancer. <i>Annual Review of Medicine</i> , 2021, 72, 473-495.	12.2	17
2339	Antiplatelet Therapy after Intracerebral Hemorrhage and Subsequent Clinical Events: A 12-Year South Korean Cohort Study. <i>European Neurology</i> , 2021, 84, 183-191.	1.4	5
2342	Atherosclerosis and Diabetic Nephropathy. , 2019, , 357-372.		1
2343	Aspirin in Prevention of Sporadic Colorectal Cancer: Current Clinical Evidence and Overall Balance of Risks and Benefits. <i>Recent Results in Cancer Research</i> , 2013, 191, 121-142.	1.8	31
2344	Antithrombotika und Antihämorrhagika. , 2016, , 351-368.		2
2345	Antithrombotika und Antihämorrhagika. , 2017, , 353-372.		1
2346	Antithrombotika und Antihämorrhagika. , 2018, , 401-421.		3
2347	Antithrombotika und Antihämorrhagika. , 2019, , 531-555.		8
2348	Residual Risk in Treated Hypertension. , 2012, , 309-321.		1
2349	Anti-inflammatory and immunosuppressant drugs. , 2012, , 318-335.		3
2350	Primary and Secondary Prevention of Coronary Heart Disease. , 2012, , 1010-1035.		18
2351	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4

#	ARTICLE	IF	CITATIONS
2352	Multi-Centre Study on Cardiovascular Risk Management on Patients Undergoing AAA Surveillance. European Journal of Vascular and Endovascular Surgery, 2017, 54, 116-122.	1.5	23
2353	Evidence-Based Pharmacotherapies for Alcohol Use Disorder. Mayo Clinic Proceedings, 2020, 95, 1964-1977.	3.0	40
2354	The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease. ReumatologÃa ClÃnica, 2020, 16, 311-312.	0.5	1
2356	Oxygen saturation target ranges and alarm settings in the NICU: What have we learnt from the neonatal oxygenation prospective meta-analysis (NeOProm)? Seminars in Fetal and Neonatal Medicine, 2020, 25, 101080.	2.3	17
2357	Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clinic Proceedings, 2009, 84, 741-57.	3.0	57
2358	Aspirin for secondary prevention of cardiovascular disease. Lancet, The, 2020, 395, 1462-1463.	13.7	13
2362	Back to Back: A polypill is the solution to the pharmacological management of cardiovascular risk: Yes. Journal of Primary Health Care, 2009, 1, 232.	0.6	4
2363	Aspirin for primary prevention: yes or no?. Journal of Primary Health Care, 2010, 2, 92.	0.6	6
2364	Diabetes management in older people: a focus on cardiovascular risk reduction. Postgraduate Medicine, 2017, 129, 169-177.	2.0	3
2365	Common risk factors for heart failure and cancer. Cardiovascular Research, 2019, 115, 844-853.	3.8	175
2366	Drug prescription patterns and factors associated with polypharmacy in >1â€‰million older adults in Tokyo. Geriatrics and Gerontology International, 2020, 20, 304-311.	1.5	18
2367	New Therapeutic Approaches to Combat Arterial Thrombosis: Better Drugs for Old Targets, Novel Targets, and Future Prospects. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 111-123.	3.4	15
2368	Aspirin for primary prevention of vascular disease in people with diabetes. BMJ: British Medical Journal, 2009, 339, b4596-b4596.	2.3	4
2369	Time to rethink aspirin in diabetes?. BMJ: British Medical Journal, 2009, 339, b5588-b5588.	2.3	1
2370	Secondary prevention of cardiovascular disease in China. Heart, 2020, 106, 1349-1356.	2.9	18
2371	Update in the treatment of extracranial atherosclerotic disease for stroke prevention. Stroke and Vascular Neurology, 2020, 5, 65-70.	3.3	8
2372	Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study. Singapore Medical Journal, 2017, 58, 535-542.	0.6	21
2373	Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly. Journal of Geriatric Cardiology, 2017, 14, 457-464.	0.2	4

#	ARTICLE	IF	CITATIONS
2374	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. Journal of Geriatric Cardiology, 2019, 16, 182-241.	0.2	380
2375	1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y ₁₂ Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent. Circulation Journal, 2020, 85, 19-26.	1.6	5
2376	Prescribing antiplatelets. Independent Nurse, 2010, 2010, .	0.1	4
2377	NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies. PLoS ONE, 2011, 6, e16780.	2.5	46
2378	An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (â€œPolypillâ€œ) in People with Raised Cardiovascular Risk. PLoS ONE, 2011, 6, e19857.	2.5	114
2379	Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease?. PLoS ONE, 2012, 7, e41842.	2.5	66
2380	Doseâ€“Risk and Durationâ€“Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies. PLoS ONE, 2013, 8, e57578.	2.5	54
2381	Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e65023.	2.5	40
2382	Aspirin in Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Review of the Balance of Evidence from Reviews of Randomized Trials. PLoS ONE, 2013, 8, e81970.	2.5	51
2383	Amelioration of Aspirin Induced Oxidative Impairment and Apoptotic Cell Death by a Novel Antioxidant Protein Molecule Isolated from the Herb Phyllanthus niruri. PLoS ONE, 2014, 9, e89026.	2.5	31
2384	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. PLoS ONE, 2014, 9, e111816.	2.5	39
2385	Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0125992.	2.5	17
2386	Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0126767.	2.5	37
2387	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. PLoS ONE, 2015, 10, e0138092.	2.5	32
2388	Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS ONE, 2016, 11, e0166166.	2.5	37
2389	Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2017, 12, e0175283.	2.5	16
2390	Design and Rationale for the ASSOS Study: Appropriateness of Aspirin Use in Medical Outpatients; A Multicenter and Observational Study. Anatolian Journal of Cardiology, 2018, 20, 354-362.	0.9	4
2391	Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis. European Journal of Endocrinology, 2019, 180, 243-255.	3.7	32

#	ARTICLE	IF	CITATIONS
2392	VKORC1-1639 G>A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 13-18.	0.9	7
2393	Antiplatelet Therapy in Acute Coronary Syndrome. European Cardiology Review, 2017, 12, 33.	2.2	18
2394	Direct-acting Anticoagulants in Chronic Coronary Syndromes. European Cardiology Review, 2020, 15, 1-7.	2.2	2
2395	Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines. European Cardiology Review, 2020, 15, 1-3.	2.2	8
2396	MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. European Cardiology Review, 2020, 15, e20.	2.2	12
2397	2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology, 2020, 25, 4076.	1.4	113
2398	Aspirin for the Primary Prophylaxis of Colorectal Cancer. Annals of Colorectal Research, 2013, 1, 77-80.	0.1	1
2399	<p>Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes<p>. Clinical Epidemiology, 2020, Volume 12, 447-455.	3.0	5
2400	Therapy Against Ischemic Injury. Current Pharmaceutical Design, 2013, 19, 4597-4621.	1.9	6
2401	The Role of Vascular Aging in Atherosclerotic Plaque Development and Vulnerability. Current Pharmaceutical Design, 2019, 25, 3098-3111.	1.9	14
2402	Diabetes and Vascular Disease: Is It All About Glycemia?. Current Pharmaceutical Design, 2019, 25, 3112-3127.	1.9	14
2403	The Role of Antithrombotic Therapy in Heart Failure. Current Pharmaceutical Design, 2020, 26, 2735-2761.	1.9	1
2404	Antiplatelets in Stroke Prevention. Current Vascular Pharmacology, 2014, 11, 803-811.	1.7	12
2405	Gender Differences in Response to Therapy for Cardiovascular Diseases. Current Pharmacogenomics and Personalized Medicine, 2017, 15, .	0.2	2
2406	Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods. JMIR Research Protocols, 2016, 5, e105.	1.0	10
2407	Technical improvements in carotid revascularization based on the mechanism of procedural stroke. Journal of Cardiovascular Surgery, 2019, 60, 313-324.	0.6	4
2408	Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. Journal of Cardiovascular Surgery, 2020, 61, 662-672.	0.6	1
2409	Corrected and republished from: Regional anesthesia and antithrombotic agents: instructions for use. Minerva Anestesiologica, 2020, 86, 341-353.	1.0	2

#	ARTICLE	IF	CITATIONS
2410	Antiplatelet agents in clinical practice and their haemorrhagic risk. <i>Blood Transfusion</i> , 2013, 11, 349-56.	0.4	20
2411	Effect of preoperative antiplatelet or anticoagulation therapy on hemorrhagic complications in patients with traumatic brain injury undergoing craniotomy or craniectomy. <i>Neurosurgical Focus</i> , 2019, 47, E3.	2.3	20
2412	Variation in outcome of hospitalised patients with out-of-hospital cardiac arrest from acute coronary syndrome: a cohort study. <i>Health Services and Delivery Research</i> , 2018, 6, 1-116.	1.4	3
2413	Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. <i>Health Technology Assessment</i> , 2013, 17, 1-253.	2.8	75
2414	An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-368.	2.8	63
2415	The prognostic utility of tests of platelet function for the detection of "aspirin resistance"™ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-366.	2.8	22
2416	Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm®, Veo system and the Vibe®, and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-252.	2.8	57
2417	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020, 14, 998.	1.1	4
2418	Interaction between <i>Helicobacter pylori</i> infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. <i>World Journal of Gastroenterology</i> , 2014, 20, 9439-50.	3.3	37
2419	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <i>Eurasian Heart Journal</i> , 2020, , 4-77.	0.8	17
2420	Effects of aspirin on the gastrointestinal tract: Pros vs. cons (Review). <i>Oncology Letters</i> , 2020, 20, 2567-2578.	1.8	18
2421	Prophylactic aspirin and public. <i>AIMS Public Health</i> , 2014, 1, 1-8.	2.6	1
2422	Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 318-326.	1.3	17
2423	Should patients stop taking aspirin for primary prevention?. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 91-96.	1.3	4
2424	Preventing cardiovascular disease in older adults: One size does not fit all. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 55-64.	1.3	16
2425	Aspirin for primary prevention of atherosclerotic cardiovascular events. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 300-311.	1.3	8
2426	Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. <i>Biomedical and Environmental Sciences</i> , 2013, 26, 249-57.	0.2	15
2427	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. <i>Indian Journal of Endocrinology and Metabolism</i> , 2020, 24, 1.	0.4	85

#	ARTICLE	IF	CITATIONS
2429	Prevalence of daily or near daily aspirin use by US adults with diabetes: A cross-sectional study using a multi-year national database. <i>Health</i> , 2012, 04, 297-303.	0.3	3
2430	Strategies for Improving Parental Involvement in Acquisition of Literacy Skills among Pupils in Primary Schools in Akithi Division, Tigania West District, Kenya. <i>Open Journal of Social Sciences</i> , 2014, 02, 250-255.	0.3	1
2431	The Use of Anti-Platelet and/or Anticoagulant Agents in the Prevention of Large Vessel Vasculitis-Associated Ischemic Complications: A Meta-Analysis. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2014, 04, 114-123.	0.2	2
2432	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. <i>World Journal of Diabetes</i> , 2019, 10, 291-303.	3.5	14
2433	Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?. <i>EuroIntervention</i> , 2019, 15, e475-e478.	3.2	5
2434	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. <i>EuroIntervention</i> , 2013, 9, 316-327.	3.2	36
2435	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	3.2	251
2436	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	3.2	367
2437	Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?. <i>EuroIntervention</i> , 2020, 15, 1125-1129.	3.2	8
2438	Aspirin resistance: Fact or fiction? A point of view. <i>World Journal of Cardiology</i> , 2010, 2, 280.	1.5	15
2439	Positive influence of aspirin on coronary endothelial function: Importance of the dose. <i>World Journal of Cardiology</i> , 2013, 5, 426.	1.5	2
2440	Severe Bleeding and Perforation Are Rare Complications of Endoscopic Ultrasound-Guided Fine Needle Aspiration for Pancreatic Masses: An Analysis of 3,090 Patients from 212 Hospitals. <i>Gut and Liver</i> , 2014, 8, 215-218.	2.9	43
2441	Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition. <i>Gut and Liver</i> , 2020, 14, 707-726.	2.9	24
2442	Aspirin in the prevention of cardiovascular disease and cancer. <i>Journal of the Korean Medical Association</i> , 2014, 57, 348.	0.3	1
2443	The impact and management of acquired platelet dysfunction. <i>Hamostaseologie</i> , 2011, 31, 28-40.	1.9	13
2444	Impact of Platelet Reactivity on Long-term Clinical Outcomes and Bleeding Events in Japanese Patients Receiving Antiplatelet Therapy with Aspirin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 1142-1153.	2.0	7
2445	Comprehensive Risk Management for the Prevention of Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 603-615.	2.0	45
2446	Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study. <i>Cardiology Journal</i> , 2013, 20, 545-551.	1.2	21

#	ARTICLE	IF	CITATIONS
2449	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.8	102
2450	Management of Non-Variceal Upper Gastrointestinal Bleeding. Clinical Endoscopy, 2012, 45, 220.	1.5	20
2451	A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally. European Heart Journal, 2021, 43, 16-17.	2.2	0
2452	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Medical Research Methodology, 2021, 21, 218.	3.1	4
2453	Rationality and safety of acetylsalicylic acid therapy in centenarians. Russian Journal of Geriatric Medicine, 2021, , 379-382.	0.6	0
2454	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
2455	Using pharmacy technicians and electronic health record capabilities to improve outcomes for patients with cardiovascular disease. Journal of the American Pharmacists Association: JAPhA, 2021, , .	1.5	0
2456	The role of platelets in the pathogenesis of atherosclerosis. , 2021, 17, 106-119.	0.1	0
2457	Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e287-e305.	1.6	92
2458	Aspirin does not affect hematoma growth in severe spontaneous intracranial hematoma. Neurosurgical Review, 2022, 45, 1491-1499.	2.4	1
2460	Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology, The, 2021, 20, 907-916.	10.2	44
2461	Cerebrovascular Disease in Hypertension. , 2007, , 392-405.		0
2462	Metabolic Syndrome in Hypertension – Treatment Challenges and Goals. European Cardiology Review, 2009, 5, 40.	2.2	1
2464	Doom?. British Journal of General Practice, 2009, 59, 554-554.	1.4	0
2465	ACETYLSALICYLIC ACID AND PREVENTION OF STROKE IN HIGH-RISK GROUP PATIENTS. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2009, .	1.2	0
2466	Indien volgens de risicokaart voor coronaire hartziekten (Nederlandse Hartstichting) er een indicatie is voor een cholesterolverlagend middel, is er dan ook een indicatie voor aspirine?. , 2010, , 87-88.		0
2467	AthÃ©rosclÃ©rose. , 2010, , 287-491.		0
2468	Editorial: Population and individual health: the two faces of Janus. Journal of Primary Health Care, 2010, 2, 90.	0.6	0

#	ARTICLE	IF	CITATIONS
2469	GPs left in a quandary. BMJ: British Medical Journal, 2010, 340, c1740-c1740.	2.3	0
2470	Is Aspirin Really Effective for Primary Cardiovascular Prevention?. Hospital Pharmacy, 2010, 45, 362-366.	1.0	0
2471	Meta-analysis: aspirin for patients with diabetes. BMJ, The, 0, , c4103.	6.0	0
2473	Oral antiplatelet therapy. , 2011, , 311-319.		0
2475	Antithrombotic therapy in secondary prevention. Srce I Krvni Sudovi, 2011, 30, 224-233.	0.1	0
2477	O uso da Aspirina na Prevenção Primária da doença cardiovascular: novas atualizações. Revista Brasileira De Medicina De Família E Comunidade, 2011, 6, 57-62.	0.4	0
2478	O uso da Aspirina na Prevenção Primária da doença cardiovascular: novas atualizações. Revista Brasileira De Medicina De Família E Comunidade, 2011, 6, 57-62.	0.4	0
2480	When people live with multiple chronic diseases: a collaborative approach to an emerging global challenge. International Journal of Integrated Care, 2011, 11, .	0.2	15
2481	Aged Garlic Extract and Its Components Inhibit Platelet Aggregation in Rat. Journal of Life Science, 2011, 21, 1355-1363.	0.2	1
2482	Diabetes and Coronary Heart Disease. , 2012, , 471-484.		0
2484	Primary and Secondary Antithrombotic Prophylaxis. , 2012, , 105-118.		0
2485	The Clinical Relevance of Response Variability to Antiplatelet Therapy. Hematology American Society of Hematology Education Program, 2011, 2011, 70-75.	2.5	0
2486	The Role of Laboratory Monitoring in Antiplatelet Therapy. Handbook of Experimental Pharmacology, 2012, , 471-494.	1.8	2
2487	Stroke Update: Risk Factors and Primary Prevention of Stroke. Korean Journal of Stroke, 2012, 14, 12.	0.1	1
2488	An Employer-Based Online Tool for Providing Appropriate Aspirin Use Advice. Primary Prevention Insights, 0, 3, 1-9.	1.0	1
2489	Anti-coagulation and anti-platelet therapy for heart disease. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 25-32.	0.1	0
2491	The Epidemiology of Coronary Artery Disease in Older Adults. , 2012, , 401-419.		0
2493	Low-Dose Aspirin Therapy Does not Increase the Severity of Acute Radiation Proctitis. World Journal of Oncology, 2012, 3, 173-181.	1.5	2

#	ARTICLE	IF	CITATIONS
2494	Antiplatelet Drugs in Coronary Artery Disease. , 0, , .		0
2496	Pharmacotherapy During Percutaneous Coronary Interventions. , 0, , .		0
2498	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81â€‰mg With or Without Esomeprazole 20â€‰mg in Healthy Volunteers. American Journal of Cardiovascular Drugs, 2012, 12, 217-224.	2.2	11
2499	Antithrombotic pharmacotherapy in patients with established coronary artery disease. , 2012, , 287-301.		0
2500	Management of Antiaggregated and Anticoagulated Patients Scheduled for Orthopedic Surgery. , 2013, , 153-165.		0
2501	The polypill: a magic bullet against cardiovascular disease?. BMJ, The, 0, , e6386.	6.0	0
2505	Zwei fixe Kombinationen mit Esomeprazol. Pharma-Kritik (discontinued), 2012, 34, .	0.0	0
2506	Antithrombotic therapy for atherothrombotic disease. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 30-37.	0.1	0
2507	Management of thrombotic risk in old patients. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 45-52.	0.1	0
2508	Cerebrovascular Disease in Hypertension. , 2013, , 303-312.		0
2509	Diabetes and the Cardiovascular System. , 2013, , 701-714.		0
2510	Perspectives and Approach to Stroke Prevention and Therapy. , 2013, , 47-60.		0
2511	Meta-Analyses of Hypertension Trials. , 2013, , 244-251.		0
2512	ASPIRIN RESISTANCE CANDIDATE GENES AND THEIR ASSOCIATION WITH THE RISK OF CARDIOVASCULAR EVENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 67-72.	1.4	1
2513	Agents antiplaquettaires et athÃ©rothrombose. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 375-388.	0.0	0
2514	Plaquettes, athÃ©rothrombose, antiplaquettaires et ischÃ©mie cÃ©rÃ©brale. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 389-394.	0.0	1
2516	A Summary of the Clinical Practice Guidelines for the Management of Patients with Peripheral Arterial Disease in Myanmar. Journal of the ASEAN Federation of Endocrine Societies, 2013, 28, 114-125.	0.2	0
2517	Antithrombotic Issues in Women. , 2014, , 321-357.		0

#	ARTICLE	IF	CITATIONS
2518	Antiplatelet therapy in patients with hypertension. Journal of Translational Internal Medicine, 2013, 1, 28-31.	2.5	0
2519	Aspirin for Primary Prophylaxis of Colorectal Cancer. Annals of Colorectal Research, 2013, 1, ..	0.1	0
2520	Nonsteroidal Anti-inflammatory Drug Hypersensitivity and Sinus Disease. , 2014, , 195-207.		0
2521	Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. , 2014, , 1-32.		0
2522	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
2523	Progress of antiplatelet therapy. Nosotchu, 2014, 36, 210-215.	0.1	0
2524	Has the Antiplatelet Therapy a Role in the Prevention of Sudden Cardiac Death?. Cardiovascular Pharmacology: Open Access, 2014, 04, .	0.1	0
2525	Recent advances in the mechanism of arterial thrombus formation and antithrombotic therapy. Tenri Medical Bulletin, 2014, 17, 1-14.	0.1	0
2526	Antiplatelet Agents in Diabetic Patients: Clinical Advances and Remaining Questions. Journal of Clinical & Experimental Cardiology, 2014, 05, .	0.0	0
2527	Risk Factor Analysis for Incidence of Major Adverse Cardiac Events after Percutaneous Coronary Intervention Treatment. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 278-284.	0.1	0
2531	El endotelio vascular. Anales De La Facultad De Medicina, 2014, 75, .	0.1	0
2532	Treatment of patient with high-risk hypertension: do we need antiplatelet therapy?. Arterial Hypertension (Russian Federation), 2015, 21, 190-196.	0.4	0
2533	Neurosurgery for Extracranial Carotid Disease. , 2015, , 2719-2738.		0
2535	Prevention of Cardiovascular Disease: The Polypill Concept. , 2015, , 613-632.		0
2536	Lipid and Inflammation in Atherosclerosis. , 2015, , 37-63.		0
2537	Gestion pÃ©ri-opÃ©ratoire des patients traitÃ©s par antithrombotiques en chirurgie orale. Argumentaire. Medecine Buccale Chirurgie Buccale, 2015, 21, S15-S81.	0.1	1
2538	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1627-1664.		0
2539	Antiplatelet Therapy. , 2015, , 133-144.		0

#	ARTICLE	IF	CITATIONS
2540	Does Utilitarian Policy such as Smoking Cessation Lend Support to Wider Aspirin Use?. AIMS Public Health, 2015, 2, 223-226.	2.6	0
2542	Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. , 2015, , 1665-1693.		0
2543	Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes. , 2015, , 347-357.		0
2544	Peripheral Artery Disease. , 2015, , 203-214.		0
2545	Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries. Current Pharmacogenomics and Personalized Medicine, 2015, 12, 133-140.	0.2	0
2547	Acetylsalicylic acid therapy in patients undergoing planned surgery. Cardiosomatics, 2015, 6, 48-57.	0.4	0
2548	Perioperative Beta-Blockade, the Pros and Cons. The Story of Beta-Blockade and Cardiac Protection. , 2016, , 143-164.		0
2549	Analyzes of antiplatelets and anticoagulants utilization in patients treated in cardiovascular rehabilitation center from Croatia. Sanamed, 2016, 11, 99-107.	0.2	0
2550	Traitements antithrombotiques aprÃs geste de revascularisation. , 2016, , 293-298.		0
2551	Abdominelles Aortenaneurysma. , 2016, , 441-448.		0
2552	S.A.M. and Breast Cancerâ€”Focus on Aspirin and Other Integrative Aspirin-Like Medicines: The Real â€œNaturalâ€•Options. , 2016, , 173-194.		0
2553	Acetylsalicylic acid use in primary prevention in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) study. Current Research Cardiology, 2016, 3, .	0.1	0
2554	Antithrombotic Therapy for Carotid and Intracranial Artery Stenosis. Japanese Journal of Neurosurgery, 2016, 25, 804-812.	0.0	1
2555	Advances in Antiplatelets. , 2016, , 827-831.		0
2556	Unmet Clinical Needs of Antithrombotic Treatment in BCR/ABL-Negative Myeloproliferative Neoplasms. , 2016, , 379-393.		0
2557	Management of Angina. , 2016, , 111-163.		0
2558	Aspirin Associated Liver Toxicity â€” The Optimal Dose of Aspirin in Liver Insufficiency. International Journal of Scientific Research in Knowledge, 2016, 4, 28-32.	0.1	1
2559	The Role of Platelet and its Interaction with Aspirin. Revista Facultad De Medicina, 2016, 64, 351.	0.2	1

#	ARTICLE	IF	CITATIONS
2580	Dual antiplatelet therapy in coronary artery disease. Srce I Krvni Sudovi, 2018, 37, 45-50.	0.1	0
2581	Effect of sociodemographic variables and other factors on the usage of different doses of aspirin in postmyocardial infarction patients: A cross-sectional study. Heart Views, 2018, 19, 49.	0.2	0
2582	Aspirin: a modern view of a well-known medicine (review). Bukovinian Medical Herald, 2018, 22, 149-153.	0.1	1
2584	Coronary heart disease: how to improve the effectiveness of treatment?. Meditsinskiy Sovet, 2018, , 46-52.	0.5	0
2585	Antiplatelet Therapy in Cardiovascular Disease. , 2019, , 195-207.		0
2586	The role of aspirin in primary prevention of cardiovascular diseases. Cardiologia Croatica, 2018, 13, 419-419.	0.0	0
2587	Features of the treatment of elderly patients with coronary heart disease at the stages of 1990, 2010 and 2017 examinations.. Medicni Perspektivi, 2018, 23, 20-30.	0.4	0
2588	"Polypill" conception in modern cardiology. Systemic Hypertension, 2018, 15, 6-7.	0.6	2
2589	Old and new face of aspirin. Pediatria I Medycyna Rodzinna, 2018, 14, 369-375.	0.1	1
2590	ASPIRINA NA PREVENÇÃO PRIMÁRIA DE EVENTOS CARDIOVASCULARES EM PACIENTES DIABÉTICOS: UMA REVISÃO. , 0, , .		0
2592	Indication, Risk and Benefit of Anti-Thrombotic Therapy for Patients with Ischemic Cerebrovascular Diseases : Basic Knowledge for Neurosurgeons. Japanese Journal of Neurosurgery, 2019, 28, 758-767.	0.0	1
2593	Benefits of a combination of clopidogrel and aspirin in patients with high cardiovascular risk. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 504.	0.3	0
2594	Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. , 2019, , 169-187.		0
2595	CONTROL OF CARDIOVASCULAR RISK FACTORS IN PATIENTS AFTER MYOCARDIAL INFARCTION. Wiadomości Lekarskie, 2019, 72, 472-483.	0.3	0
2596	High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-ST Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. Arquivos Brasileiros De Cardiologia, 2019, 113, 357-363.	0.8	2
2598	Antiplatelet Therapy Considerations in Women. Cardiovascular Innovations and Applications, 2019, 3, .	0.3	0
2601	Two Case Reports of Elderly Patients with Anorexia: the Importance of Confirming Medication and a Potential Infectious Disease. The Journal of Internal Korean Medicine, 2019, 40, 491-498.	0.3	0
2602	Akut Koroner Sendrom ile Başlıyuran Hastalarda Asetil Salisilik Asit Direncinin Araştırılması. Sağlık Bilimleri Dergisi, 2019, 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
2603	Should we stop aspirin before noncardiac surgery?. Cleveland Clinic Journal of Medicine, 2019, 86, 518-521.	1.3	2
2605	The death of aspirin for primary prevention“should aspirin be changed to a prescription only medication?. Annals of Translational Medicine, 2019, 7, 402-402.	1.7	1
2606	Safety and efficacy of restarting antiplatelet therapy after intracerebral hemorrhage. Annals of Translational Medicine, 2019, 7, S218-S218.	1.7	0
2607	The dilemma of aspirin resistance in obese patients. Annals of Translational Medicine, 2019, 7, 404-404.	1.7	9
2609	Precision Oncology vs Phenotypic Approaches in the Management of Cancer: A Case for the Postmitotic State. Human Perspectives in Health Sciences and Technology, 2020, , 169-201.	0.4	0
2610	Antithrombotika und Antihämorrhagika. , 2020, , 395-420.		0
2611	Analysis of the Occurrence of Major Hemorrhagic Incidents in Patients with Low-Dose Aspirin Usage in Korean Populations “ Does Low-Dose Aspirin Really Increase the Risk of Bleeding?. Neurointervention, 2020, 15, 52-54.	0.8	0
2614	Antiplatelet “la“ Kullan“m“n“n Mesane Kanseri Tan“s““ “zerindeki Etkileri: Kolayla“t“r“c“ m“, Zorla“t“r“c“ m“, Yeni “eroloji Dergisi, 2020, 15, 3-4.	0.1	0
2615	Isparta ve “sevresinde klopidoğrel direncinin ara“t“r“lmas“. S“leyman Demirel “niversitesi Tıp Fak“ltesi Dergisi, 0, , .	0.2	0
2616	Birinci basamakta re“seteleme trendi ve s“k kar“la“lan tan“lara ait re“setelerin incelenmesi: T“rkiye versiy. Cukurova Medical Journal, 2020, 45, 695-708.	0.2	2
2619	Aspirin for primary prevention. Cleveland Clinic Journal of Medicine, 2020, 87, 458.1-458.	1.3	0
2620	In Reply: Aspirin for primary prevention. Cleveland Clinic Journal of Medicine, 2020, 87, 458.2-459.	1.3	0
2621	Prevalencia de prescripci“n del “cido acetilsalic“ico a dosis bajas en prevenci“n primaria en poblaci“n espa“ola, evoluci“n temporal y factores asociados. Medicina Cl“nica, 2020, 155, 104-111.	0.6	0
2622	PENGUNAAN STATIN DAN ANTIPLATELET SEBAGAI PENCEGAHAN SEKUNDER KOMPLIKASI KARDIOVASKULER PADA PASIEN DIABETES MELITUS TIPE 2. Majalah Farmasi Dan Farmakologi, 2020, 24, 42-48.	0.1	0
2623	Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats. Pharmaceutics, 2021, 13, 1827.	4.5	6
2625	Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs “ an analysis of real-world data. BMC Health Services Research, 2020, 20, 1145.	2.2	4
2626	Prevention of Ischemic Stroke. Contemporary Cardiology, 2021, , 581-609.	0.1	0
2627	Investigation of Blood Pressure Control in Hypertensive Patients with and without Antithrombotic Therapy in a Real-World Setting. Clinical and Experimental Hypertension, 2021, 43, 263-269.	1.3	2

#	ARTICLE	IF	CITATIONS
2628	Meta-analysis of Duration of Continuous Dual Antiplatelet Therapy and Late Stent Thrombosis After Second-Generation Drug Stent Implantation. <i>Advances in Therapy</i> , 2021, 38, 1068-1077.	2.9	0
2629	New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease. <i>Kardiologiya</i> , 2020, 60, 110-116.	0.7	4
2630	Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. <i>Journal of Clinical Hypertension</i> , 2021, 23, 352-362.	2.0	3
2633	Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey. <i>CMAJ Open</i> , 2020, 8, E41-E47.	2.4	2
2634	ACETYSALICYLIC ACID RESISTANCE: RISK FACTORS, MECHANISMS, DIAGNOSTIC TESTS. <i>Juvenis Scientia</i> , 2020, 6, 16-34.	0.2	2
2636	Arteriosklerotische Stenosen der extrakraniellen A. carotis: Operative Therapie. <i>Springer Reference Medizin</i> , 2020, , 471-487.	0.0	0
2637	Risikofaktoren und Primärprävention. , 2020, , 21-31.		0
2641	For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, .	0.1	0
2645	Latent opportunities for the prevention of ischemic stroke in patients with atherosclerosis-related diseases: additional analysis of randomized trials on rivaroxaban. <i>Russian Journal of Cardiology</i> , 2020, 25, 81-89.	1.4	0
2646	Medical Management for Secondary Stroke Prevention. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 435-456.	0.8	6
2647	Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. <i>Journal of Medical Economics</i> , 2021, 24, 1231-1239.	2.1	2
2648	â€žBaby-ASSâ€œ ohne Nachteile. <i>Deutsche Medizinische Wochenschrift</i> , 2021, 146, 1440-1441.	1.0	0
2649	Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12029.	4.1	61
2650	Aspirin prescribing pattern and guidelines-adherence evaluation for primary prevention of cardiovascular diseases at a teaching hospital. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 1426-1431.	2.7	0
2651	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap. <i>European Cardiology Review</i> , 2021, 16, e41.	2.2	12
2652	Possibilities for treating aspirin-i lesions of the stomach and duodenum in patients with chronic coronary heart disease. <i>Klinicheskaia Meditsina</i> , 2020, 98, 231-235.	0.1	0
2653	Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 465-473.	0.8	0
2654	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	1.6	0

#	ARTICLE	IF	CITATIONS
2655	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds â€”Gastrointestinal Adverse Effects. <i>Drugs in R and D</i> , 2011, 11, 277-288.	2.2	0
2656	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , 2014, 112, .	3.4	0
2658	Clinical impacts of cerebral microbleeds in patients with established coronary artery disease. <i>Journal of Hypertension</i> , 2021, 39, 259-265.	0.5	2
2659	Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy. <i>Clinical Endoscopy</i> , 2020, 53, 663-677.	1.5	7
2661	Ratio and interconnections of functional fitness structure key components of elite combat athletes at the stage of maximum realization of individual capabilities. <i>Fizieskoe Vospitanie Studentov</i> , 2020, 24, 286-292.	0.9	0
2663	Diabetes & coronary heart disease: current perspectives. <i>Indian Journal of Medical Research</i> , 2010, 132, 584-97.	1.0	27
2664	Surveying the medical literature: five notable articles in general internal medicine from 2008 and 2009. <i>Open Medicine</i> , 2010, 4, e181-6.	1.5	2
2665	Therapy for stable angina in women. <i>P and T</i> , 2012, 37, 400-4.	0.9	2
2666	Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. <i>Canadian Family Physician</i> , 2013, 59, 55-61.	0.4	7
2667	Aspirin in primary prevention: can we individualize care?. <i>Cardiovascular Diagnosis and Therapy</i> , 2012, 2, 169-72.	1.7	4
2668	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. <i>Indian Journal of Medical Research</i> , 2013, 138, 461-91.	1.0	14
2669	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis. <i>Ontario Health Technology Assessment Series</i> , 2014, 14, 1-67.	1.8	12
2670	Critical views in gastroenterology & hepatology: aspirin prophylaxis: putting gut bleeds into perspective. <i>Gastroenterology and Hepatology</i> , 2014, 10, 61-3.	0.1	3
2671	Use of Aspirin for Prevention of Recurrent Atherosclerotic Cardiovascular Disease Among Adults â€” 20 States and the District of Columbia, 2013. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 733-7.	15.1	5
2672	Different perspective on ASA use. <i>Canadian Family Physician</i> , 2016, 62, 30-1.	0.4	0
2673	Optimization and Characterization of Aspirin Encapsulated Nano-liposomes. <i>Iranian Journal of Pharmaceutical Research</i> , 2018, 17, 11-22.	0.5	4
2674	Specifications of Clinical Quality Measures and Value Set Vocabularies Shift Over Time: A Study of Change through Implementation Differences. <i>AMIA ... Annual Symposium proceedings</i> , 2017, 2017, 575-584.	0.2	2
2675	The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. <i>Gastroenterology and Hepatology</i> , 2018, 14, 169-175.	0.1	4

#	ARTICLE	IF	CITATIONS
2676	Aspirin for Primary Cardiovascular Prevention. Are we making a mistake for decades?. <i>MÃ dica</i> , 2018, 13, 176-178.	0.1	0
2677	Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 103-113.	0.2	11
2678	Acetylsalicylic acid for primary prevention of cardiovascular events. <i>Canadian Family Physician</i> , 2019, 65, 480.	0.4	0
2679	For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, 58-61.	0.1	0
2680	Racial and Gender Disparity in Achieving Optimal Medical Therapy for Inpatients with Peripheral Artery Disease. <i>Annals of Vascular Medicine and Research</i> , 2020, 7, .	0.8	1
2681	PURL:Rethinking daily aspirin for primary prevention. <i>Journal of Family Practice</i> , 2020, 69, 461-462.	0.2	0
2682	De-risking primary prevention: role of imaging. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2021, 15, 175394472110512.	2.1	2
2683	Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 497-504.	1.9	15
2684	Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. <i>ESC Heart Failure</i> , 2022, 9, 685-694.	3.1	10
2685	Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong. <i>BMC Cancer</i> , 2021, 21, 1202.	2.6	5
2686	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). <i>Eurasian Heart Journal</i> , 2021, , 6-59.	0.8	4
2687	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 143-151.	13.7	199
2688	OUP accepted manuscript. <i>Age and Ageing</i> , 2022, 51, .	1.6	0
2689	Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease. <i>Pharmacophore</i> , 2021, 12, 97-103.	1.2	3
2690	Antithrombotika und AntihÃmorrhagika. , 2021, , 299-326.		3
2691	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2022, 79, e21-e129.	2.8	561
2692	Application of a novel electrostatic dry powder coating technology on capsules for enteric release. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 68, 103058.	3.0	2
2693	Profiling oxylipins released from human platelets activated through the GPVI collagen receptor. <i>Prostaglandins and Other Lipid Mediators</i> , 2022, 158, 106607.	1.9	5

#	ARTICLE	IF	CITATIONS
2694	Kardiovaskuläre Prophylaxe: Wenn man Surrogatmarker "therapiert". , 0, , .		0
2695	RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF ASPIRIN AND OMEPRAZOLE IN BINARY COMBINATION. Indian Drugs, 2018, 55, 38-43.	0.1	2
2696	Acetylsalicylsäure: Heutiger Stellenwert in der antithrombotischen Therapie. , 0, , .		0
2697	Rethinking daily aspirin for primary prevention. , 2020, 69, .		0
2699	Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis. Annals of Translational Medicine, 2021, 10, 0-0.	1.7	2
2700	Factors Associated with Nonachievement of Target Blood Pressure in Patients on Antithrombotic Therapy: A Real-World Study. JMA Journal, 2022, 5, 74-82.	0.8	0
2701	Asymptomatic carotid stenosis: Several guidelines with unclear answers. Annals of Indian Academy of Neurology, 2022, 25, 171.	0.5	3
2702	Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study. Pharmaceutics, 2022, 14, 187.	4.5	1
2703	The effects of dual anti-platelet therapy on titanium implant osseointegration: an experimental study. Journal of Health Sciences and Medicine, 2022, 5, 144-149.	0.1	0
2704	Oral antiplatelet therapy for acute ischaemic stroke. The Cochrane Library, 2022, 2022, CD000029.	2.8	8
2706	Discontinuing low-dose acetylsalicylic acid after gastrointestinal bleeding is associated with increased mortality. Scandinavian Journal of Gastroenterology, 2022, , 1-7.	1.5	1
2707	Concurrent stimulation of monocytes with CSF1 and polarizing cytokines reveals phenotypic and functional differences with classical polarized macrophages. Journal of Leukocyte Biology, 2022, , .	3.3	2
2708	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121007979.	2.2	7
2709	Antiplatelet Use in Ischemic Stroke. Annals of Pharmacotherapy, 2022, 56, 1159-1173.	1.9	18
2710	Antiplatelet therapy in cardiovascular disease: Current status and future directions. British Journal of Clinical Pharmacology, 2022, 88, 2686-2699.	2.4	21
2711	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal, 2022, 43, 1715-1727.	2.2	40
2712	Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis. Current Cardiology Reports, 2022, 24, 87-91.	2.9	0
2713	Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data.. Current Diabetes Reviews, 2022, 18, .	1.3	0

#	ARTICLE	IF	CITATIONS
2714	Estándares SEA 2022 para el control global del riesgo cardiovascular. Clínica E Investigaci3n En Arteriosclerosis, 2022, 34, 130-179.	0.8	11
2715	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
2716	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
2717	Contemporary Management of Stable Coronary Artery Disease. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 207-219.	2.2	9
2718	Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease. Medicine (United States), 2022, 101, e28779.	1.0	0
2721	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2022</i>. Diabetes Care, 2022, 45, S144-S174.	8.6	282
2722	Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index. European Journal of Preventive Cardiology, 2022, 29, 1817-1826.	1.8	2
2723	Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review. Semergen, 2022, , .	0.5	0
2724	Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications. Frontiers in Cardiovascular Medicine, 2022, 9, 737592.	2.4	1
2725	Antiplatelet agents for chronic kidney disease. The Cochrane Library, 2022, 2022, CD008834.	2.8	6
2726	JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circulation Journal, 2022, 86, 882-915.	1.6	37
2727	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC Open, 2022, 4, 568-576.	1.5	4
2728	Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 859962.	2.4	4
2729	Clopidogrel Versus Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Current Problems in Cardiology, 2022, , 101174.	2.4	1
2730	Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy. Journal of the Advanced Practitioner in Oncology, 2022, 13, 127-142.	0.4	2
2731	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. European Heart Journal Open, 2022, 2, .	2.3	18
2732	Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial. Clinical Therapeutics, 2022, 44, 482-490.	2.5	4
2733	Direct Oral Anticoagulants and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 553-564.	2.4	4

#	ARTICLE	IF	CITATIONS
2735	Effect of anticoagulant/antiplatelet therapy on the development and progression of diabetic retinopathy. <i>BMC Ophthalmology</i> , 2022, 22, 127.	1.4	2
2736	Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Current Cardiology Reports</i> , 2022, 24, 277-293.	2.9	3
2737	Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. <i>Blood</i> , 2022, 139, 2871-2881.	1.4	2
2738	Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. <i>Stroke</i> , 2022, 53, 1813-1822.	2.0	18
2739	The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2022, 20, 189-196.	1.0	5
2740	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1407-1425.	2.8	21
2741	The VA Vascular Injury Study: a glimpse at quality of care in Veterans with traumatic vascular injury repair. <i>Injury</i> , 2022, , .	1.7	0
2742	An Evaluation of Aspirin Treatment Preferences ORIGINAL INVESTIGATION of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey. , 2022, 26, 260-268.		1
2743	Long-term Cardiovascular Risk and Management of Patients Recorded in Primary Care With Unattributed Chest Pain: An Electronic Health Record Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023146.	3.7	3
2744	Influenza vaccine improves cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis. <i>Travel Medicine and Infectious Disease</i> , 2022, 47, 102311.	3.0	11
2745	Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?. <i>Russian Journal of Cardiology</i> , 2021, 26, 4734.	1.4	1
2746	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1097-1117.	1.5	4
2747	Trends and Determinants of Self-Reported Aspirin Use among Patients with Diabetes Stratified by the Presence and Risk of Cardiovascular Diseases - Repeated Pan-Canadian Cross-Sectional Study. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.8	0
2748	Effect of soft beverages on the in vitro dissolution of gastro-resistant tablets containing low dose Acetylsalicylic acid. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 6345-6352.	0.8	1
2750	The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. <i>Drugs and Aging</i> , 2022, 39, 97-106.	2.7	1
2753	Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review. <i>PLOS Global Public Health</i> , 2022, 2, e0000072.	1.6	3
2754	Contextualizing National Policies Regulating Access to Low-Dose Aspirin in America and Europe Using the Full Report of a Transatlantic Patient Survey of Aspirin in Preventive Cardiology. <i>Journal of the American Heart Association</i> , 2022, 11, e023995.	3.7	2
2755	Low-Dose Aspirin Augments the Anti-Inflammatory Effects of Low-Dose Lithium in Lipopolysaccharide-Treated Rats. <i>Pharmaceutics</i> , 2022, 14, 901.	4.5	7

#	ARTICLE	IF	CITATIONS
2756	Antiphospholipid Syndrome and Stroke. , 0, , .		0
2757	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. <i>Trials</i> , 2022, 23, 331.	1.6	8
2758	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	1.2	27
2763	Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1585.	7.4	71
2764	Aspirin Use to Prevent Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1577.	7.4	151
2765	Aspirin for Primary Prevention—Time to Rethink Our Approach. <i>JAMA Network Open</i> , 2022, 5, e2210144.	5.9	11
2768	Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. , 2022, 1, 105-110.		0
2769	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 666-678.	8.1	31
2770	Causal Relationship of Coronary Artery Calcium on Myocardial Infarction and Preventive Effect of Antiplatelet Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 871267.	2.4	2
2771	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3235.	1.4	37
2772	How to optimize treatment in patients with different forms of coronary artery disease. <i>Meditinskiy Sovet</i> , 2022, , 273-279.	0.5	1
2773	Review and update of the concept of embolic stroke of undetermined source. <i>Nature Reviews Neurology</i> , 2022, 18, 455-465.	10.1	26
2774	Risk-benefit analysis of emergency vaccine use. <i>Scientific Reports</i> , 2022, 12, 7444.	3.3	2
2775	Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?. <i>Expert Opinion on Investigational Drugs</i> , 2022, , 1-23.	4.1	1
2776	Cardiovascular risk management requires a combination of cardiovascular preventive pharmacotherapy and non-pharmacological interventions. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e312-e313.	1.8	2
2778	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 515-532.	4.8	18
2779	Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 560-587.	1.7	38
2780	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. <i>Cardiovascular Diabetology</i> , 2022, 21, 74.	6.8	82

#	ARTICLE	IF	CITATIONS
2781	Lifestyle changes and medical therapy in slowing the growth of small abdominal aortic aneurysms. , 2016, 50, 10-13.		0
2782	Guiding Army Commandersâ€™ Decision-making Process in Managing Their Suicide Prevention Programs. Current Psychiatry Reports, 2022, , .	4.5	0
2783	Early P2Y<sub>12</sub> Inhibitor Single Antiplatelet Therapy for High-Bleeding Risk Patients After Stentingâ€• PENDULUM Mono 24-Month Analysis â€•. Circulation Journal, 2022, 86, 1352-1361.	1.6	3
2784	Impact of antithrombotic drugs on the accuracy of fecal occult blood testing for advanced colorectal neoplasia screening: a meta-analysis and systematic review. Zeitschrift Fur Gastroenterologie, 2022, , .	0.5	0
2785	Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. American Journal of Cardiovascular Drugs, 2022, 22, 657-675.	2.2	6
2786	The predictive value of internal carotid artery wall thickness in computed tomography angiography to avoid complications of plaque removal failure in modified eversion carotid endarterectomy. Vascular, 2022, , 170853812211027.	0.9	1
2789	Study of the effect of low-dose aspirin on physiological and biochemical parameters of patients with diabetes and hypertension in Thi- Qar governorate. International Journal of Health Sciences, 0, , 433-444.	0.1	0
2790	Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimerâ€™s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies. Alzheimer's Research and Therapy, 2022, 14, .	6.2	16
2791	Editor's Choice â€• European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery, 2023, 65, 7-111.	1.5	190
2792	Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis. American Journal of Preventive Medicine, 2022, 63, 440-449.	3.0	10
2793	Long-term Risk of Bleeding and Ischemic Events After Ischemic Stroke or Transient Ischemic Attack in Young Adults. Neurology, 2022, 99, .	1.1	2
2794	Aspirin use and the risk of liver cancer. American Journal of Gastroenterology, 2022, 117, .	0.4	0
2795	Insights from Egyptian ticagrelor study in patients who presented with acute coronary syndrome (ETS) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.2	0
2796	Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease. Frontiers in Pharmacology, 0, 13, .	3.5	2
2797	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	13.7	30
2798	IUA position statement on perioperative drug and hemostasis management in vascular surgery. International Angiology, 0, , .	0.9	1
2799	Dual Antiplatelet Therapy. , 0, , .		0
2800	A survey of internistsâ€™ recommendations for aspirin in older adults and barriers to evidence-based use. Journal of Thrombosis and Thrombolysis, 2022, 54, 639-646.	2.1	1

#	ARTICLE	IF	CITATION
2801	Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study. Journal of Clinical Medicine, 2022, 11, 3554.	2.4	2
2802	Possibilities of antiplatelet therapy in non-cardioembolic ischemic stroke. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 81-86.	1.2	1
2803	Diabetes: how to manage cardiovascular risk in secondary prevention patients. Drugs in Context, 0, 11, 1-12.	2.2	1
2804	Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease. American Journal of Preventive Cardiology, 2022, 11, 100363.	3.0	0
2806	SEA 2022 standards for the comprehensive control of cardiovascular risk. Clínica E Investigación En Arteriosclerosis (English Edition), 2022, 34, 130-179.	0.2	1
2807	Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology. Atherothrombosis, 2022, 12, 8-18.	0.3	0
2808	P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis. Current Problems in Cardiology, 2022, 47, 101292.	2.4	6
2809	Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2810	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 2022, 6, e750.	2.7	29
2811	Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Severe Mental Illness: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2022, 48, 981-998.	4.3	9
2812	The Role of Colchicine in Atherosclerosis: From Bench to Bedside. Pharmaceutics, 2022, 14, 1395.	4.5	6
2813	Chest pain in patients recovering from noncardiac surgery: A retrospective analysis. Journal of Clinical Anesthesia, 2022, 82, 110932.	1.6	3
2815	Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum. Cardiology Plus, 2022, 7, 64-69.	0.7	0
2816	Antiplatelet agents and anticoagulants for hypertension. The Cochrane Library, 2022, 2022, .	2.8	9
2817	Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?. Nephron, 2023, 147, 193-198.	1.8	3
2818	Stroke pathway “ An evidence base for commissioning “ An evidence review for NHS England and NHS Improvement. NIHR Open Research, 0, 2, 43.	0.0	2
2819	Role of P-Selectin in the Development of Hemostasis Disorders in COVID-19. Biology Bulletin Reviews, 2022, 12, 406-413.	0.9	1
2820	Colchicine as a Modulator of Platelet Function: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2022, 48, 552-567.	2.7	4

#	ARTICLE	IF	CITATIONS
2821	Managing thrombotic risk in patients with diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	8
2822	Association of erigerative spirin- esis ance and ardio ascular utcome (POPART- CVO) â€“ a prospective non-interventional cohort study. European Journal of Vascular and Endovascular Surgery, 2022, , .	1.5	2
2824	A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT2A Receptor Inhibits Platelet Function. International Journal of Molecular Sciences, 2022, 23, 8794.	4.1	3
2826	Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. Mayo Clinic Proceedings, 2022, 97, 1483-1492.	3.0	7
2827	Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly. International Journal of Angiology, 2022, 31, 244-250.	0.6	2
2828	Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes. Diabetes Research and Clinical Practice, 2022, 191, 110043.	2.8	1
2829	The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. European Journal of Clinical Pharmacology, 2022, 78, 1801-1811.	1.9	3
2830	Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 1207-1216.	2.4	10
2831	An Aspirin a Dayâ€™. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 1217-1219.	2.4	0
2832	Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com. Journal of Atherosclerosis and Thrombosis, 2022, , .	2.0	1
2833	<i>Helicobacter Pylori</i> Eradication for Primary Prevention of Upper Gastrointestinal Ulcer Bleeding in Older Patients Prescribed Aspirin (HEAT): A Randomised Placebo-Controlled Trial in Primary Care. SSRN Electronic Journal, 0, , .	0.4	0
2834	Aspirin and cancer: biological mechanisms and clinical outcomes. Open Biology, 2022, 12, .	3.6	14
2835	Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology, 0, 13, .	3.5	8
2836	Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology, 2023, 39, 187-197.	1.7	1
2837	Prescribing aspirin to older people â€“ where is the line between cardiovascular benefit and upper gastrointestinal bleeding risk?. Internal Medicine Journal, 2022, 52, 1468-1470.	0.8	0
2838	Outcomes Associated with 50 mg/d and 100 mg/d Aspirin for the Prevention and Management of Cardiovascular Disease in Chinese Elderly: Single-Center Interim Analysis of a Multicenter, Prospective, Observational Study. International Journal of General Medicine, 0, Volume 15, 7089-7100.	1.8	3
2839	Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2022, 54, 1094-1120.	1.8	48
2840	Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials. International Journal of General Medicine, 0, Volume 15, 7201-7208.	1.8	2

#	ARTICLE	IF	CITATIONS
2841	Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. <i>Clinical Medicine</i> , 2022, 22, 449-454.	1.9	3
2842	Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Kidney Medicine</i> , 2022, 4, 1005-47.	2.0	2
2843	Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 435-443.	4.4	2
2844	Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1948-1960.	2.9	1
2845	Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	7
2846	Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 77-87.	2.2	1
2847	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1169-1177.	10.7	14
2848	Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2023, 103, 403-410.	5.2	8
2849	Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 789-802.	4.2	1
2850	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 1005-13.		3
2851	Optimal periprocedural antithrombotic treatment in carotid interventions: An international, multispecialty, expert review and position statement. <i>Progress in Cardiovascular Diseases</i> , 2022, 74, 28-37.	3.1	4
2852	Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1160-1168.	10.7	9
2853	Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 442, 120457.	0.6	1
2854	Aspirin and Helicobacter pylori interaction. <i>Lancet</i> , 2022, 400, 1560-1561.	13.7	1
2855	Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2022, 400, 1597-1606.	13.7	23
2856	Novel approaches to antiplatelet therapy. <i>Biochemical Pharmacology</i> , 2022, 206, 115297.	4.4	4
2857	Very important pharmacogenes polymorphism landscape and potential clinical relevance in the Chinese Mongolian. <i>Gene</i> , 2023, 850, 146960.	2.2	0
2858	PRZEGLĄD AKTUALNYCH WYTYCZNYCH I BADAŃ ZASTOSOWANIA KWASU ACETYLOSALICYLOWEGO W PREWENCJI PIERWOTNEJ INCYDENTÓW SERCOWO-NACZYNIOWYCH. , 2019, 17, 20-23.		0

#	ARTICLE	IF	CITATIONS
2859	Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE). Cureus, 2022, , .	0.5	0
2860	Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication. Toxins, 2022, 14, 769.	3.4	2
2861	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. Seminars in Interventional Radiology, 2022, 39, 364-372.	0.8	0
2864	Optimal medical therapy after percutaneous coronary intervention in very elderly patients with coronary artery disease. International Journal of Cardiology Cardiovascular Risk and Prevention, 2023, 16, 200162.	1.1	0
2866	Modern possibilities and prospects of conservative treatment of patients with peripheral arterial diseases. Ambulatorna Ć Hirurģi Ć, 2022, 19, 50-60.	0.4	0
2867	Rationale and Design of LAPIS: A Multicenter Prospective Cohort Study to Investigate the Efficacy and Safety of Low-Dose Aspirin in Elderly Chinese Patients. International Journal of General Medicine, 0, Volume 15, 8333-8341.	1.8	0
2868	Safety of Rigid Bronchoscopy for Therapeutic Intervention at the Intensive Care Unit Bedside. Medicina (Lithuania), 2022, 58, 1762.	2.0	0
2869	Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 1413-1421.	1.9	3
2870	An international perspective on low-dose aspirin for the primary prevention of myocardial infarction. International Journal of Cardiology, 2022, , .	1.7	0
2871	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. Frontiers in Cardiovascular Drug Discovery, 2022, , 191-229.	0.0	0
2872	Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro. Frontiers in Pharmacology, 0, 13, .	3.5	0
2873	Preference and Adherence to a Fixed-Dose Combination of Bisoprolol Ć Aspirin and Blood Pressure Control: Results of an Open-Label, Multicentre Study. Journal of Clinical Medicine, 2023, 12, 17.	2.4	4
2874	10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes Ć 2023</i>. Diabetes Care, 2023, 46, S158-S190.	8.6	156
2875	Preoperative antiplatelet therapy may be a risk factor for postoperative ischemic complications in intracranial hemorrhage patients. International Journal of Neuroscience, 0, , 1-7.	1.6	1
2876	Effect of aspirin in patients with established asymptomatic carotid atherosclerosis: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	3.5	3
2877	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	2
2878	Drug therapy of arterial hypertension: assessment of the senior students Ć™ basic knowledge. Final results of the PHYSTARH project. Systemic Hypertension, 2022, 19, 5-10.	0.6	0
2879	Acute, periprocedural and longterm antithrombotic therapy in older adults. European Heart Journal, 2023, 44, 262-279.	2.2	18

#	ARTICLE	IF	CITATIONS
2880	Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of Cardiovascular Disease: A Population-Based Cohort Study. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	1.7	2
2881	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-92.	0.7	1
2882	Current Understanding of Diabetic Dyslipidemia: A Review. <i>Journal of the Indian Institute of Science</i> , 0, , .	1.9	0
2883	Gout Flare and Cardiovascular Eventsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 96.	7.4	0
2884	Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial. <i>Renal Failure</i> , 2023, 45, .	2.1	0
2885	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. <i>Contemporary Cardiology</i> , 2023, , 1-65.	0.1	0
2886	The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 311-317.	3.0	2
2887	Timing of Antiplatelet Resumption After Intracerebral Hemorrhage: A Sophieâ€™s Choice. <i>Stroke</i> , 2023, 54, 546-548.	2.0	0
2888	Adherence to European guidelines for the use of acetylsalicylic acid in primary health care. <i>Revista Portuguesa De Cardiologia</i> , 2023, , .	0.5	1
2889	Acute Coronary Syndrome in the Older Adult Populations. <i>Contemporary Cardiology</i> , 2023, , 303-341.	0.1	0
2890	Long-Term P2Y ₁₂ Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention. <i>Circulation</i> , 2023, 147, 118-121.	1.6	2
2891	Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
2892	Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition). <i>Cardiology Plus</i> , 2022, 7, 162-177.	0.7	5
2893	Aspirin and Primary Cancer Risk Reduction in Ischemic Cardiac or Cerebrovascular Disease Survivors: A Nationwide Population-Based Propensity-Matched Cohort Study. <i>Cancers</i> , 2023, 15, 97.	3.7	0
2894	SOD2 in platelets: with age comes responsibility. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1077-1081.	3.8	0
2896	Acetylsalicylic acid in the primary prevention of vascular complications in patients without clinically apparent atherosclerosis: how to balance risk and benefit?. <i>Atherothrombosis</i> , 2023, 12, 8-20.	0.3	0
2897	Crystalline Nanocellulose Anchored on Reduced Graphene Oxide for the Removal of Pharmaceuticals from Aqueous Systems: Adsorbent Characterization and Adsorption Performance. <i>ChemistrySelect</i> , 2023, 8, .	1.5	6
2898	Antithrombotic treatment after stroke due to intracerebral haemorrhage. <i>The Cochrane Library</i> , 2023, ,	2.8	5

#	ARTICLE	IF	CITATIONS
2899	Evaluation of the Effects of Dual Antiplatelet Therapy on Guided Bone Regeneration in Peri-Implant Bone Defect. <i>Journal of Craniofacial Surgery</i> , 2023, 34, 1590-1594.	0.7	0
2900	Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 762-769.	2.1	3
2901	What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season?. <i>European Heart Journal Supplements</i> , 2023, 25, A1-A4.	0.1	1
2902	Antithrombotische Therapie. , 2022, , 233-263.		0
2903	Monitoring antiplatelet therapy: where are we now?. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, e24-e35.	1.5	4
2904	Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1148-1155.	3.8	0
2905	Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. <i>Stroke</i> , 2023, 54, 697-705.	2.0	7
2907	Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. <i>Aging Medicine (Milton (N S W))</i> , 2023, 6, 4-24.	2.1	0
2908	Kinetics of Circulating Extracellular Vesicles Over the 24-Hour Dosing Interval After Low-Dose Aspirin Administration in Patients at Cardiovascular Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1096-1106.	4.7	1
2910	Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 89-97.	3.0	4
2911	Aspirin With or Without Statin in Individuals Without Atherosclerotic Cardiovascular Disease Across Risk Categories. , 2023, 2, 100197.		4
2912	Prospective, randomized, controlled, trial to assess ASA</i> <sc>ing</sc> by body mass index in <sc>H</sc> <sc>E</sc> <sc>althy</sc> volunteers (<sc>DOSE</sc> study). <i>Pharmacotherapy</i> , 2023, 43, 215-225.	2.6	0
2913	What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?. <i>Cardiometabolic Syndrome Journal</i> , 2023, 3, 41.	0.6	1
2914	Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 908-914.	1.5	0
2915	Small-vessel disease in the brain. <i>American Heart Journal Plus</i> , 2023, 27, 100277.	0.6	1
2917	The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. <i>Clinical Hypertension</i> , 2023, 29, .	2.0	27
2919	Long Term Mortality Rate in Patients Treated with Carotid Endarterectomy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 778-786.	1.5	4
2920	Medical Therapy After CABG: the Known Knowns, the Known Unknowns, and the Unknown Unknowns. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 141-149.	2.6	1

#	ARTICLE	IF	CITATIONS
2921	Step-down multiple testing procedures for the overall population and partitioning subgroups. <i>Journal of Biopharmaceutical Statistics</i> , 2024, 34, 240-250.	0.8	0
2922	Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial. <i>Chinese Medical Journal</i> , 2023, 136, 541-549.	2.3	2
2923	Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study. <i>Atherosclerosis</i> , 2023, 371, 54-60.	0.8	0
2925	Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6280.	4.1	1
2926	Aspirin should be stopped at day 0 after PCI: pros and cons. <i>EuroIntervention</i> , 2023, 18, e1304-e1306.	3.2	0
2927	Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III. <i>Cerebrovascular Diseases</i> , 2023, 52, 720-729.	1.7	1
2928	Current concepts and novel targets for antiplatelet therapy. <i>Nature Reviews Cardiology</i> , 2023, 20, 583-599.	13.7	7
2929	Editor's Choice — European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 627-689.	1.5	29
2930	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 164.	1.6	6
2931	Prevention of falls in the elderly and senile patients with cardiovascular diseases. <i>Russian Journal of Geriatric Medicine</i> , 2023, , 14-28.	0.6	1
2932	Myopenic Obesity Determined by Fat Mass Percentage Predicts Risk of Aspirin-Induced Bleeding in Chinese Older Adults. <i>Clinical Interventions in Aging</i> , 0, Volume 18, 585-595.	2.9	2
2933	A Systematic Review and Meta-Analysis of the Incidence and Risk Factors for Major Adverse Cardiovascular Events in Patients with Unrepaired Abdominal Aortic Aneurysms. <i>Biomedicines</i> , 2023, 11, 1178.	3.2	1
2934	Sex and hypertensive organ damage: stroke. <i>Journal of Human Hypertension</i> , 0, , .	2.2	1
2935	Ischemia of lower limbs in the activity of a general practitioner — family physician: from widely spread to rare disorders (literature review with some results of the own clinical observations). <i>Emergency Medicine</i> , 2023, 19, 21-31.	0.2	1
2936	Differences in primary and secondary stroke prevention strategies for Chinese men and women. <i>Preventive Medicine Reports</i> , 2023, 33, 102219.	1.8	0
2937	Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients. <i>Cancers</i> , 2023, 15, 2457.	3.7	2
2939	Carotid Artery Stenosis: A Look Into the Diagnostic and Management Strategies, and Related Complications. <i>Cureus</i> , 2023, , .	0.5	1
2940	From guidelines to decision aids and adherence supports: Insights from the process of evidence translation. <i>Patient Education and Counseling</i> , 2023, 113, 107806.	2.2	1

#	ARTICLE	IF	CITATIONS
2941	Ergothioneine improves myocardial remodeling and heart function after acute myocardial infarction via S-glutathionylation through the NF- κ B dependent Wnt5a-sFt-1 pathway. <i>European Journal of Pharmacology</i> , 2023, 950, 175759.	3.5	2
2942	The conundrum of percutaneous coronary intervention without aspirin: a call for clarity. <i>EuroIntervention</i> , 2023, 19, 13-14.	3.2	0
2943	The Royal College of Ophthalmologists's™ National Ophthalmology Database Study of Cataract Surgery: Report 12, Risk factors for suprachoroidal haemorrhage during cataract surgery. <i>Eye</i> , 2023, 37, 1778-1787.	2.1	4
2944	Immature platelets and cardiovascular events in patients with stable coronary artery disease. <i>Platelets</i> , 2023, 34, .	2.3	2
2945	Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials. <i>PLoS Medicine</i> , 2023, 20, e1004176.	8.4	2
2946	Rates of Stroke in Patients With Different Presentations of Carotid Artery Stenosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, , .	1.5	1
2947	Impact of vascular screening interventions on perceived threat, efficacy beliefs and behavioural intentions: a systematic narrative review. <i>Health Promotion International</i> , 2023, 38, .	1.8	1
2948	The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications. <i>Progress in Cardiovascular Diseases</i> , 2023, 79, 89-99.	3.1	6
2950	Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?. <i>Interventional Cardiology Review</i> , 0, 18, .	1.6	0
2951	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. <i>Contemporary Diabetes</i> , 2023, , 779-819.	0.0	0
2952	Disorders of lipid metabolism. <i>Clinical Guidelines 2023. Russian Journal of Cardiology</i> , 2023, 28, 5471.	1.4	20
2953	Glycemic control and outcome after carotid intervention in patients with T2D: A Swedish nationwide cohort study. <i>Diabetes and Vascular Disease Research</i> , 2023, 20, .	2.0	0
2954	Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. <i>Medicine (United States)</i> , 2023, 102, e34109.	1.0	0
2955	Icariin alleviates ferroptosis-related atherosclerosis by promoting autophagy in <sc>xoâ€DL</sc>â€induced vascular endothelial cell injury and atherosclerotic mice. <i>Phytotherapy Research</i> , 2023, 37, 3951-3963.	5.8	12
2956	Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2957	Protocol for a cohort study to evaluate the effectiveness and cost-effectiveness of general population screening for cardiovascular disease: the Viborg Screening Programme (VISP). <i>BMJ Open</i> , 2023, 13, e063335.	1.9	2
2958	Cyclooxygenases and platelet functions. <i>Advances in Pharmacology</i> , 2023, , 133-165.	2.0	2
2960	O sofrimento futuro pode ser evitado: o yoga como estratégia na prevenÃ§Ã£o primÃ¡ria das doenÃ§as cardiovasculares. <i>Physis</i> , 0, 33, .	0.3	0

#	ARTICLE	IF	CITATIONS
2961	Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. , 2023, 2, .		10
2962	Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation. Journal of Cardiovascular Medicine, 2023, 24, e156-e167.	1.5	7
2963	Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction. Stroke, 2023, 54, 1954-1959.	2.0	0
2964	Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding. European Heart Journal Supplements, 2023, 25, E25-E32.	0.1	1
2965	Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis, 2024, 124, 263-273.	3.4	3
2966	Ischaemic stroke despite antiplatelet therapy: Causes and outcomes. European Stroke Journal, 0, , 239698732311749.	5.5	0
2967	Large-vessel-occlusion in patients with previous ischemic stroke: an analysis of adherence to secondary preventive medication for different etiologies. Neurological Research and Practice, 2023, 5, .	2.0	0
2968	Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. European Heart Journal, 0, .	2.2	1
2969	Atherosclerotic Disease. Medical Clinics of North America, 2023, 107, 793-805.	2.5	3
2971	Ischemic Stroke Prevention After Intracerebral Hemorrhage. Current Treatment Options in Cardiovascular Medicine, 2023, 25, 325-345.	0.9	0
2972	P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. Journal of the American College of Cardiology, 2023, 82, 89-105.	2.8	30
2973	ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration. Contemporary Clinical Trials Communications, 2023, 35, 101184.	1.1	2
2974	A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. International Journal of Molecular Sciences, 2023, 24, 11132.	4.1	1
2975	The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-Analysis. Cancers, 2023, 15, 3518.	3.7	2
2976	Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Diagnostics, 2023, 13, 2356.	2.6	2
2977	Sex Differences in the Evaluation and Treatment of Stroke. Handbook of Experimental Pharmacology, 2023, , .	1.8	0
2978	Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer. JAMA Network Open, 2023, 6, e2323752.	5.9	0
2979	Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-irradiated patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 0, , .	3.7	3

#	ARTICLE	IF	CITATIONS
2980	Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 3153-3165.	3.8	2
2981	Comparing secondary prevention for patients with coronary heart disease and stroke attending Australian general practices: a cross-sectional study using nationwide electronic database. <i>BMJ Quality and Safety</i> , 0, , bmjqs-2022-015699.	3.7	0
2982	Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People. <i>JAMA Network Open</i> , 2023, 6, e2325803.	5.9	7
2983	2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 0, , .	2.2	1
2984	2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2023, 82, 1131-1174.	2.8	1
2985	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2023, 82, 833-955.	2.8	48
2986	Effects of acetylsalicylic acid alone or with omega-3 in patients with chronic coronary artery disease. <i>REC: CardioClinics</i> , 2023, 58, 303-313.	0.1	0
2987	The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis. <i>Atherothrombosis</i> , 2023, 13, 23-34.	0.3	0
2988	Balancing Benefits and Risks of Oral Antiplatelet Strategies in patients With Coronary Artery Diseases: An Evolving Issue. <i>Current Problems in Cardiology</i> , 2023, 48, 102025.	2.4	0
2989	Direct Oral Anticoagulants: Navigating Through Clinical Challenges. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	2
2990	Paired risk scores to predict ischaemic and bleeding risk twenty-eight days to one year after an acute coronary syndrome. <i>Heart</i> , 2023, 109, 1827-1836.	2.9	1
2991	Peripheral Arterial Disease and the Pharmacist's Role in Management. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2023, 2023, 1-12.	1.5	0
2992	Detection rates of asymptomatic carotid artery stenosis and atrial fibrillation by selective screening of patients without cardiovascular disease. <i>International Journal of Cardiology</i> , 2023, , 131262.	1.7	2
2993	Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. <i>Cardiovascular Therapeutics</i> , 2023, 2023, 1-12.	2.5	0
2994	2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. <i>European Heart Journal</i> , 2023, 44, 4043-4140.	2.2	88
2995	Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 5562.	2.4	0
2996	Antithrombotic Treatment in Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2023, 29, .	1.9	1
2997	Very High Risk of Recurrent Cardiovascular Events in Indonesian Patients with Established Coronary Heart Disease. , 0, 2, .		0

#	ARTICLE	IF	CITATIONS
2998	Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. World Journal of Cardiology, 0, 15, 375-394.	1.5	1
2999	2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 2023, 44, 3720-3826.	2.2	288
3000	Kindness: Definitions and a pilot study for the development of a kindness scale in healthcare. PLoS ONE, 2023, 18, e0288766.	2.5	0
3001	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023, 148, .	1.6	84
3002	Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After PCI: A Post-hoc Analysis from the HOST-EXAM Extended Study. Canadian Journal of Cardiology, 2023, , .	1.7	0
3003	Gastrointestinal Dysfunction in Stroke. Seminars in Neurology, 2023, 43, 609-625.	1.4	2
3004	Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)â€”A review of the evidence. American Journal of Preventive Cardiology, 2023, 15, 100579.	3.0	2
3005	Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023. Russian Journal of Cardiology, 2023, 28, 5555.	1.4	1
3006	Aspirin for primary prevention in patients with high cardiovascular risk: insights from CORE-Thailand registry. Scientific Reports, 2023, 13, .	3.3	0
3007	Aspirin and lipoprotein(a) in primary prevention. Current Opinion in Lipidology, 2023, 34, 214-220.	2.7	0
3008	Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study. Frontiers in Neurology, 0, 14, .	2.4	1
3009	Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials. Inflammopharmacology, 2023, 31, 2369-2381.	3.9	0
3010	Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries. JAMA - Journal of the American Medical Association, 2023, 330, 715.	7.4	2
3011	Contemporary secondary prevention in survivors of ST-elevation myocardial infarction with and without chronic kidney disease: a retrospective analysis. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
3012	Sex differences in the management of atherosclerotic cardiovascular disease. Atherosclerosis, 2023, 384, 117268.	0.8	6
3014	Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East-Asians With Westerners. JACC Asia, 2023, 3, 846-862.	1.5	0
3017	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care, 2024, 47, 81-88.	8.6	2
3018	Oral Nanomedicine: Challenges and Opportunities. Advanced Materials, 2024, 36, .	21.0	2

#	ARTICLE	IF	CITATIONS
3019	Antiphospholipid syndrome and kidney involvement. <i>Kidney and Blood Pressure Research</i> , 0, , .	2.0	0
3020	2023 ESC Guidelines for the management of acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2024, 13, 55-161.	1.0	10
3021	Direct Oral Anticoagulants: An Overview of Indications, Pharmacokinetics, Comorbidities, and Perioperative Management. <i>Cardiology in Review</i> , 0, , .	1.4	0
3022	Quality of care for secondary cardiovascular disease prevention in 2009â€“2017: population-wide cohort study of antiplatelet therapy use in Scotland. <i>BMJ Quality and Safety</i> , 0, , bmjqs-2023-016520.	3.7	1
3023	Meta-Analyses of Blood Pressure Lowering Trials. , 2024, , 577-592.		0
3025	The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15328.	4.1	0
3026	Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines. <i>American Journal of Medicine</i> , 2024, 137, 85-91.	1.5	0
3027	Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2024, 83, 17-31.	2.8	2
3028	Global disease burden and its attributable risk factors of peripheral arterial disease. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
3029	Atherosclerosis in Patients with Congenital Hemophilia: A Focus on Peripheral Artery Disease. <i>Life</i> , 2023, 13, 2221.	2.4	0
3030	Antiplatelet strategies: past, present, and future. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 3317-3328.	3.8	0
3031	Identifying and reducing inappropriate aspirin use in primary care. <i>BMJ Open Quality</i> , 2023, 12, e002457.	1.1	0
3032	Preventive Therapies in Peripheral Arterial Disease. <i>Biomedicines</i> , 2023, 11, 3157.	3.2	1
3033	The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty. <i>Journal of Orthopaedic Surgery and Research</i> , 2023, 18, .	2.3	0
3034	Do We Still Need Aspirin in Coronary Artery Disease?. <i>Journal of Clinical Medicine</i> , 2023, 12, 7534.	2.4	0
3035	Discordance Between Neutrophil to Lymphocyte Ratio and High Sensitivity C-Reactive Protein to Predict Clinical Events in Patients with Stable Coronary Artery Disease: A Large-Scale Cohort Study. <i>Journal of Inflammation Research</i> , 0, Volume 16, 5439-5450.	3.5	2
3036	Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage. <i>Stroke</i> , 2023, 54, 3173-3181.	2.0	0
3037	Improving Effect Size Interpretations. <i>Journal of Nursing Education</i> , 2023, 62, 653-654.	0.9	0

#	ARTICLE	IF	CITATIONS
3038	Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. <i>Stroke</i> , 2023, 54, 2972-2980.	2.0	1
3039	Progression of Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JAMA Network Open</i> , 2023, 6, e2343219.	5.9	1
3040	Complications of Spinal Cord Stimulator Trials and Implants: A Review. <i>Current Pain and Headache Reports</i> , 0, , .	2.9	0
3041	The Efficacy and Safety of Antiplatelet Therapy in Patients With Acute Coronary Syndrome: A Scoping Review. <i>Cureus</i> , 2023, , .	0.5	0
3042	Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. <i>British Journal of Cancer</i> , 0, , .	6.4	1
3043	Age and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure. <i>Biomedicines</i> , 2023, 11, 3208.	3.2	0
3044	Incidence, impact and predictors of residual device patency after left atrial appendage closure with the LACbes device. <i>International Journal of Cardiology</i> , 2023, , 131640.	1.7	0
3045	SGLT2 inhibitors: a therapy for everybody but not for anything?. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	0
3046	Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disordersâ€”Is There a Breakthrough?. <i>Antioxidants</i> , 2023, 12, 2088.	5.1	0
3047	Using aspirin to prevent and treat cancer. <i>Inflammopharmacology</i> , 2024, 32, 903-908.	3.9	0
3048	10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetesâ€”2024</i>. <i>Diabetes Care</i> , 2024, 47, S179-S218.	8.6	8
3049	Qihuang Zhuyu formula alleviates coronary microthrombosis by inhibiting PI3K/Akt/Î±IIbÎ²3-mediated platelet activation. <i>Phytomedicine</i> , 2024, 125, 155276.	5.3	0
3050	Ecotoxicity effect of aspirin on the larvae of <i>Musca domestica</i> through retinol metabolism. <i>Ecotoxicology and Environmental Safety</i> , 2024, 270, 115845.	6.0	1
3051	The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient. <i>Journal of Clinical Medicine</i> , 2023, 12, 7644.	2.4	0
3053	Reduced risk of gastrointestinal bleeding associated with eipatilin in aspirin plus acid suppressant users: nationwide population-based study. <i>Korean Journal of Internal Medicine</i> , 2024, 39, 261-271.	1.7	0
3054	Anti-Oomycete Effect and Mechanism of Salicylic Acid on <i>Phytophthora infestans</i>. <i>Journal of Agricultural and Food Chemistry</i> , 0, , .	5.2	0
3055	Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	7.2	0
3056	Aspirin Dosing in Cardiovascular Disease and Diabetes: Insights From ADAPTABLE. <i>Diabetes Care</i> , 2024, 47, 52-53.	8.6	0

#	ARTICLE	IF	CITATIONS
3057	Effectiveness of buffered acetylsalicylic acid compared to other drugs in diseases patients in clinical practice: results of the CARDINAL observational retrospective study. Russian Journal of Cardiology, 2023, 28, 5709.	1.4	0
3058	CURRENT PHARMACOLOGICAL MANAGEMENT IN UPPER GASTROINTESTINAL BLEEDING. Proceedings of the Shevchenko Scientific Society Medical Sciences, 2023, 72, .	0.3	0
3060	Differential Proteoglycan Expression in Atherosclerosis Alters Platelet Adhesion and Activation. International Journal of Molecular Sciences, 2024, 25, 950.	4.1	0
3061	Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2024, 13, .	3.7	1
3062	Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines. European Heart Journal: Acute Cardiovascular Care, 2024, 13, 173-180.	1.0	0
3063	Pregnancy-associated risk factors for future cardiovascular disease – early prevention strategies warranted. Climacteric, 2024, 27, 41-46.	2.4	1
3064	The Pathophysiologic Basis of Managing Chronic Atherosclerotic Cardiovascular Disease. Medical Clinics of North America, 2024, 108, 419-425.	2.5	0
3065	Aspirin-free antiplatelet strategies after percutaneous coronary interventions. European Heart Journal, 2024, 45, 572-585.	2.2	1
3066	The impact of pre-stroke aspirin exposure on radiographic appearance and disability outcomes: A post-hoc analysis of the SPS3 trial. Journal of Stroke and Cerebrovascular Diseases, 2024, 33, 107566.	1.6	0
3068	Predictive value of antiplatelet resistance on early stent thrombosis in patients with acute coronary syndrome. Chinese Medical Journal, 2013, 126, 626-633.	2.3	0
3069	The debatable role of aspirin as a primary prophylactic drug for coronary artery disease: A review. , 2023, 2, 45-48.		0
3070	Platelet Mitochondrial Fusion and Function in Vascular Integrity. Circulation Research, 2024, 134, 162-164.	4.5	0
3071	ASCEND-Eye. Ophthalmology, 2024, , .	5.2	0
3072	Antiplatelet therapy in the prevention of recurrent ischemic stroke. Meditsinskiy Sovet, 2024, , 98-104.	0.5	0
3073	Pantoprazole and Vonoprazan Performed Well in Preventing Peptic Ulcer Recurrence in Low-Dose Aspirin Users. Digestive Diseases and Sciences, 2024, 69, 670-682.	2.3	0
3074	Metaanalyse. , 2023, , 1-33.		0
3075	Perioperative myocardial injury and infarction after noncardiac surgery: a review of pathophysiology, diagnosis, and management. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
3076	Long-term aspirin adherence following myocardial infarction and risk of cardiovascular events. European Heart Journal Quality of Care & Clinical Outcomes, 0, , .	4.0	0

#	ARTICLE	IF	CITATIONS
3077	Pharmacogenetics and Pharmacogenomics Impact on Aspirin Response. , 0, , .		0
3078	Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology, 2024, 31, 754-762.	1.8	0
3079	Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
3080	Microencapsulation for Pharmaceutical Applications: A Review. ACS Applied Bio Materials, 2024, 7, 692-710.	4.6	0
3081	METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients. Open Medicine (Poland), 2024, 19, .	1.3	0
3082	Colchicine in atherosclerotic cardiovascular disease. Heart, 0, , heartjnl-2023-323177.	2.9	0
3083	Interrelationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management. Diabetes, Obesity and Metabolism, 2024, 26, 1567-1581.	4.4	1
3084	Effects of sodium ferulate for injection on anticoagulation of warfarin in rats in vivo. BMC Complementary Medicine and Therapies, 2024, 24, .	2.7	0
3086	The effect of colchicine on cholesterol crystal formation, expansion and morphology: a potential mechanism in atherosclerosis. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
3087	Results of Preclinical Studies of 4-(2-(4-nitrophenyl)-2-oxoethyl)-1-(thietane-3-yl)-1H-1,2,4-triazole-4-th Bromide in Relation to the Hemostasis System &in vivo&. Drug Development and Registration, 2024, 13, 241-246.	0.6	0
3088	Antithrombotische Therapie. , 2023, , 255-287.		0
3089	Effect of Low-Dose Aspirin on the Elderly. Cureus, 2024, , .	0.5	0
3091	Salicylic Acid: A Phytohormone of Antistress and Insecticidal Essence. , 2024, , 173-190.		0
3092	Thromboxane biosynthesis and future events in diabetes: the ASCEND trial. European Heart Journal, 2024, 45, 1355-1367.	2.2	0
3093	A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients's A Review PART II's Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory. Journal of Clinical Medicine, 2024, 13, 1508.	2.4	0
3094	The contemporary conundrum of antithrombotic drugs after intracerebral haemorrhage. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2015, , .	0.1	0
3095	Clinical evaluation of side effects resulting from the use of aspirin cardio. AIP Conference Proceedings, 2024, , .	0.4	0
3096	Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis. Indian Heart Journal, 2024, , .	0.5	0

#	ARTICLE	IF	CITATIONS
3098	Guidance for Healthcare Providers on Newest Guidelines for Over-the-Counter Drug Treatment of Mild Symptoms of COVID-19. American Journal of Medicine, 2024, , .	1.5	0
3099	JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease. Circulation Journal, 2024, 88, 763-842.	1.6	0
3100	KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 2024, 105, S117-S314.	5.2	0